 
 
 
Protocol I5B-MC-JGDL(c)  
 
 
A Phase 1b (Open -Label) / Phase 2 (Randomized, Double-Blinded) 
Study Evaluating Gemcitabine and Docetaxel With or Without 
Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma  
 
 
[STUDY_ID_REMOVED]   
 
 Approval Date: 19- Jul-2017  
,%0&-*'/ F&OLQLFDO3URWRFRO 3DJH
/< 3URWRFRO,%0&-*'/F
$3KDVHE 2SHQ/DEHO 3KDVH5DQGRPL]HG
'RXEOH%OLQGHG 6WXG\(YDOXDWLQJ*HPFLWDELQHDQG
'RFHWD[HO:LWKRU:LWKRXW2ODUDWXPDELQWKH7UHDWPHQWRI
$GYDQFHG6RIW7LVVXH6DUFRPD
&RQILGHQWLDO,QIRUPDWLRQ
7KHLQIRUPDWLRQFRQWDLQHGLQWKLVSURWRFROLVFRQILGHQWLDODQG LVLQWHQGHGIRUWKHXVHRI
FOLQLFDOLQYHVWLJDWRUV,WLVWKHSURSHUW\RI(OL/LOO\DQG&R PSDQ\RULWVVXEVLGLDULHVDQG
VKRXOGQRWEHFRSLHGE\RUGLVWULEXWHGWRSHUVRQVQRWLQYROYHG LQWKHFOLQLFDOLQYHVWLJDWLRQRI
RODUDWXPDE/<XQOHVVVXFKSHUVRQVDUHERXQGE\DFRQI LGHQWLDOLW\DJUHHPHQW
ZLWK(OL/LOO\DQG&RPSDQ\RULWVVXEVLGLDULHV7KLVGRFXPHQW DQGLWVDVVRFLDWHG
DWWDFKPHQWVDUHVXEMHFWWR8QLWHG6WDWHV)UHHGRPRI,QIRUPDWLRQ $FW([HPSWLRQ
2ODUDWXPDE/<
7KLVLVD3KDVHEVWXG\LQWKHWUHDWPHQWRISDWLHQWVZLWKDG YDQFHGRUPHWDVWDWLFVRIW
WLVVXHVDUFRPD7KHVWXG\FRQVLVWVRID3KDVHESDUWDQG 3KDVH SDUW7KH3KDVHE
SDUWLVD VLQJOHDUPRSHQODEHOGRVHHVFDODWLRQVWXG\WRGHWH UPLQHWKHUHFRPPHQGHG
GRVH RIRODUDWXPDEIRUWKH3KDVHSDUW7KH3KDVH SDUWLVDU DQGRPL]HG
GRXEOHEOLQGHGSODFHERFRQWUROOHGVWXG\WRHYDOXDWHHIILFDF\D QGVDIHW\RIRODUDWXPDEZLWK
JHPFLWDELQH SOXVGRFHWD[HOFRPSDUHGZLWKSODFHERZLWKJHPFLWDELQ H SOXVGRFHWD[HO
(OL/LOO\DQG&RPSDQ\
,QGLDQDSROLV,QGLDQD86$
3URWRFRO(OHFWURQLFDOO\6LJQHGDQG$SSURYHGE\/LOO\ RQ6HSWH PEHU
$PHQGP HQWD(OHFW URQLFDOO\6LJQHGDQG$SSURYHGE\/LOO\ RQ -XQH
$PHQGP HQWE(OHFWURQLFDOO\6LJQHGDQG$SSURYHGE\/LOO\
RQ-DQ $PHQGPHQWF(OHFWURQLFDOO\6LJQHGDQG$SSURYHG E\/LOO\RQ
DSSURYDOGDWHSURYLGHGEHORZ
Approval Date: 19-Jul-2017 GMT
I5B-MC-JGDL( c) Clinical Protocol Page 2
LY30122072.Synopsis
Study Rationale
The platelet-derived growth factor receptor alpha ( PDGFR ï¡ï€©antibody  olaratum ab in 
combinat ion with doxorubi cin dem onstrated a si gnificant improvement in overall survival ( OS)
over doxorubicin alone in pat ients with advanced soft ti ssue sarco ma(STS) (Tap et al. 201 6).
Since so me pat ients may not be appropriate candidates for doxorubicin -based chemotherapy , or 
have received prior anthracycline treatment, exploring olaratumab co mbinat ions with other 
chemotherapeut ic agents that are often used in STS treatment is of considerable interest.  Study  
I5B-MC-JGDL is a mult icenter Phase 1b /2 study  ofolaratum ab in co mbinat ion with gemci tabine 
and docetaxel in pat ients with advanced or m etastati c STS, notamenable to treatment with 
surgi cal resect ion or radi otherapy  with curative int ent.  The first part (Phase 1b) of the study  will 
consist of an open -label, single -arm, 
dose-escalat ion assessment of the safet y and tol erabili ty of 
olaratum abadministered at 15mg/kg(Days1 and 8) or20mg/kg(Days1 and 8 ) with 
gemcitabine (900 mg/m2[fixed dose rate :  10 mg/m2/minute] Day s 1and 8 ) and docetaxel (75 
mg/m2Day 8), of a 21 -day cycle.  After the dose of o laratumab in co mbinat ion with gemci tabine 
and docetaxel has been determined from the analysis of the Phase 1b pa rt, the Phase 2 , 
rando mized, double -blinded , placebo -controlled partof the study  will open to enrollment.
Approximately  256 pat ients will be rando mized in Phase 2 in a 1:1 ratio to Arm  A (olaratum ab 
plus gemcitabine and docetaxel ) or Arm  B (pl acebo pl us gemci tabine and docetaxel).
I5B-MC-JGDL( c) Clinical Protocol Page 3
LY3012207Clinical Protocol Synopsis:  Study I5B-MC-JGDL
Name of Investigational Product:  Olaratumab (LY3012207)
Title of Study:   A Phase 1b (Open -Label) / Phase 2 (Randomized, Double -Blinded) Study Evaluating Gemcitabine 
and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Number of Planned Patients:
Phase 1b :
Entered: Approximately 60patients
Enrolled : Approximately 45 55 patients
Phase 2:
Entered : Approximately 314
Randomized: 256Phase of Development:  1b/2
Length of Study :approximately 47months
Planned first patient visit:  January 201 6
Planned last patient visit:  November 2020
Phase 1b planned analysis: All patients in Phase 1b have received at least 1 cycle:  safety and pharmacokinetics 
(PK)
Planned interim safety analy sesin the Phase 2 partof the study :
1.Approximately 60patients in Phase 2 have completed at least 2 cycle sof treatment :  required safety ,
PKdata if needed.
2.Every 6 months thereafter until approximately 1year after completing enrollment: required safety ,PK
data if needed .
Planned interim efficacy analy sesin the Phase 2 part of the study :
1.After 40 OS events in olaratumab -pretreated patients .
Objectives:   
The primary objective of the Phase 1b pa rt is to determine a recommended Phase 2 dose of olaratumab that may be 
safely administered in combination with gemcitabine and docetaxel to pati ents with locally advanced or metastatic 
STS.
The primary objective of the Phase 2 partis to compare the overall survival (OS) in olaratumab -naÃ¯ve patients with 
locally advanced or metastatic STS treated with olaratumab plus gemcitabine and docetaxel versus placebo plus 
gemcitabine and docetaxel.
The secondary objectives of Phase 1b partare to: 
ï‚·characterize the safety and toxicity profile of olaratumab in combination with gemcitabine and docetaxel
ï‚·evaluate the PK and immunogenicity of olaratumab in c ombination with gemcitabine and docetaxel
ï‚·evaluate the PK of gemcitabine and docetaxel in combination with olaratumab
ï‚·document any antitumor activity of gemcitabine and docetaxel in combination with olaratumab
Asecondary objective of the Phase 2 part is to compare OSin olaratumab -
pretreated patients with locally advanced
or metastatic STS treated with olaratumab plus gemcitabine and docetaxel versus placebo plus gemcitabine and 
docetaxel.
The secondary objectives of the Phase 2 partare to compare olaratumab plus gemcitabine and docetaxel versus 
placebo plus gemcitabine and docetaxel in both olaratumab -naÃ¯ve and olaratumab -pretreated groups, for the
follow ing:
ï‚·progression - free survival (PFS)
ï‚·objective response rate (ORR) (complete response [CR] + parti al response [PR])
ï‚·disease control rate (DCR; CR + PR + stable disease)
ï‚·patient -reported outcomes (PROs):  Pain, Health -related Quality of Life (HRQoL), and health status 
ï‚·safety  and tolerability
ï‚·evaluate the PK and immunogenicity of olaratumab
I5B-MC-JGDL( c) Clinical Protocol Page 4
LY3012207The explorat ory objective s for both Phase 1b and Phase 2 are:
ï‚·to explore biomarkers associated with clinical outcome and/or pathogenesis of STS
ï‚·to explore the exposure response relationship of olaratumab for efficacy and/or safety
The exploratory objectives for Phase 2are: 
ï‚·to evaluate change in tumor size from baseline to best overall response
ï‚·assessment of the association between clinical variables, such as histological subtypes, and clinical 
outcomes
Study Design:   This trial is a Phase 1b open -label, dose -escalation part followed by a randomized, double -blind, 
placebo -controlled Phase 2 study of olaratumab plus gemcitabine and docetaxel in patients with locally advanced or 
metastatic STS, not amenable to treatment w ith surgical resection or radiotherapy with curative intent .  In the Phase 
1bpart, 2 cohorts (15 mg/kg or20 mg/kg) will be studied to determine the olaratumab dose that may  be safely  
administered in combination with gemcitabine and docetaxel.   After the dose ofolaratumab in combination with 
gemcitabine and docetaxel has been determined from the Phase 1b part, the Phase 2 part of the study will open to 
enrollment .  In Phase 2 ,approximately 256 patients will be randomized 1:1 , in a doub le-blinded manner, to Arm A 
(olaratumab plus gemcitabine and docetaxel) or Arm B (placebo plus gemcitabine and docetaxel). Randomization 
will be stratified by prior treatment with olaratumab (yes versus no), number of prior systemic therapies for locally
advanced or metast atic disease (0 versus â‰¥1), histological tumor type (leiomyosarcoma versus non -
leiomyosarcoma), Eastern Cooperative Oncology Group performance status ( ECOG PS )(0 versus 1),and prior
pelvic radiation (yes versus no).   Patients will continue treatment unt il there is documented disease progression, 
unacceptable toxicity, death, or other discontinuation criteria are met.
Diagnosis and Main Criteria for Inclusion and Exclusions:   Patients at least 16 years of age, ECOG PS 0 to 1, 
gemcitabine anddocetaxel naÃ¯ve, with histologically confirmed, locally advanced, unresectable or metastatic STS, 
and not amenable to curative treatment with surgery or radiotherapy .  Patients with gastrointestinal stromal tumor or 
Kaposiâ€™s sarcoma will be excluded.  Patients previ ously enrolled in Study I5B-MC -JGDJ or any other blinded study 
with olaratumab are not eligible to participate in this trial.
Test Product, Dosage, and Mode of Administration:   
Olaratumab: injection for intravenous (IV) use, supplied in single -use 500 mg/50 -mL vials containing 10 mg/mL of 
product in histidine buffer, administered to patients as an IVinfusion over approximately 60 minutes
For the Phase 1bpart: Olaratumab will be administered at a dose of 15 mg/kg or 20 mg/kg on Days 1 and 8 of each 
21-day cycle.
For the Phase 2 part : Olaratumab will be administered at the dose determined by the analysis in the Phase 1b part 
on Day s1 and 8 of each 21-day cycle.
Reference Therapy, Dose, and Mode of Administration:
For the Phase 1b and 2 part s:
Gemcit abine is a commercially available product and should be stored, reconstituted ,and discarded per 
manufacturerâ€™s instructions .  Gemcitabine isadministered at a dose of 900mg/m 2over approximately 90 minutes 
(fixed dose rate:  10mg/m2/min
ute) on Days 1 and 8 of each 21-day  cycle.
Docetaxel is a commercially available product and should be prepared and administered according to the 
manufacturerâ€™s instructions.   Docetaxel  is administered at a dose of 75 mg/m2(IV) over approximately 60 minutes 
on Day  8 of each 21-day cycle.
For the Phase 2 part :
Placebo:   injection for IVuse, supplied in single -use vial s, administered to patients as an IVinfusion over 
approximately 60 minutes on Days 1 and 8 of each 21-day cycle
I5B-MC-JGDL( c) Clinical Protocol Page 5
LY3012207Planned Duration of Treatment:   Treatment continue suntil there is evidence of disease progression, death, 
intolerable toxicity, or other withdrawal criteria are met . In the event of permanent discontinuation of 
olaratumab/placebo therapy due to an olaratumab/placebo -related toxicity, patients may continue on gemcitabine 
and docetaxel treatment per protocol .  If either gemcitabine or docetaxel are permanently discontinued due to 
toxicity, the patient should discontinue active treatment with the gemcitabine/docetaxel combination.  Howev er, the 
patient may continue treatment with olaratumab/placebo alone , at the discretion of the investigator.  Any changes in 
treatments being added to or removed from patient care will be recorded on the eCRF.
Short -term follow -up (postdiscontinuation):   30 days (Â±7 days)
Long -term follow -up (postdiscontinuation): Patients that discontinue study treatment for reasons other than 
progression will be followed every 6 weeks (Â±7 days) until progr essive disease ( PD), thereafter ever y 3months 
(Â±7days)for the f irstyear, then ever y 6 mo nths (Â±14 days )until the patientâ€™s de ath o r overall study completion.
Continued access:   After study completion, patients on study treatment who continue to experience clinical benefit 
and no undue risks , in the opinion of the investigator, may continue to receive study treatment until one of the 
criteria for discontinuation is met .  A continued access follow -up visit will occur 30 days (Â±7 day s)after 
discontinuation.
I5B-MC-JGDL( c) Clinical Protocol Page 6
LY3012207Criteria for Evaluation
Efficacy:   Overall survival (time f rom randomization to death) is the primary per -patient measure for efficacy in the 
Phase 2 p art.
Radiographic assessments according to Response Evaluation Criteria In Solid Tumors, Version 1.1 criteria, will be 
performed every 6 weeks (Â±7 days) until radiographic documentation of PD.
In the Phase 2 part, t he following additional efficacy measures will be determined for each patient, with planned 
statistical analyses specified in Section 12 and in the statistical analysis plan (SAP; a separate document) .  Specific 
definitions of each of these measures (such as defining events and censoring for each time to event endpoint) will be 
provided in the SAP.
ï‚·progression - free survival (PFS)
ï‚·objective response rate (ORR)
ï‚·disease control r ate (DCR)
ï‚·time to first wo rsening of the mBPI-sf (Brief Pain Inventory Short Form Modified) â€œworst painâ€ score
ï‚·time to any progression (censoring for death without progression)
ï‚·time to any new metastases (censoring for death and for other type of PD)
ï‚·new-metastases -free survival (n MFS)
ï‚·time to any progression based solely on increased sum of target lesions
ï‚·time to sustained worsening of The European Organization for Research and Treatment of Cancer Quality of 
Life Que stionnaire Co re 30 Versio n 3.0 (EORTC QLQ -C30) scale scores (for example, Global Health Status / 
Quality  of Life score, Physical Functioning score, and Role Functioning score)
ï‚·time to first worsening of ECOG PS
ï‚·second PFS (PFS2) after end of study treatment while on subsequent anticancer therapy
Safet y:
Phase 1b : will inc lude a Cycle 1 dose-limiting toxicity  (DLT )evaluation period
Phase 1b and 2: Safety will be evaluated based on reported adverse events (AEs), physical examinations, vital 
signs, laboratory tests ,andelectrocardiograms (ECGs) .  Adv erse events will be coded using the Medical Dictionary 
for Regulatory Activities (MedDRA Â®) and graded using the National Cancer Institute -Common Terminology 
Criteria for Adverse Events (NCI CTCAE), Version 4.0.  Clinical laboratory toxicity will be graded using NCI 
CTCAE criteria, Version 4.0.
Patient
-Reported Outcomes (PROs):   Pain will be assessed with the Brief Pain Inventory Short Form Modified 
[mBPI -sf], HRQoL will be assessed with the EORTC QLQ -C30 and he alth stat uswill be assessed with the EuroQol 
5 Dimension 5 -Level (EQ-5D-5L).  Patients will complete the instruments on Day 1 of ever y cycle and at the 
30-day  short - term follow -up visit.  For those patients who discontinued for reasons other than PD, afull due 
diligence will be taken to collect PRO measures during long -term follow -up,every 6 weeks [Â±7 days] until PD .
Immunogenicity:   Blood samples will be collected to evaluate immunogenicity at baseline, during the study , and at 
the30 day follow -up visi t.  In the event of an olaratumab/placebo infusion -related reaction (IRR), serum will be 
collected asclose as possible to the onset of the IRR, at the resolution of the IRR , and 30 day s (Â±3 days) after the 
IRR.
Pharmacokinetic s:
Phase 1b : PK parameters, such as maximal concentration (C max),time of C max(tmax), area under the concentration-
time curve (AUC ), volume of distribution at steady state (Vss), clearance ( CL), and half-life ( t1/2)for olaratumab, 
gemcitabine and its metabolite (dFdU ),and docetaxel
Phase 2 : Population PK parameters for olaratumab
Biomarke rs:  Assessment of the association between biomarkers and clinical outcomes
I5B-MC-JGDL( c) Clinical Protocol Page 7
LY3012207Statistical Methods:
Statistical:
Efficacy:   Phase 2: The primary objective is to compare OS in olaratumab -naÃ¯ve patients with locally advanced or 
metastatic STS treated with olaratumab plus gemcitabine and docetaxel versus placebo plus gemcitabine and 
docetaxel.  Patients will be randomized 1:1 to the 2treatment arms.  The intent ion-to-treat (ITT) sample size of 166 
for olaratumab -naÃ¯ve patients (83 in the experimental arm and 83 in the control arm) was selected assuming the 
final analysis of OS will occur after 108 OS events have been observed (35% censoring).     
The final total of 108OS events in the olaratumab -naÃ¯ve patients (deaths) provides 80% statistical power for a two -
sided log -rank test at a 0. 20significance level (assuming the true OS hazard ratio [ HR]is 0.665).  An OS HR of 
0.
665corresponds approximately to an increased median surviv al from 15 mo nths (estimated from published 
clinical data in various types of patients with locally advanced or metastatic STS) in placebo plus gemcitabine and 
docetaxel to 2 2.5 months for olaratumab p
lus gemcitabine and docetaxel.
An additional 90 olara tumab-pretreated patients (45 in the experimental arm and 45 in the control arm) will be
randomized to compare the same regimens as a secondary objective.   
The primary efficacy outcome for the Phase 2 part of the study is OS in the olaratumab -naÃ¯ve cohort of the ITT 
populatio n.  A nalysis of OS will be based on the stratified log rank test, stratified by the 3of the 4 randomization 
strata; that is, number of prior systemic therapies for locally advanced or metastatic disease (0 versus â‰¥1), 
histological tumor type (leiomyosarcoma versus non -leiomyosarcoma) ,and ECOG PS (0 versus 1) .
Overall survival curves, the median with 95% confidence interval ( CI)and survival rates at various time points for 
each treatment group will be estimated using Kapl an-Meier method (Kaplan and Meier 1958).  The HR will be 
estimated using a stratified Cox regression model, stratified by the aforementioned 3 randomization strata. All ITT 
populatio n will be included in the analysis of this endpoint. The same OS analyse s will also be performed 
separately for the olaratumab -pretreated cohort of the ITT population.  
Safety:   The s afety analy ses will be performed on the safety population defined as all enrolled patients in Phase 1b 
and all randomized patients in Phase 2, who received at least 1 dose, including a partial dose, of any study  
treatment .
In the Phase 1b part, DLT will be summarized by cohort in the patients who are evaluable for DLT assessments and 
be listed by patient.   For Phase 1 b and Phase 2 ,the incidence s of treatment -emergent adverse events (TEAEs) by 
maximum CTCAE grade that occurred during the study treatment period or within approximately 30 days after the 
decision is made to discontinue study treatment will be summarized .  Additionally, for Phase 1b and Phase 2 the 
following (but not limited to) safety -relate d outcomes will be summarized: study treatment discontinuation due to 
TEAEs, deaths during the study treatment period or within 30 days after the decision is made to discontinue study 
treatment, treatment -emergent serious adverse events during the study treatment period or within 30 days after the 
decision is made to discontinue study treatment, hospitalizations, and transfusions during the study treatment period 
or within 30 days after the decisi on is made to discontinue study treatment.
Adverse events, including TEAEs, will be listed and summarized in frequency tables using MedDRA.  Severity of 
AEs will be grade d using CTCAE version 4.0.  Other safety data, such as laboratory tests, ECGs ,and vital signs ,
will be listed and summarized, if appropriate.
Patient-Reported Outcomes (PROs):   For each instrument (mBPI -sf, EORTC QLQ -C30, and EQ -5D-5L), 
percentage compliance will be calculated as the number of completed assessments divided by the numbe r of 
expected assessments.  Data will be separately summarized using descriptive statistics.  Analyses of time to 
worsening of pain as well as HRQoL scales will be conducted.
I5B-MC-JGDL( c) Clinical Protocol Page 8
LY3012207Immunogenicity : Incidence of treatment -emergent anti-olaratumab antibodies and any  additional related assays will 
be tabulated.  Correlation to olaratumab drug level, efficacy , and safety  will be assessed, as appropriate.
Pharmacokinetics:
Phase 1b part: the PK parameter estimates for olaratumab, gemcitabine and its metabolite (dFdU) ,and docetaxel
will be calculated by standard noncompartmental methods.  Descriptive statistics will be calculated for PK 
parameters, but no formal statistical analysis is planned.
Phase 2 part: PK parameters for olaratumab ( CL, exposure, Vss, and t1/2) and inter -individual PK variability will be 
computed using nonlinear mixed effect modeling implemented in NONMEM.   Gemcitabine, dFdU ,and docetaxel
plasma levels will be reported using descriptive methods.
Explo ratory  biomarkers:   Assay results wil l be summarized and correlated with clinical outcomes.
Interim analysis :
There will be safety interim reviews for both Phase 1b and Phase 2 parts.  In addition, aninterim efficacy analys is is
planned for the Phase 2 part of the study.
The safety review for Phase 1b will be conducted by Lilly clinical research personnel.  The study investigators and 
the Lilly clinical research physician /clinical research scientist (CRP/CRS) will make the determination regarding 
dose escalation based upon their review of the safety/tolerability data and the PK data from the previous cohorts. In 
addition, an interim safety review will be conducted prior to proceeding to Phase 2 including safety andPK.
An independent data monitoring committee (iDMC) will be established to conduct Phase 2 safety interim reviews.  
The first iDMC meeting to review interim data will occur when approximately 60 patients (approximately 30 
patients from each arm) have received at least 2 cycles of treatment or discontinued all st udy treatment due to any 
reasons prior to Day 8 in Cycle 2.  Subsequent iDMC meetings will occur regularly thereafter.
Aninterim efficacy analys is isplanned for the Phase 2 part of the study.  After observing 40 OS events among the 
olaratumab -pretreated cohort of the ITT population, interim analysis will occur .  Any  positive interim efficacy 
results may be used for planning of additional separate clinical studies, but will not be used to modify the design 
and conduct of this current trial.
I5B-MC-JGDL( c) Clinical Protocol Page 9
LY30122073.Table of Con tents
A Phase 1b (Open -Label) /Phase 2 (Randomized, 
Double -Blinded) Study  Evaluating Gemcitabine and 
Docetaxel With or Without Olaratumab in the Treatment of 
Advanced Soft Tissue Sarcoma
Section Page
1. Protocol  I5B-MC-JGDL(c)  A Phase 1b (Open- Label) / Phase 2 
(Rando mized, Double -Blinded) Study  Evaluating Gem citabine and 
Docetaxel Wit h or Wi thout Ol aratum ab in the Treatm ent of 
Advanced Soft Ti ssue Sarcom a........................................................................................... 1
2. Synopsis ............................................................................................................................. 2
3. Table of Conten ts................................................................................................................ 9
4. Abbreviat ions and Definit ions........................................................................................... 17
5. Introduction ...................................................................................................................... 23
5.1. Soft Tissue Sarco ma..................................................................................................... 23
5.2. Olaratum ab Background ............................................................................................... 25
5.3. Study  Rati onale ............................................................................................................ 25
5.4. Rationale for Sel ection of Dose .................................................................................... 26
5.5. Rationale for Amendments ........................................................................................... 27
5.5.1. Rationale for Amendment (a) ............................................................................... 27
5.5.2. Rationale for Amendment (b) ............................................................................... 28
5.5.3. Rationale for Amendment (c) ............................................................................... 28
6. Object ives......................................................................................................................... 29
6.1. Primary Object ive........................................................................................................ 29
6.2. Secondary  Object ives................................................................................................... 29
6.3. Exploratory  Objectives .................................................................................................29
7. Study  Popul ation............................................................................................................... 31
7.1. Inclusio n Cri teria.......................................................................................................... 31
7.2. Exclusio n Cri teria........................................................................................................ 34
7.2.1. Rationale for Excl usion of Certain Study  Candidates ........................................... 35
7.3. Discontinuati on............................................................................................................ 35
7.3.1. Discontinuati on of  Inadvertent ly Enrolled Patients ............................................... 35
7.3.2. Discontinuati on of  Patients................................................................................... 36
7.3.3. Patients who are Lost to Follow -Up..................................................................... 37
I5B-MC-JGDL( c) Clinical Protocol Page 10
LY30122077.3.4. Discontinuati on of  Study  Sites............................................................................. 37
7.3.5. Discontinuati on of  the Study ................................................................................ 37
8. Invest igational Pl an........................................................................................................... 38
8.1. Summary  of Study  Design ............................................................................................ 38
8.1.1. Phase 1b Dose Escalat ion..................................................................................... 39
8.1.2. Phase 2 ................................................................................................................. 41
8.1.3. Definit ions of Study  Periods................................................................................. 41
8.1.4. Baseline and Study  Treatm ent Peri od Assessments .............................................. 42
8.1.5. Postdiscontinuati on Foll ow-Up Peri od Assessments ............................................. 44
8.1.6. Study  Com pletion and End of Trial ...................................................................... 45
8.1.7. Continued Access Period ...................................................................................... 47
8.1.8. Committees .......................................................................................................... 48
8.1.9. Study  Durati on..................................................................................................... 49
8.2. Discussi on of  Design and Control ................................................................................ 49
9. Treatment .......................................................................................................................... 50
9.1. Treatments Administered ............................................................................................. 50
9.1.1. Prem edicat ion...................................................................................................... 52
9.1.1.1. Olaratum ab or Pl acebo ................................................................................... 52
9.1.1.2. Gem citabine ................................................................................................... 53
9.1.1.3. Docetaxel ....................................................................................................... 53
9.1.1.4. Granulocyte -Colony St imulat ing Factors ........................................................ 53
9.2. Materi als and Supplies .................................................................................................53
9.2.1. Olaratum ab/Placebo ............................................................................................. 54
9.2.2. Gem citabine ......................................................................................................... 54
9.2.3. Docetaxel ............................................................................................................. 54
9.3. Method of Assignment to Treatment ............................................................................ 55
9.4. Selection and Timing o f Doses ..................................................................................... 55
9.4.1. Speci al Treatm ent Consi derat ions........................................................................ 56
9.4.1.1. Dose -Limit ing Toxicit y Determination (Phase 1b Part) ................................... 56
9.4.1.2. Dose Delays, Modificat ions, and Discont inuations......................................... 56
9.4.1.2.1. Gem citabine and Docetaxel ...................................................................... 60
9.4.1.2.1.1. Dose Level Reduct ions........................................................................ 60
9.4.1.2.1.2. Hem atologic Toxi city.......................................................................... 61
9.4.1.2.1.3. Nonhematologic Toxicit y.................................................................... 61
9.4.1.2.2. Olaratum ab/Placebo .................................................................................. 63
9.4.1.2.2.1. Infusio n-Related Reactions .................................................................63
9.4.1.2.2.2. Hem atologic Toxi city.......................................................................... 64
9.4.1.2.2.3. Nonhematologic Toxicit y.................................................................... 65
I5B-MC-JGDL( c) Clinical Protocol Page 11
LY30122079.5. Blinding ....................................................................................................................... 66
9.5.1. Emergency  Unblinding ........................................................................................ 67
9.5.2. Inadvertent Unblinding ........................................................................................ 67
9.6. Concomitant Therapy ................................................................................................... 67
9.6.1. Supportive Care ................................................................................................... 68
9.6.1.1. Granulocyte -Colony St imulat ing Factors ........................................................ 68
9.6.1.2. Transfusio n of Blood Products ........................................................................ 68
9.6.1.3. Antiemetic Therapy ........................................................................................ 68
9.6.2. Prohibited Therapies ............................................................................................ 68
9.6.2.1. Effect of CYP3A4 Inhibitors and Inducers on Docetaxel ................................ 68
9.7. Treatment Compliance .................................................................................................69
10. Efficacy, Patient Reported Outcomes, Resource Utilizat ion, Safet y 
Evaluat ions, Sample Co llection and Test ing, and Appropriateness of 
Measurements ................................................................................................................... 70
10.1. Efficacy Measures ........................................................................................................ 70
10.1.1. Radiographic Assessments at Baseline and during Study  
Treatment ............................................................................................................. 70
10.1.2. Radiographic Assessments during the Study  Period 
Postdiscontinuati on Foll ow-Up............................................................................ 71
10.1.3. Primary Efficacy  Measure .................................................................................... 71
10.1.4. Addit ional Efficacy  Measures .............................................................................. 71
10.2. Patient-Reported Outcomes/Resource Utilizat ion......................................................... 72
10.2.1. mBPI -sf............................................................................................................... 72
10.2.2. EORTC QLQ -C30............................................................................................... 73
10.2.3. EQ-
5D-5L ............................................................................................................ 74
10.2.4. Resource Utilization ............................................................................................. 74
10.3. Safety Evaluat ions........................................................................................................ 74
10.3.1. Adverse Events .................................................................................................... 75
10.3.1.1. Serious Adverse Events .................................................................................. 76
10.3.1.2. Suspected Unexpected Serious Adverse React ions.......................................... 77
10.3.1.3. Adverse Events of Special Interest (AESI) ...................................................... 77
10.3.2. Other Safet y Measures ......................................................................................... 78
10.3.2.1. Electrocardiograms ......................................................................................... 78
10.3.3. Safety Moni toring ................................................................................................ 79
10.3.4. Com plaint Handling ............................................................................................. 79
10.4. Sample Collect ion and Test ing..................................................................................... 80
10.4.1. Samples for Study  Qualificat ion and Healt h Monit oring ....................................... 80
10.4.2. Biomarker Sam ples f or Storage and Research ...................................................... 80
10.4.2.1. Who le Blood Sample for Genet ic Research .................................................... 81
I5B-MC-JGDL( c) Clinical Protocol Page 12
LY301220710.4.2.2. Tumor Ti ssue for Bi omarker Research ............................................................ 82
10.4.2.3. Plasma Samples for Bio marker Research ........................................................ 82
10.4.3. Samples for Immunogenicit y Research .................................................................83
10.4.4. Samples for Drug Concentration Measurements 
Pharmacokinet ics.................................................................................................83
10.5. Appropriateness of Measurements ................................................................................ 84
11. Data Qualit yAssurance ..................................................................................................... 85
11.1. Data Capture System .................................................................................................... 85
12. Sample Si ze and Statist ical Methods ................................................................................. 86
12.1. Determinat ion of Sample Size ...................................................................................... 86
12.2. Statistical and Analyt ical Plans ..................................................................................... 87
12.2.1. General Considerations ........................................................................................ 87
12.2.2. Analysis Populat ions............................................................................................ 87
12.2.3. Patient Disposi tion............................................................................................... 88
12.2.4. Patient Characteri stics.......................................................................................... 88
12.2.5. Concomitant Therapy ........................................................................................... 88
12.2.5.1. Postdiscontinuati on Therapy ........................................................................... 88
12.2.6. Treatment Compliance ......................................................................................... 88
12.2.7. Primary Outcome and Methodology ..................................................................... 89
12.2.8. Other Analyses of Efficacy .................................................................................. 89
12.2.8.1. Progression -Free Survival ............................................................................... 89
12.2.8.2. Addit ional Efficacy  Analyses ......................................................................... 89
12.2.9. Pharmacokinet ic and Immunogenicit y Analyses ................................................... 89
12.2.9.1. Pharmacokinet ics............................................................................................ 89
12.2.9.2. Immunogenicit y.............................................................................................. 90
12.2.10. Exploratory  Translat ional Research Analyses ....................................................... 90
12.2.11. Analyses of Pat ient-Reported Outcomes (PROs) .................................................. 90
12.2.12. Safety Analyses .................................................................................................... 91
12.2.13. Subgroup Analyses .............................................................................................. 92
12.2.14. Interim Analyses .................................................................................................. 92
13. Inform ed Consent, Ethi cal Review, and Regulatory  Considerat ions.................................. 94
13.1. Inform ed Consent ......................................................................................................... 94
13.2. Ethical Review ............................................................................................................. 94
13.3. Regulatory  Considerat ions........................................................................................... 94
13.3.1. Country -Specific Protocol Addenda ..................................................................... 95
13.3.2. Invest igator Informat ion....................................................................................... 95
13.3.3. Protocol  Signatures .............................................................................................. 95
13.3.4. Final Report Signature ......................................................................................... 95
I5B-MC-JGDL( c) Clinical Protocol Page 13
LY301220714. References ........................................................................................................................ 96
I5B-MC-JGDL( c) Clinical Protocol Page 14
LY3012207List of Tables
Table Page
Table JGDL.1. Treatment Regimens/Dosing Schedule ................................................... 51
Table JGDL.2. Dosing Algorithm on Days 1 and 8 for Gemcitabine, Docetaxel, 
Olaratum ab, and G -CSF Use Based on Abso lute Neutrophil Count 
and Platel et Count .................................................................................. 59
Table JGDL.3. Dose Level Reduct ions for Gem citabine and Docetaxel .......................... 60
Table JGDL.4 . General Guidelines for Gemcitabine and Docetaxel Dose 
Modificat ion Due to Other Hematologic Toxicit y................................... 61
Table JGDL.5. Dosage Reduction Guidelines for Docetaxel and Gemcitabine Due 
to Hepati c Toxi cities............................................................................... 62
Table JGDL.6. General Guidelines for Olaratumab/Placebo Dose Modificat ion 
Due to Hematologic Toxicit y Deemed Related to Olaratumab ................ 65
Table JGDL.7. General Guidelines for Dose Modificat ion Due to Nonhematologic 
Toxicit ies Deemed Related to Olaratumab/Placebo .................................66
Table JGDL.8. World Heal th Organizat ion Pain Scale .................................................... 73
Table JGDL.9. Adverse Event and Serious Adverse Event Reporting Guidelines ........... 75
Table JGDL.10. Fridericiaâ€™s QT Correcti on Form ula........................................................ 78
I5B-MC-JGDL( c) Clinical Protocol Page 15
LY3012207List of Figures
Figure Page
Figure JGDL.1. Illustrati on of  study  design. ..................................................................... 39
Figure JGDL.2. Phase 1b: Study  period and cont inued access diagram. ........................... 46
Figure JGDL.3. Phase 2: Study  period and cont inued access diagram. ............................. 47
I5B-MC-JGDL( c) Clinical Protocol Page 16
LY3012207List of Attachments
Attachment Page
Attachm ent 1. Protocol  JGDL Study  Schedule ............................................................ 100
Attachm ent 2. Protocol  JGDL Clinical Laboratory  Tests ............................................. 108
Attachm ent 3. Protocol  JGDL Hepat ic Monitoring Tests for Treatment -Emergent 
Abnorm ality......................................................................................... 111
Attachm ent 4. Protocol  JGDL ECOG Performance Status ........................................... 112
Attachm ent 5. Protocol  JGDL RECIST Criteria 1.1 ..................................................... 113
Attachm ent 6. Protocol  JGDL Pharmacokinetic, Immunogenicit y, and 
Translat ional Research Sampling Schedule ........................................... 120
Attachm ent 7. Protocol  JGDL List of Commo n CYP3A4 Inhibitors and Inducers 
of Docetaxel ......................................................................................... 123
Attachm ent 8. Protocol  JGDL Creat inine Clearance Formula ...................................... 124
Attachm ent 9. Protocol  JGDL Amendment (c) Summary
A Phase 1b (Open -Label ) / Phase 2 (Randomized, Double -
Blinded) Study  Evaluat ing Gemcitabine and Docetaxel Wit h or 
Without Olaratumab in the Treatment of Advanced Soft Tissue 
Sarcom a............................................................................................... 125
I5B-MC-JGDL( c) Clinical Protocol Page 17
LY30122074. Abbreviations and Definitions
Term Definition
AEadverse event
Any untoward medical occurrence in a patient or clinical inves tigation subject 
administered a pharmaceutical product and that does not necessarily have a causal 
relatio nship with this treatment.  An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally  associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
AESI adverse event of special interest
ALT alanine aminotransferase
ANC absolute neutrophil count
ASCO American Society of Clinical Oncology
assent Agreement from a child or other individual who is not legally capable of providing 
consent, but who can understand the circumstances and risks involved in participating 
in a study required by some ethical review boards [ERBs]) or (required by some 
institutional review boards [IRBs]).
AST aspartate aminotransferase
AUC area under the curve
audit A systematic and independent examination of the trial -related activities and documents
to determine whether the evaluated trial -related activities were conducted, and the data 
were recorded, analyzed, and accurately reported according to the protocol, applicable 
standard operating procedures (SOPs), good clinical practice (GCP), and the app licable 
regulato ry requirement(s).
blinding/maskingA procedure in which one or more parties to the trial are kept unaware of the treatment 
assignment(s).  Unless otherwise specified, blinding will remain in effect until final 
database lock.
A single -blin d study is one in which the investigator and/or his staff are aware of the 
treatment but the patient is not, or vice versa, or when the Sponsor is aware of the 
treatment but the investigator and/his staff and the patient are not.
A double -blind study is on e in which neither the patient nor any of the investigator or 
Sponsor staff who are involved in the treatment or clinical evaluation of the patients are 
aware of the treatment received.
BSA body surface area
CI confidence interval
CNS central nervous system
collection database A computer database where clinical trial data are entered and validated.
I5B-MC-JGDL( c) Clinical Protocol Page 18
LY3012207complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, p urity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all the trial -related requirements, good clinical practice (GCP) 
requirements, and the applicable regulatory requirements.
continued access 
periodThe period between study completion and end of trial during which patients on 
olaratumab who continue to experience clinical benefit and no undue risks may 
continue to receive study  treatment until one of the criteria for discontinuation is met.
CR complete response
CrCl creatinine clearance
CRF/eCRF case report form/electronic case report form
Sometimes referred to as clinical report form:  A printed or electronic form for 
recording study participantsâ€™ data during a clinical study, as required by the protocol.
CRP clinical research physician
Individual responsible for the medical conduct of the study.  Responsibilities of the 
CRP may be performed by a physician, clinical research scientist (CRS) , global safety 
physician, or other medical officer.
CRS clinical research scientist
CT computed tomography
CTCAE Common Terminology Criteria for Adverse Events
DCR disease control rate
dFdU 2',2'-difluorodeoxyuridine
DLT dose-limiting toxicity
DoR duration of response
ECG Electrocardiogram
ECOG Eastern Cooperative Oncology Group
end of trial End of trial is the date of the last visit or last scheduled procedure for the last patient.
Enroll /randomize The act of assigning a patient to a treatment.  Patients who are enrolled in the trial are 
those who have been assigned to a treatment .
Phase 1b part:  Enroll
Phase 2 part :  Randomize
enter Patients entered into a trial are those wh o sign the informed consent form directly or 
through their legally acceptable representatives.
I5B-MC-JGDL( c) Clinical Protocol Page 19
LY3012207EORTC QLQ -C30 European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire Core 30 Version 3.0
EQ-5D-5L EuroQol 5 Dimension 5 -Level
ERB/IRB ethical review board/institutional review board
A board o r committee (institutional, regional, or national) composed of medical and 
nonmedical members whose responsibility is to verify that the safety, welfare, and 
human rights of the patients participating in a clinical trial are protected.
FSH follicle -stimulating hormone
GCP good clinical practice
G-CSF granulocyte - colon y-stimulating factor
GIST gastrointestinal stromal tumors
HIV human immunodeficiency virus
HR hazard ratio
HRQoL health -related quality of life
IB Investigatorâ€™s Brochure
ICF informed consent form
ICH International Conference on Harmonisation
iDMC independent data monitoring committee
IgG1 immunoglobulin G su bclass 1
Informed consent A process by which a patient voluntarily confirms his or her willingness to participate 
in a particular trial, after having been informed of all aspects of the trial that are relevant 
to the patientâ€™s decision to participate.  Informed consent is documented by means of a 
written, signed, and dated informed consent form .  
INR internatio nal no rmalized ratio
interim analysis An interim analysis is an analysis of clinical trial data, separated into treatment groups, 
that is conducted before the final reporting database is create d/locked.
investigational 
product (IP)A pharmaceutical form of an active ingredient substance or placebo being tested, or 
used as a reference, in a clinical trial.  Investigational product (IP) includes a product 
with a marketing aut horizatio n when:
1.used or assembled (formulated or packaged) in a way different from the 
autho rized form ,
2.used for an unauthorized indication, or 
3.used to gain further information about the authorized form.
I5B-MC-JGDL( c) Clinical Protocol Page 20
LY3012207investigator A person responsible for the conduct of the clinical trial at a trial site.  If a trial is 
conducted by a team of individuals at a trial site, the investigator is the responsible 
leader of the team and may be called the principal investigator.
IRR infusion -related reaction
ITT intention -to-treat
The principle that asserts that the effect of a treatment policy can be best assessed by 
evaluating on the basis of the intention to treat a patient (that is, the planned treatment 
regimen) rather than the actual treatment given.  It has the consequence that patients 
allocated to a treatment group should be followed up, assessed, and analyzed as 
members of that group irrespective of their compliance to the planned course of 
treatment.
IV intravenous
IWRS interactive web-response sy stem
legal representative An individual, judicial, or other body authorized under applicable law to consent on 
behalf of a prospective patient to the patientâ€™s participation in the clinical study.
Lilly Safety System Global safety database that tracks and reports serious adverse and spontaneous events 
occurring while using a drug/drug delivery system.
LMS Leiomyosarcoma
mBPI -sf modified Br iefPain Inventory -short form
MedDRA Medical Dictionary for Regulatory Activities
MRI magnetic resonance imaging
NCI Natio nal Cancer Institute
NSCLC
Olaratumab naÃ¯ve
Olaratumab pretreatednon-small cell lung cancer
A study  participant who has never received olaratumab prior to enrollment or 
randomization
A study  participant who has previously received commercially available olaratumab , as 
defined by the inclusion criteria
ORR overall response rate
OS overall survival
patient A study  participant who has the disease or condition for which the investigational 
product is targeted.
PD progressive disease
PDGF platelet -derived growth factor
PDGFR platelet -derived growth factor receptor
I5B-MC-JGDL( c) Clinical Protocol Page 21
LY3012207PET positron emission tomography
PFS progression -free survival
PFS2 second progression -free survival ( after end of study treatment while on subsequent 
anticancer therapy )
PK Pharmacokinetics
PR partial response
PRO/ePRO patient -reported outcome/electronic patient -reported outcome
PS performance status
PT Preferred Term
QTc corrected QT interval
randomize the process of assigning patients to an experimental group on a random basis
RECIST Response Evaluation Criteria in Solid Tumors
reporting database A point -in-time copy of the collection database.  The final reporting database is used to 
produce the analyses and output reports for interim or final analyses of data.
re-screen to screen a patient who was previously declared a screen failure for the same study
SAE serious adverse event
SAP Statistical Analysis Plan
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study.  In this study, 
screening involves invasive or diagnostic procedures and/or tests (for example, 
diagnostic psychological tests, x -rays, blood draws).  
screen failure patient who does not meet one or more criteria required for participation in a trial
SD stable disease
STS soft tissue sarcoma
Study completion This Phase 1b/2 study will be considered complete after the final analysis/evaluation of 
overall survival is performed .
Study Treatment olaratumab/ placebo, gemcitabine, and d ocetaxel
SUSARs suspected unexpected serious adverse reactions
I5B-MC-JGDL( c) Clinical Protocol Page 22
LY3012207TEAE treatment -emergent adverse event
Any untoward medical occurrence that either occurs or worsens at any time after 
treatment baseline and that does not necessarily have to have a causal relationship with 
this treatment.
UK United Kingdom
ULN upper limits of normal
US United States
VAS visual analog scale
I5B-MC-JGDL( c) Clinical Protocol Page 23
LY3012207A Phase 1b (Open- Label) / Phase 2 (Randomized, 
Double -Blinded) Study  Evaluating Gemcitabine and 
Docetaxel With or Without Olaratumab in the Treatment of 
Advanced Soft Tissue Sarcoma
5.Introduction
5.1. Soft Tissue Sarcoma
Soft tissue sarco ma (STS) is a heterogeneous group of malignant tumors that ari se from tissue of 
mesenchymal origin .  Sof t tissue sarco maarises primarily from the embry onic m esoderm , with 
some neuroectodermal contribut ion and different iation to non -epithelial extraskeletal t issue,
including striated skeletal  and smooth muscle, adipose, and fibrous tissue ( Sharma et al. 2013; 
Dâ€™Angelo et al. 2014 ; Linch et al. 2014 ).  There are approximately 50 different types of  STS that
can be found in almost any anatomic location (American Cancer Society 2014; Linch et al. 
2014).  STS is rare,comprising approximately 1% of adult cancers . The annual  incidence o f 
STS in the United Kingdo m (UK)and United States ( US)is 3300 and 10,000
, respectively
(Jemal et al .2009; Nat ional Cancer Institute 2013 ).  A multidisciplinary  setting wit h teams 
specializing in the treatm entof STS is the best treatm ent approach for these tum ors.  
Management oflocalized disease is usually wit h curative intent ,using surgical resect ion with or 
without radi otherapy  and chemotherapy.  In spite of init ial aggressive management , there is a 
frequent recurrence of local inoperable or metastatic disease , and at thispoint sy stemic therapy  
plays a prominent role in the mult idisciplinary  management of STS (Linch et al. 2014 ).
The mainstay  therapy for treating advanced -stage STS has bee n chemotherapy , which in the 
first-line setting has provi dedoverall  response rates of approximately 25% (Linch et al . 2014).  
Even with the use of chemotherapy , advanced -stage STS is usually fatal and there remains a
need for novel and effect ive therapies .  
Doxorubicin either alone or in combinat ion has served as 
the init ial treatm ent for metastatic sarcoma for many years .  Vari ous other drug combinat ions 
have also been explored (Linch et al . 2014) .
In recent y ears, som e groups have reported that the combination o f gemci tabine plus docetaxel  is 
effect ive against metastatic STS
due to its broad spectrum of act ivity and has a favorable toxicit y 
profile (in co mpar ison with doxorubicin and ifo sfamide) (Ravi et al . 2015) .  Maki  et al  (2007)
studi ed the combination of gemci tabine plus docetaxel v ersus gemcitabine alone in 122 patients 
with metastati c STS .  In this study , gemci tabine (fixed dose rate of 900 mg/m 2on Days 1 and 8)
in combinat ion withdocetaxel (100 m g/m2on Day 8) yielded alonger progression -free survival
(PFS) (6.2months versus 3 months) and overall survival (OS) (17.9 months versus11.5 m onths ) 
when compared to gemcitabine alo ne.The most commo n Commo n Termino logy Criteria for 
Adverse Even ts (CTCAE )
Grade 3 to 4 toxicit y was thrombocy topenia (38%). Grade 3 to 4 
thrombocy topenia was 35% and 40% in the gemcitabine (N=49) and gemcitabine plus docetaxel 
(N=73) arm s,respect ively (Maki  et al . 2007).
I5B-MC-JGDL( c) Clinical Protocol Page 24
LY3012207In the randomized Phase 3 trial of doxorubicin versus intensified doxorubicin plus ifo sfamide for 
first-line treatment of advanced or metastatic STS (Judson et al. 2014), doxorubicin in 
combinat ion with ifosfamide had a higher overall response (ORR) (26% versus 14%) and a 
longer PFS (7.4 mo nths versus 4.6 months) ,although there was no significant difference in OS. 
The m ost comm on Grade 3 to 4 toxicit y in the combinat ion arm  was febrile neutropenia (46%). 
Ifosfamide -related Grade 2 encephalopathy  occurred in 2% (4 of 224) of patients and 
ifosfamide -related Grade 3 encephalopathy  occurred in 4% (10 of 224 ) ofpatients. Only 5cases 
of treatm ent-related renal dysfunct ion occurred, all in the doxorubicin plus ifosfamide arm
(Judson et al. 2014).
Hensley  et al  (2008 a, 2008b )studi ed the combin ation of gemci tabine and docetaxel in patients 
with le
iomyosarcomas(LMS) .Gemcitabine was administered ata fixed dose rate of 900 mg/m2
over 90 minutes on D ays 1 and 8 while docetaxel was administered at 100 mg/m2on D ay 8. 
Object ive response rates w ere36% and 27% when the combinat ion was used as first -line and 
second -line agents ,respectively. When the combinat ion was used as first -line therapy (N= 42 ; 
Hensley  et al  2008b ), myel osuppressio n was the major toxicit y: neutropeni a Grade 3 in 5%of 
patients , Grade 4 i n 12%; anemia Grade 3 in 24%; and thrombocy topeni a Grade 3 in 9.5%, 
Grade 4 in 5%. Fatigue was Grade 3 in 17% of patients .  When the combinat ion was used as 
second -line therapy (N= 51 ; Hensley  et al . 2008a), the predominant toxicit y was unc omplicated 
myelosuppressio n: thrombocy topenia Grade 3 (29%), Grade 4 (10.4%); neutropenia Grade 3 
(12.5%), Grade 4 (8.3%) ;anemia Grade 3 (20.8%), Grade 4 (4.2%). While pulmo nary toxicity 
was reported, no patient had drug -related pneum onitis/hypoxia -typetoxicity.
AFrench study  group (Pautier et al .2012) compared
,prospectively ,the gem citabine and 
docetaxel co mbinat ion to gem citabine m onotherapy  in advanced LMS after anthracycline failure. 
In a group of 90 patients ,they confirmed the efficacy  of bothregimens ;the 3-month PFS rate s in 
the gem citabine monotherapy  arm and gemci tabine pl us docetaxel  arm 
were57% and71% in the 
uterine group and 68% and 53% in the non -uterine group, respectively ,with no si gnificant 
difference between the 2arms .
A more recent Phase 2 study (N=44) conducted in first -line metastatic / advanced LMS pat ients 
in London demonstrated that gemcitabine plus docetaxel  is an active regimen with 70.5% and 
59.1% pa tients with no progressi on at 3 and 6 months , respectively (Seddon et al . 2015a ).The 
most commo n Grade 3 or 4 toxicit ies were fat igue (30%), anemia (24%), dy spnea (16%), 
neutropeni a (12%), and infect ion (any, 12%). Thrombocy topeni a Grade 3 or 4 was 7%
(Seddon et al. 2015a )
.In a recent ly completed randomized Phase 3 tri al of gemci tabine pl us 
docetaxel ver sus doxorubi cin in the first-line treatment of pat ients with unresectable or 
metastati c STS, the re was no statistical difference in the 6-month PFS rate, median PFS , and OS 
between the 2 treatm ent arms (Seddon et al. 2015b) .Gemcitabine was administered at a fixed 
dose rate of 675 mg/m 2on Day s 1 and 8 while docetaxel was administered at 75 mg/m 2on 
Day 8.Significant Grade 3 to 4 toxicit ies include dfebrile neutropenia o f 20.3% and 11.9% in 
the doxorubicin (N=128) and gemcitabine pl
usdocetaxel (N=126) arms ,respect ively. Grade 3 
to 4 oral  mucosi tis was 12.5% and 1.6% in the doxorubicin and gemcitabine plus docetaxel  arms ,
respectively . However , Grade 3 to 4 fat igue was more commo n in the co mbinat ion arm ,13.5% 
I5B-MC-JGDL( c) Clinical Protocol Page 25
LY3012207versus 6.3%. Grade 3 to 4 diarrhea was also more commo n in the combinat ion arm ,7.9% versus 
1.6% (Seddon et al. 2015b ). Although the PFS hazard rati o (HR)favored the doxorubicin arm 
(1.28 [95% confidence interval { CI}0.98-1.67]; p=0.07), it was concl uded that doxorubicin
remains a first -line standard and confirmed gemcit abine/docetaxel activ ityinpatients with 
unresectable or metastatic STS (Seddon et al. 2015 b).
5.2. Olaratumab Background
Olaratum ab is a recombinant human immunoglobulin G su bclass 1 (IgG1) -type m onoclonal 
antibody  that binds to platelet -derived growth factor receptor alpha (PDGFRÎ± ).  Thi s ant ibody
possesses high affinit y binding for PDGFRÎ± and blocks platel et-derived growth factor 
(PDGF) -AA, -BB, and -CC fro m binding to the receptor. In addition to blocking ligand -induced 
cellmitogenesis and receptor autophosphorylat ion, olaratumab inhibits ligand -induced
phosphorylat ion of the downstream signaling mo lecul es Akt and mitoge n-activated protein
kinase (Loizos et al . 2005; Study  Report IMC -3G3- 01).
In norm al mesenchymal bi ology,PDGF/PDGFR signaling has a significant role in mesenchymal 
stem cell different iation, growth of mesenchymal cells, angiogenesis ,and wound healing 
(Andrae et al . 2008; Ng et al . 2008 ;Li et al . 2014). PDGF/PDGFRÎ± signaling has been 
implicated in the pathogenesis o f mu
ltiple cancers, including osteosarcoma, chondrosarcoma, 
prostate cancer, breast cancer, ovarian cancer, and others.  In malignant disease, the 
PDGF/PDGFRÎ± axis prom otes tumor growth and proliferat ion through both autocrine and 
paracrine mechanisms.   PDGFRÎ± is expressed on stromal cells, as well as the cancer cells 
themselves, wi thin certain tum ors.  Furthermore, studies have shown that PDGF/ PDGFRÎ± 
signaling affects tumor vasculature through paracrine mediat ion of vascular endothelial growth 
factor production (Shah et al. 2010).   Addit ional inform ation is available in the olaratumab 
investigatorâ€™s brochure (IB).
5.3. Study Rationale
The rando mized Phase 2 part of Study I5B-IE-JGDG ([JGDG; [IMCL CP15 -0806] ; olaratum ab 
plusdoxorubicin versus doxorubicin alo ne)met its protocol -defined primary  endpoint of PFS .  
The combinat ion of o laratumab and doxorubicin (investigational arm) in this trial showed a 
statist ically significant and clinically meaningful improvement in median OS (11.8 -mont
h 
improvement; HR=0.463; p=0.0003) over doxorubicin alo ne(control  arm).  Furtherm ore, in the 
primary  analysis (using the intent ion-to-treat [ITT] population based on in vestigator assessment), 
the study  met the protocol -defined final significance level for PFS (2- sided alpha=0.1999). The 
combinat ion of olaratumab and doxorubicin improved median PFS by 2.5 months over 
doxorubi cin alo ne(stratified HR=0.672 [95% CI: 0.442 , 1.021]; p=0.0615 ), corresponding to a 
32.8% reducti on in the risk of progression or death.  Grade â‰¥3 treatment -emergent adverse 
events (TEAEs) were reported in 79.7% of patients in the invest igational arm and 69.2% of 
patients in the control  arm.  Grade â‰¥3 adverse events (AEs) occurring in at least 10% of patients 
intheinvest igational arm included neutropenia (consolidated term ; 54.7% [invest igationalarm] 
versus 33.8% [control arm] ), anemia (consolidated term ; 12.5% versus 9.2%),and febrile
neutropeni a(12.5% versus 13.8%) .  Although the incidence of neutropenia was increased in the 
I5B-MC-JGDL( c) Clinical Protocol Page 26
LY3012207investi gational arm, the combinat ion of o laratumab and doxorubicin did not result in an 
increased overall incidence of febrile neutropenia or infect ions.  In gen eral, t heoverall safety 
profile of the co mbination o f olaratum ab and doxorubicin was consistent with the known 
toxicities of doxorubicin.
While doxorubicin alo ne or in combinat ion has been the mainstay  of treatm ent for decades, 
(Linch et al. 2014), in mor e recent y ears, g emci tabine pl us docetaxel  has demo nstrated to be an 
effect ivetreatm entagainst metastatic STS (Maki  et al . 2007 ;Hensley  et al . 2008 a, 2008b ,2013).  
In apatient-derived xenograft model of human liposarcoma ,olaratum ab in co mbinat ion with 
gemcitabine plus docetaxel  inhibited tumor growth to a greater extent than docetaxel plus
gemcitabine al one (p=0.05) .
The posi tive efficacy  resul ts seen wi th olaratum ab in combinat ion with doxorubi cin in 
Study JGDG
(Tap et al . 201 6)warrant further study o f olaratumab with gemci tabine plus 
docetaxel, another active treatment regimen ,for pati ents wi th advanced or m etastati c STS.
Study  I5B-MC-JGDL will eval uate the efficacy  and safet y of olaratum ab, in combinat ion with 
docetaxel and gemcitabin e(fixed dose rate: 10 m g/m2/minute) in pat ients with locally advanced
or metastati cSTS.   The study  will allow this evaluati on in both ol aratum ab-naÃ¯ve and 
olaratum ab-pretreated populat ions.  Olaratumab -naÃ¯ve patients are those who may be ineligible 
for treatm ent wi th doxorubi cin or for whom gemcitabine/docetaxel is more appropriate as init ial 
chemotherapy than doxorubicin .
More informat ion about the known and expected benefits, risks ,
and reasonably antici pated AEs 
of olaratum abmay be found in the IB.  Informat ion on AEs expected to be related to olaratumab
may be found in Sect ion 7 (Development Core Safety Information) of the IB.  Information on 
serious adverse events (SAEs) expected in the study  populati on independent of drug exposure 
and that will be assessed by the Sponsor in aggregate, periodically during the course of the study , 
may be found in Sect ion6 (Effects in Humans) of the IB.
5.4. Rationale for Selection of Dose
Olaratumab:
The current dose -selection strategy  for this study  is based on the integrated safet y, efficacy , and 
pharmacokinet ics (PK)data for olaratumab across previous Phase 1 and Phase 2 studies. In 
2Phase 1 d ose-escalation trials ( Studies I5B-IE-JGDC and I5B-IE-JGDF ) and in the 2 Phas e 2 
monotherapy  studi es (Studi es I5B-IE-JGDE and I5B-IE-JGDH ), single -agent ol aratum ab has 
consistent ly been well tol erated ,with no dose-limiting toxicit ies (DLTs )observed up to a dose of 
20 m g/kg administered every  2 weeks and up to a dose of 15 mg/kg administered o nDays1 and 
8 of a 21- day cycle.   When used in co mbinat ion with liposomal doxorubicin in Study  I5B-IE-
JGDA (olaratum ab dose of 20 mg/kg every  2 weeks) , and wi th paclitaxel plus carbopl atin in 
Study  I5B-IE-JGDB (olaratumab dose of 15 mg/kg Day s1 and 8 every  3 weeks), a higher rate of 
toxicities such as neutropenia and infect ions was observed versus the comparator agents . As of 
30June 2016, 790 patients have received o laratumab .  through Phase 1, Phase 2, and Phase 3 
studi es.  In Study JGDG , although there was a higher incidence of some known doxorubicin 
I5B-MC-JGDL( c) Clinical Protocol Page 27
LY3012207toxicities such as m ucosi tis, nausea/vomit ing, and di arrhea, these were monitorable, 
predominant ly Grade â‰¤2, and di d not l ead to a hi gher incidence of treatment discont inuat ion.  
Overall, t hese toxicit ies are consistent with the toxicit y profile of the combinat ion agents used 
and are considered monitorable and acceptable for the patient populat ions studied.
In addit ion, final PFS and OS data from Study JGDG show that the combinat ion of olara tumab 
15 m g/kg wi th doxorubi cin 75 mg/m2provi des a significant benefit compared to single- agent 
doxorubi cinin patients with advanced metastatic STS, without an increase in serious toxicit y.
Based on th e available clinical evidence , the Phase 1b partof this study will start the olaratumab 
dose escalat ion at 15 m g/kg.  Based on the safet y and PK results fro m the dose escalat ion atthe 
end of the Phase 1b part of this study , 
an appropri ate dose wil l be selected for the Phase 2.
Gemcitabine and Docetaxel:
The combinat ion of gemcitabine and docetaxel is an effect ive option for patients with metastatic 
sarcoma and has been studied using a diverse range of doses and across subtypes (Maki et al . 
2007).
Infusio n of gemcitabine at a f ixed-dose rate refers to infu sing gemcitabine at a continuous rate 
enabling the maintenance ofthe gem citabine concentrati on at a level that will optimize the 
incorporation of gemcitabine triphosphate, which is the active gemcitabine metabo lite, into 
deoxy ribonucleic acid (DNA) (Hensl ey et al . 2008 a
).  Studies have shown that gemcitabine may 
have greater activit y when given as a fixed -dose rate i nfusi on (10 m g/m2/min) com pared w ith the 
recommended schedule (a 30-minute infusio n) (Tempero et al. 2003 ).
Fixed -dose rate gemcitabine (900 m g/m2over 90 minutes [fixed dose rate of 10 m g/m2/min], 
Days 1and 8, plus docetaxel  100 m g/m2on Day 8) yielded high object ive response rates among 
patients wi th advanced leio myosarco ma in both the second -line, and first -line setting (Hensley et 
al. 200 8a, 2008b ).  However, to increase the tolerabilit y of thischem otherapy regimen a 
docetaxel dose of 75 m g/m2,which is lower than 100 mg/m2,has been selected for this study . 
Some of the toxi city seen in previ ous clinical  experi ence (fat igue, ast henia, and fluid retention) 
wasmore typical  of thedocetaxel counterpart , suggesting that this docetaxel dose modificat ion 
could improve the tolerabili ty of this regimen.   This i s consistent with the 75-mg/m2 docetaxel  
dose chosen in recent Phase 3GeDDi S trial (Seddon et al. 2015
b). Therefore, this Phase 1b/2
trial investigate sthe efficacy and safet y of olaratumab in co mbinat ion with gemci tabine (900 
mg/m2over 90 minutes [ fixed -dose rate of 10 m g/m2/min])and docetaxel (75 mg/m2)for the 
treatm ent of locally advanced or m etastati c STS that i s not am enable to treatm ent wi th surgical 
resection or radi otherapy  with curative intent.
5.5. Rationale for Amendments
5.5.1. Rationale for Amendment (a)
The rationale for amendment (a)wasbased on feedback received fro mglobal regulatory  
authori tiesand com pliance wi th local regulatory  requi rements for submissions.  Major changes 
for amendment (a)included the fo llowing: new descri ptive language on prem edicat ion prior to 
I5B-MC-JGDL( c) Clinical Protocol Page 28
LY3012207olaratum ab/placebo doses on Days 1 and 8 of Cy cle 1 and in subsequent cy cles.  Clarificat ion 
was also added related to the olaratumab observat ion period.  Additionally, the introduction was 
updated to include commo nly observed AEs for gemcitabine and docetaxel from published 
studi es, and to include data from the final primary analysis forefficacy and safet y for Study  I5B-
IE-JGDG .
5.5.2. Rationale for Amendment (b)
The protocol was amended to allow for expansio n of the olaratumab 20 mg/kg dose level
(Cohort 2 )by enrolling approximately 15 addit ional patients. The r ationale for adding an 
additional 15 pati ents to Cohort 2 is to confirm  the safet y of the20 m g/kg dose l evel prior to 
opening the Phase 2 randomized double -blinded porti on of  the tri al. Refer to Section 8.1.1 for 
further details.
5.5.3 .Rationale for Amendment (c) 
As doxorubi cin in co mbination wit h olaratum ab becom es more comm on in clinical pract ice for 
advanced or metastati c STS, addi tional evaluati on in ol aratum ab-pretreated patients is warranted 
in order to understand the effect of olaratumab as continuat ion therapy  with regimens such as 
gemcitabine/docetaxel  that are customarily administered after m aximal  doxorubicin dosing.  
Addit ionally , the concept of continuing a bio logic treatm ent wi th a change in chemotherapy  
backbone is supported by  evidence of on -going treatment effect of trastuzumab and bevacizumab 
in multiple lines of t herapy in HER2 posit ive breast cancer and metastatic colon cancer, 
respectively .  Furtherm ore, resistance to antibody  therapy in cancer is via separate mechanisms 
than chemotherapy  resistance, supporting the theory  that continued benefit from olaratumab is
possible after progressive disease on other chemotherapy regimens.  Finally , due to potenti al 
effect on PDGFRÎ± expressing stromal cells, continued olaratumab exposure may lead to 
favorable changes in the tumor microenvironment irrespect ive of change in chem otherapy  
regimen.  The evaluat ion of olaratumab in co mbination with gemcitabine and docetaxel in 
olaratum ab pre -treated patients will be a secondary object ive. Ninet y patients will be added as 
this is deemed to be an adequate number to observe a signal f or strategi c planning of future 
studi es.  The protocol  amendment also adds aninterim efficacy analysis of all study  outcom esto 
allow for timely Phase 3 development strategies.
I5B-MC-JGDL( c) Clinical Protocol Page 29
LY30122076.Objectives
6.1. Primary  Objective
Phase 1b
The primary  object ive of the Phase 1b partis to determine a recommended Phase 2 dose of 
olaratum ab that m ay be safely administered in combinat ion with gemci tabine and docetaxel to 
patients wi th locally advanced or metastati c STS.
Phase 2
The primary object ive of the Phase 2 partis to compare the OS in olaratumab -naive patients with 
locally advanced or metastatic STS treated with olaratumab plus gemcitabine and docetaxel 
versus placebo plus gemcitabine and docetaxel.
6.2. Secondary Objectives
Phase 1b
The secondary  objective sof Phase 1b partarethe foll o wing :
ï‚·characterize the safet y and toxi city profile of ol aratum ab in co mbinat ion with 
gemcitabine and docetaxel
ï‚·evaluate the pharmacokinet ics (PK) and immunogenicity of o laratumab in combinat ion 
with gemci tabine and docetaxel
ï‚·evaluate the PK of gemcitabine and docetaxel in combinat ion with olaratum ab
ï‚·docum ent any  antitumor activit y of gemci tabine and docetaxel  in combinat ion with 
olaratum ab
Phase 2
A secondary  obje ctive of the Phase 2 part is to compare OSin olaratum ab-pretreated patients 
with locally advanced or metastati c STS treated with olaratumab plus gemcitabine and docetaxel 
versus placebo plus gemcitabine and docetaxel.
The secondary  objectives of the Phase 2 partare to compare olaratum ab pl us gemci tabine and 
docetaxel versus placebo pl us gem
citabine and d ocetaxel in both ol aratum ab-naÃ¯ve and 
olaratum ab pre -treated groups, for the fo llowing:
ï‚·progression -free survival (PF S)
ï‚·object ive response rate (ORR) (complete response [CR] + partial response [PR])
ï‚·disease control  rate (DCR; CR + PR + stable disease [SD])
ï‚·patient-reported outcomes (PROs):  pain, health-related qualit y of l ife (HRQoL), and health 
status
ï‚·safety and tolera bility
ï‚·evaluate the PKand immunogenicit yof olaratum ab
6.3. Exploratory Objectives
For both Phase 1b and Phase 2
I5B-MC-JGDL( c) Clinical Protocol Page 30
LY3012207ï‚·to explore biomarkers associated with clinical outcome and/or pathogenesis of STS
ï‚·to explore the exposure -response relat ionship of olaratumab for efficacy and/or safet y
For Phase 2 Only
ï‚·to evaluate change in tumor size fro m baseline to best overall response
ï‚·assessment of the associat ion between clinical variables, such as histol ogical subt ypes, and 
clinical outcomes
I5B-MC-JGDL( c) Clinical Protocol Page 31
LY30122077.Study  Population
Eligible pat ients will have a histological diagnosis of locally advanced or m etastati c STS, by 
local pathol ogy review, not am enable to treatm ent wi th surgical  resecti on or radi otherapy  with 
curative intent.
All patients meeting the eligibilit y requirements will be considered for enrollment regardless of 
race, religio n, or gender.  The invest igator or the Spo nsor will not grant except ions to eligibilit y 
criteria.  The duration of the screening period is 14 day s for the m ajority of procedures 
(Attachm ent 1 ); certain noted procedures may be performed wit hin 28 days of randomization.  
Individuals who do not meet the criteria for participation in this study  within the extended 
28-day screening period (screen failure) may be re -screened.  Note that repeating laboratory  tests 
during the 28 -
day screening period does not constitute re- screening.  Screening laboratory tests 
may not be repeated more than once in order to meet eligibilit y during the 28 -day screening 
period.  If a repeat screening laboratory  value m eets eligibilit y, it is recommended that the test is 
rechecked to confirm stabilit y.
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay be re -
screened .  Patients may be considered for re -screening after discussio n with the Lilly study  
physician or designee.  Patients may  be re-screened up to 1 time.  The interval between re -
screenings should be at least 28 days.  Patients who will be re -screened must sign a new 
informed consent form  (ICF) and will be assigned a new identificat ion number.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria (also known as 
protocol  waivers or exempt ions) is not permitted.
7.1. Inclusion Criteria
Patients are eligible to be included in the study  only  if they  meet allof the fo llowing cri teria:
[1] The patient or pati entâ€™s parent/guardian signed an informed consent /assent
form and authori zation for release of healt h information for research prior to 
any study -specific procedures being performed .
[2] The patient is aged â‰¥16years at time of consent .
[3] The pati ent has histol ogically confirmed diagnosis of locally advanced ,
unresectable or metastatic STS not amenable to curative treatment with 
surgery  or radi otherapy .  Pati ents wi th a diagnosi s of Grade 1 liposarcoma 
(Atypical Lipo matous Neoplasms) are elig ible if there is histological or 
radiographic evidence of evolut ion to m ore aggressive di sease.
Note: Evidence of disease progression is required for patients that are not newly 
diagnosed.
I5B-MC-JGDL( c) Clinical Protocol Page 32
LY3012207[4] The patient has measurable or nonmeasurable but eva luable disease as defined 
by the Response Evaluat ion Cri teria in Soli d Tum ors (RECIST 1.1, 
Eisenhauer et al. 2009; refer to Attachment 5).  Tumors within a previously 
irradi ated field will be designated as â€œnontargetâ€ lesions unless progression is 
docum ented or a bi opsy  is obtained to confirm persistence at least 90 days 
following co mpletion of radiotherapy .
[5] The patient has a performance status 0 -1 on the Eastern Cooperative 
Onco logy Group (ECOG) scale (refer to Attachment 4
).
[6] The patient may  have no m ore than 2prior lines of systemic therapies 
(neoadj uvant and adj uvant therapi es will not be considered as a prior line of 
therapy ) for locally advanced or metastatic disease and is suitable to receive
gemcitabine and docetaxel  therapy .  All previous anticancer treatments must 
have co mpleted â‰¥ 3weeks ( 21days) prior to first dose of study  drug .
ï‚·In the Phase 2 part, pri or olaratumab/doxorubicin combinat ion 
therapy  in 1prior treatm ent line is allo wed.
oPrior olaratum ab therapy  must have been received with 
doxorubi cin as indicated on the olaratumab label.
oPrior olaratum ab therapy  must have included at least 2 full 
cycles of olaratum ab/doxorubicin (i.e. a minimum of 4 
doses of ol aratumab).
oPatients,who completed at least 2 cy cles of combinat ion 
olaratum ab/doxorubi cin therapy  then discont inued 
doxorubi cin due to toxicit yor maximum dosing and 
proceeded to olaratumab mo notherapy ,are eligible.
oThe m ost recent dose of olaratum ab m ust have been 
received wit hin 180 days of randomizat ionin this study.
[7]The patient has reso lution of adverse events , 
with the except ionofalopecia,
and of all clinically significant toxic effects of prior locoregional therapy, 
surgery , radi otherapy , or systemic ant icancer therapy  to â‰¤ Grade 1, by 
National Cancer Inst itute -Common Termino logy Criteria for Adverse Events 
(NCI -CTCAE) Version 4.0.
[8] Availabilit y of tumor tissue is mandatory  for study eli gibili ty.  The pati ent 
must have consented to provide archived formalin -fixed paraffin -embedded 
tumor tissue or be subject to a pre -treatm ent re -biopsy of primary  or 
metastati c tum or tissue f or future central  pathol ogy review and translat ional 
research (if archived tissue is unavailable) (refer to Section 10.4.2.2 regarding 
tissue collection parameters)
.
[9] The patient has adequate hematologic, organ ,and coagul ation function wi thin
2 weeks (14 days) prior to enrollment (Phase 1 b) or randomizat ion(Phase 2) :
I5B-MC-JGDL( c) Clinical Protocol Page 33
LY3012207ï‚·Absolute neutrophil count (ANC) â‰¥1.5 x 109/L.  Granulocy te-colony-stimulating 
factor ( G-CSF)cannot be administered within 2 weeks (14 day s) pri or to 
enrollment (Phase 1b) or randomizat ion(Phase 2) .
ï‚·Platelet coun t â‰¥100 x 10 9/L
ï‚·Hem oglobin â‰¥9.0 g/dL.  No transfusio ns are allowed within 2 weeks (14 days) 
prior to enroll ment (Phase 1b) or randomizat ion(Phase 2) .
ï‚·Serum creatinine â‰¤1.5 times upper limit of normal ( ULN ).  If creatinine is above 
the upper limit of normal ( ULN ), the pati entâ€™s creatinine clearance is â‰¥ 45 
mL/min (refer to Attachment 8 for the Cockcroft -Gaul t formulafor creatinine 
clearance ).
ï‚·Total  bilirubin below ULN (except for patients with Gilbertâ€™s Syndro me, who 
must have a total biliru bin <3 m g/dL)
ï‚·Alanine aminotransferase/aspartate aminotransferase ( ALT/ AST) â‰¤3.0Ã—ULN; if 
the liver has tumor invo lvement, AST and ALT â‰¤5.0 Ã— ULN are acceptable
ï‚·The patient has an adequa te coagul ation function as defined by Internat ional 
Norm alized Rat io(INR) â‰¤1.5 Ã—ULN or prothrombin t ime (PT) â‰¤1.5 Ã—ULN, and 
partial thromboplast in time (PTT or aPTT) â‰¤1.5 Ã—ULN if not on anticoagulant 
therapy .  For patients receiving ant icoagulants, excepti ons to these coagul ation 
param eters are allowed if they are within the intended or expected range for their 
therapeuti c use. Patients m ust have no history  of active bleeding (defined as 
within 14 days of first dose of study  drug) or pathological condit ion that carri es a 
high ri sk of  bleeding (for example, tumor invo lving major vessels or known 
esophageal varices) . 
ï‚·If routine urinalysis indicates â‰¥2+ proteinuria ,patient must have â‰¤1000 m g
protein on a 24-hour urine, or uri ne protein/creat inine ratio â‰¤ 1onspot urine .
[10] Females of child -bearing potential must have a negative serum pregnancy test 
within 7 days pri or to enrollment (Phase 1b) or randomizat ion(Phase 2) .
(a)Except ions:  Females notof child -bearing potenti al due to surgical  
sterilizat ion (at l east 6 weeks fo llowing surgical bilateral oophorectomy 
with or wi thout hy sterectomy or tubal ligat ion) confirmed by medical 
history  or m enopause.
A â€œpostmenopausal womanâ€ is a woman meet ing eit her of the fo llowing cri teria:
ï‚·spontaneous amenorrhea for at least 12 months, not induced by a medical 
condi tion such as anorexia nervosa and not taking medicat ions during the 
amenorrhea that induced the amenorrhea (for example, oral contraceptives, 
horm ones, gonadotropin releasing hormone, ant iestrogens, select ive estrogen 
receptor modulators [SERMs ], or chemotherapy )
ï‚·spontaneous amenorrhea for 6 to 12 months and a fo llicle -stimulat ing 
horm one (FSH) l evel >40 m IU/mL
I5B-MC-JGDL( c) Clinical Protocol Page 34
LY3012207[11] Females of child -bearing potential and males must agree to use highly 
effect ive contraceptive precautions during the trial and up to 3 months 
following the last dose of study  treatm ent.  A highly effect ive method of birth 
control  is defined as one that res ults in a l ow failure rate (that is, <1% per 
year) when used consistent ly and correctly , such as implants, injectables, 
combined oral contraceptives, some intrauterine contraceptive devices (IUDs), 
sexual abst inence, or a vasectomized partner.
[12] The patient has, in the opinio n of the invest igator, a life expectancy o f at least 
3months.
7.2. Exclusion Criteria
Patients will  be excluded from  the study  if they  meet anyof the fo llowing cri teria:
[13] The patient is di agno sed wi th gastrointest inal stromal tumor ( GIST )or Kaposi  
sarcoma.
[14] The patient has act ive central nervous system (CNS) or leptomeningeal 
metastasis (brain metastasis) at the time o f enrollment (Phase 1b) or 
rando mizat ion(Phase 2) .  Pati ents wi th a history  of a CNS metastasis 
previously treated with curative intent (for example, stereotactic radiat ion or 
surgery ) that have not progressed on fo llow-up imaging, have been 
asymptomat ic for at least 60 days,and are not receiving systemic 
corticosteroi ds and or/anti convulsants, are eligible.  Patients with signs or 
symptoms of neuro logical com promise shoul d have appropriate radiographic 
imaging performed before enrollment (Phase 1 b) /rando mizat ion (Phase 2) to 
rule out brain metastasis.
[15] The patient has received prior treatment with gemcitabine ordocetaxel
Note: Patients previously enrolled in the I5B-MC-JGDJ or any  other blinded 
study  with olaratum ab are not eligible to participate in this trial.
[16] The patient has hi story  of another primary malignancy , with the excepti on of
ï‚·Curatively treated non -melanomatous skin cancer or
ï‚·Curatively treated cervical carcino ma in situ or
ï‚·Non-metastatic prostate cancer ,treated only wit h observat ionor
ï‚·Other primary  nonhematologic malignancies or solid tumor streated with 
curative intent, no known active disease ,and no treatment administered 
during the last 3 y ears pri or to enrollment (Phase 1 b) or randomizat ion
(Phase 2) .
[
17]The patient has elect ively planned or will require major surgery  during the 
course of the study .
I5B-MC-JGDL( c) Clinical Protocol Page 35
LY3012207[18] The patient has a serious cardiac condit ion, such as congestive heart failure; 
New York Heart Associat ion Class III/IV heart disease; unstable angina 
pectoris, cardi ac stenting wit hin 6 months of enrollment (Phase 1b) or 
rando mizat ion(Phase 2) ; myocardial  infarct ion within the last 3 months; 
valvulopathy that is severe, moderate, or deemed clinically  significant; or 
arrhy thmias that are symptomatic or r equire treatment.
[
19]Females who are pregnant or breastfeeding .
[20]The patient is enrolled in, or discont inued study  treatm ent from another tri al 
involving an invest igational agent or use of non -approved drug or device 
within 28 days of being enrolled (Phase 1 b) or randomized (Phase 2) in this 
trial, or concurrent enroll ment in any  other ty pe of medical research judged 
scientifically or medically inco mpatible wit h this tri al.  Pati ents parti cipat ing 
in surveys or observat ional studi es are eligible to participate in this study .
[21] The patient has aknown activ e fungal, bacterial, or viral infect ion including 
human immunodeficiency virus (HIV) or vi ral (A, B, or C) hepatit is 
(screening is not required).
[22] The patient has Grade 3 or 4 peripheral neuropathy by NCI -CTC AE 
Versi on4.0.
[23] The patient h as a history  of Grade 3 or 4 infusio n
-related reacti on (IRR) to 
olaratum abor discont inued olaratumab due to other significant toxicit y.
7.2.1. Rationale for Exclusion of Certain Study Candidates
The exclusio n criteria have been carefully  selected by  the Sponsor to ensure their ethical and 
scientific acceptabilit y, and to help establish specificit y of the pati ent popul ation for both 
efficacy  and safety  analyses.
7.3. Discontinuation
The reason for discontinuat ion and the date of di scontinuat ion will be collected for all patients.  
All enrolled (Phase 1b) and rando mized (Phase 2) patients who discont inue, regardless of 
whether or not they  received study  treatm ent, will have procedures performed as shown in the 
Study  Schedule ( Attachment 1 ).
Patients who are di scont inued fro m the study  treatment early will have fo llow-up procedures 
perform ed as shown in the Study  Schedule ( Attachment 1 )
.
If a patient withdraws informed consent, he or she must not be contacted unless he or she has 
explicit lyprovide dpermissio n and consent.  Lilly may cont inue to use previously co llected 
medical research data prior to the withdrawal consistent with the original authorizat ion.
7.3.1. Discontinuation of Inadvertently Enrolled Patients
The cri teria for enro llment must be fo llowed explici tly. If the invest igator site ident ifies a patient 
who did not meet enrollment criteria and who was inadvertent ly enro lled, the Sponsor must be 
notified.   If the Sponsor i dentifies a patient who did not meet enrollment crite ria and who was 
I5B-MC-JGDL( c) Clinical Protocol Page 36
LY3012207inadvertent ly enro lled, the invest igator site will be notified .  A discussio n must occur between 
the Sponsor clinical research physician ( CRP )/clinical research scient ist (CRS) and the 
investigator to determine whether the patient may conti nue in the study , with or wi thout 
investigat ional product ( IP).  Inadvertent ly enro lled patients may be maintained in the study  and 
on study  treatm entwhen the Lilly CRP /CRS agrees with the invest igator that it is medically 
appropriate f or that patient. The patient may  not continue in the study  with or wi thout study 
treatm entif the Lilly CRP /CRS does not agree with the investigatorâ€™s determination it is 
medically appropriate for the patient to continue.
The patient may  continue to receive study  drugs if allof the f ollowing condi tions are m et:
ï‚·In the opinion o f the invest igator, the patient is receiving benefit .
ï‚·The Lilly CRP /CRS and the invest igator determine that no effect ive alternat ive therapy 
exists .
ï‚·The Lilly CRP/CRS and the invest igator agree there is no safety concern merit ing 
discontinuat ion of study  drugs .
The invest igator must obtain documented approval fro m the Lilly CRP /CRS to allow the 
inadv ertent ly enro lled pat ient to conti nue in the study  with or wi thout study  treatm ent.
7.3.2. Discontinuation of Patients
In addition, pati ents will  be discont inued from the study  drug and/or from the study  in the
following circumstances:
ï‚·enrollment in any other clinical trial invo lving an investigational product or enrollment in 
any other ty pe of medical research judged not to be scient ifically or medically co mpat ible 
with this study
ï‚·investig ator/phy sician or Sponsor decisio n
othe invest igator or Lilly stops the study or stops the patientâ€™s participat ion in the 
study  for m edical, safet y, regul atory , or other reasons consistent with applicable 
laws, regulations, and good clinical practice
othe invest igator decides that the patient should be discontinued fro m study  
treatm ent or fro m the study
othe pati ent, f or any  reason, requi res treatm ent wi th another therapeuti c agent that 
has been demonstrated to be effect ive for treatm ent of the study  indicat ion, 
discontinuat ion from the study  drugs occurs pri or to introducti on of  the new agent
ï‚·patient deci sion
othe pati ent or the pati entâ€™s designee (for example, parents or legal guardian) 
requests that the patient be withdrawn fro m the study  drug or study
ï‚·evidence of progressive disease (Attachm ent 5 )
ï‚·unacceptable toxicit y
ï‚·pregnancy
I5B-MC-JGDL( c) Clinical Protocol Page 37
LY3012207ï‚·significant nonco mpliance with study  procedures and/or treatment
The discont inuation reason and date will be collected for all pat ients.  The date of 
discontinuat ion (for any  of the above reasons) from study  treatm ent is to be reported on the case 
report form (CRF).  Patients who discont inue will have fo llow-up procedur es performed as 
shown in the Study  Schedule (Attachment 1 ).
7.3.3. Patients who are Lost to Follow -Up
A pat ient willbe considered lost to fo llow-up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  the study  site.  Site personnel are expected to make 
diligent attempts to contact patients (for exam ple, by  phone calls, cert ified letters, etc.) who fail 
to return for a scheduled visit or who the site is otherwise unable to follow.
Site personnel , or an independent third party ,will attempt to collect the vital status (that i s, alive 
or dead) for all enrolled (Phase 1b) or randomized (Phase 2) patients who are lost to fo llow-up, 
including enrolled or randomized pati
ents who do not receive study  treatm ent, within legal and 
ethical boundaries .  Site personnel , or an independent third party ,may search public sources for 
vital status inform ation.If the pati ent's vi tal status is determined, the vital status will be 
docum ented and the pati ent will not be considered lost to follow -up.
Lilly personnel will not be invo lved in any attempts to collect vital status informat ion.
7.3.4. Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly , the invest igator, or the ethical review board 
(ERB) or institutional review board (IRB) of the study  site judges discont inuat ion of study  site 
participat ion necessary  for m edical, safet y, regul atory , ethi cal, or other reasons consistent with 
applicable laws, regulat ions, and good clinical practices ( GCP ).
7.3.5. Discontinuation of the Study
The study  will be di scontinued if Lilly judges discontinuat ion of the study  necessary for medical, 
safet y, regul atory , ethi cal, or other reasons consistent with applicable laws, regulat ions, and 
GCP.   Prior to discont inuat ion, the ERB or IRB (which approve d the tri al) will be notified 
according to local regulation.
I5B-MC-JGDL( c) Clinical Protocol Page 38
LY30122078.Investigational Plan
8.1. Summary of Study Design
Study  I5B-MC-JGDL is a mult icenter Phase 1b /2 study  ofolaratum ab in co mbinat ion with 
gemcitabine and docetaxel  in pat ients with locally advanced or metastatic STS, not amenable to 
treatm ent wi th surgical  resecti on or ra diotherapy  with curative intent.   The first part (Phase 1b) 
of the study  will consist of a n open -label, single -arm, dose -escalat ion assessment of the safet y 
and tol erabilit y of olaratumab administered at 15mg/kg(Days1 and 8) or20mg/kg(Day s1 and 
8) withgemci tabine (900 mg/m2[fixed dose rate :  10 m g/m2/minute] , Days 1and 8 ) and 
docetaxel ( 75 mg/ m2, Day8),ona 21-day cycle (Figure JGDL .1).  After the dose of olaratumab 
in combinat ion with gem citabine and docetaxel  has been determined from the analysis o f the 
Phase 1b part, the Phase 2, randomized, double -blinded , placebo -controlled part of the study  will 
open to enrollment.  Patients will be rando mized in a 1:1 ratio in a double -blinded manner to 
Arm A (ol aratum ab plus gemcitabine and docetaxel) or Arm B (placebo plus gemcitabine and 
docetaxel).  
 Figure JGDL .1illustrates the study  design.
Patients will  cont inue treatment until there is documented disease progression, unacceptable 
toxicity, death, or other discont inuat ion criteria are met.
I5B-MC-JGDL( c) Clinical Protocol Page 39
LY3012207Abbreviations: D = Day 1; IV = intravenous; n= number of patients .
*  Based on the outcome of the Phase 1b part, the dose selected for the Phase 2 part of 
JGDL will be either 15 mg/kg or20 mg/kg . Depending on the sa fety and 
pharmacokinetic profile of these dose levels, it is possible that an intermediate dosing 
regimen of 2loading doses of 20 mg/kg during Cycle 1followed by 15 mg/kg in every 
subsequent cycle could be utilized in Phase 2 , as is being studied in the Phase 3 Study 
JGDJ.
Figure JGDL .1. Illustration of study design.
8.1.1. Phase 1b Dose Escalation
The Phase 1b part is a single -arm dose escalat ion to determine the recommended dose of 
olaratum ab for the Phase 2 part that may be safely administered in combinat ion with gemci tabine 
(900 m g/m2) and docetaxel  (75 m g/m2) inpatients wi th locally advanced or metastati c STS .  This 
dose escalat ion has a starting o laratumab dose of 15 mg/kg and the highest olaratumab dose of 
20mg/kg. No intrapatient dose escalat ion is permitted. Patients in any cohort who do not 
complete Cycle 1 treatm ent for reasons other than a DLT will be replaced.
The DLT assessment will be performed as outlined in Sect ion 9.4.1.1 .The safet ydata for the 
cohort will be reviewed prior to dose escalat ionor dose determinat ion for Phase 2
.  The total  
number of patients with DLTs, the ty pe of DLTs ,and relevant PK information will be considered 
prior to m aking a decisio n.  At the time of analysis of safet y data for Phase 1b ,if review of the 

I5B-MC-JGDL( c) Clinical Protocol Page 40
LY3012207data determines that G -CSF use is required with this combinat ion,then this requi rement will be 
implemented in the Phase 2 part.
15 mg/kg Olaratumab Dose Level (Cohort 1)
Approximately  15 pati ents will be treated with olaratumab at 15 mg/kg, in co mbinat ion with 
gemcitabine and docetaxel , in the fi rst cohort.
Of the DLT -evaluable pat ients in the 15- mg/kg cohort, if one -third or more patients wi th DLTs 
are observed, no further dose escalat ion of o laratumab will occur.  If review of safet y data 
indicates that DLTs of prolonged neutropenia and/or febrileneutropeni a occurred that might be 
prevented by  more extensive prophylact ic use of G -CSF, then addit ional pat ients may be added 
to this cohort to determine if such G -CSF use would pro vide an overall DLT rate acceptable for 
Phase 2 study , after di scussio n with study  investigators.  Otherwise, if the DLT criteria are met 
or exceeded despite these measures, then the Phase 2 part of the study  will not open.
20 mg/kg Olaratumab Dose Level (Cohort 2)
Of the DLT -evaluable pat ients in the 15- mg/kg cohort, i f fewerthan one-thirdof patients wi th
DLT sare observed ,a new cohort with approximately 15 patients will be treated with olaratumab 
at 20 mg/kg in co mbinat ion with gemci tabine and docetaxe l, using the same DLT criteria 
described above for the 15-mg/kg olaratumab dose level.
If the DLT criteria are met or exceeded for the olaratumab 20 -mg/kg dose level, and review of 
safet y data indicates that DLTs of prolonged neutropenia and/or fever neutropeni a occurred that 
might be prevented by  more extensive prophylact ic use of G -CSF, then addit ional pat ients may 
be added to this cohort to determine if such G -CSF use woul d provi de an overall DLT rate 
acceptable for Phase 2, after discussio n with study investi gators.  A PK analysis of the 15
-mg/kg 
and 20 -mg/kg olaratumab dose level swill also be performed to determine if the serum  levels 
observed in this study  are consistent wi th those previously associated with a posi tive benefit/risk
in the STS pat ient populat ion.
Of the DLT -evaluable pat ients in the 20- mg/kg cohort, i f fewerthan one-thirdof patients wi th
DLTs are observed, then the 20 -mg/kg dose level may be chosen for Phase 2 study.
Patients in each cohort will cont inue treatment until there is docum ented disease progression, 
unacceptable toxicit y, death, or other discont inuat ion criteria are met.
Expansion of the20 mg/kg Olaratumab Dose Level (Cohort 2)
The 15-mg/kg olaratumab dose level (Cohort 1) safet y review has been co mpleted with 19 DLT -
evaluable pat ients (Cy cle 1).  There were no DLTs observed in Cohort 1.  Based on the safet y 
review of Cohort 1
, escalat ion to the 20-mg/kg olaratum ab dose level (Cohort 2) was 
implemented.
Inthe 18 DLT -evaluable pat ients enro lled in Cohort 2 ,DLTs were observed in 3patients (Grade 
3 febrile neutropenia in 2 pat ients
,one of who m hadbacteremia ,and a Grade 3 elevation o f 
I5B-MC-JGDL( c) Clinical Protocol Page 41
LY3012207hepat ic transaminases in 1patient).  Two patient deaths were observed in Cohort 2 , one onCycle 
2 Day 9 (patient died in his sleep) and one on Cy cle 3 Day 5 (chest pain and cardiac arrest).  The 
first pati ent had a history  of hypertensio n and prior MI, and the sec ond pati ent had a history  of 
coronary artery  bypass graft surgery , cardi ac stent placement, and peri pheral  vascular disease; 
both deaths were deemed unrelated to study  treatment by  their investi gators. PK analysis o f 
Cohort 2 patients indica ted that t he olaratum ab C maxand AUC of the DLT pati ents were similar 
to other patients in the cohort .  The 2 patients who had died in Cohort 2 had olaratumab C maxand 
AUC very  close to the median of Cohort 2 , and their values overlapped wit h some patients from 
Cohort 1 .  Altogether ,these clinical and PK findings indicated it was unlikely that the 2 deaths in 
Cohort 2 were due to an olaratumab -related factor. Although the DLT rule was not exceeded in 
Cohort 2 (3 out of 18 patients), after discussio n with study  invest igators ,it was decided that it 
was reasonable to further confirm pat ient safet y at the 20 -mg/kg dose level prior to ini tiation of 
the Phase 2 portion of the study  by enrolling approximately 15 additional patients to Cohort 2.
8.1.2. Phase 2
After the dose of olaratumab in co mbination wit h gemcitabine and docetaxel has been 
determined fro m the Phase 1b part, the Phase 2 randomized, double -blinded partof the study  will 
open t o enrollment.  In the Phase 2 part, approximately 256patients will  be randomized 1:1 to 
receive eit her olaratum abplus gemci tabine and docetaxel (A
rm A) or pl acebo pl us gemci tabine 
and docetaxel (Arm  B).  Out of the 256 patients, 166 will be olaratumab na Ã¯ve and 90 will be 
olaratum ab pretreated patients.  Randomizat ion will  be stratified by prior treatm ent wi th 
olaratumab (y es versus no), number of prior sy stemic therapies for locally advanced or 
metastati c disease (0 versus â‰¥1), histol ogical  tumor type (leiomyosarcoma versus non -
leiomyosarcom a),ECOG perform ance status ( PS)(0 versus 1) ,and prior pelvic radiat ion (yes 
versus no).
Patients will  cont inue treatment until there is documented disease progression, unacceptable 
toxicity, death, or other discon tinuation criteria are met.
8.1.3. Definitions of Study Periods
Terms used to describe the periods during the study are defined below:
ï‚·Baseline:   begins when the ICF is signed and ends at the first study treatment (or at 
discontinuat ion, if no treatm ent is given) .
ï‚·Study Period:   begins at the first study treatment and ends at study  com pletion.The 
study  period 
does not i nclude the continued access period .
oTheunblinded Phase1b partwill be co mpleted prior to opening the Phase 2 partof 
the study  to randomizat ion.  Continuat ion of the study  into Phase 2 will be 
dependent on data from the Phase 1 b part.
oStudy Treatment Period :  begins at the first study treatment and ends when the 
patient and the investigator agree that the patient will n o longer continue study  
treatm ent.  The date of this agreement is to be reported on the CRF as the Date of 
Discontinuati on from study  treatm ent.
I5B-MC-JGDL( c) Clinical Protocol Page 42
LY3012207oPostdiscontinuation Follow -Up:  begins the day  after the pati ent and the 
investigator agree that the patient wi ll no longer cont inue study  treatm ent.
ï‚§Short -term follow -upbegins the day after the pati ent and the invest igator 
agree that the patient will no longer continue study treatment and lasts 
approximately  30 days (Â±7days).   The short -term follow -up visit occurs at or 
near the end of the short -term follow-up peri od (Â± 7days).
ï‚§Long -term follow -upbegins theday after short -term follow-up is completed 
and cont inues unt il the patientâ€™s death ,or un til the patient is lost to fo llow-up
or overal l study  com pletion.
ïƒ˜Follow -up for progression -Patients that discont inue study  
treatm ent for reasons other than progression will be assessed for 
progression every  6weeks (Â±7 day s) until progressive disease 
(PD).
ïƒ˜Follow -up for survival -Patients will be followed every 
3months (Â±7 day s) for the fi rst year, then every  6 months (Â±14 
days) unt il the patientâ€™s death or overall study complet ion.
ï‚·Continued Access Period:   Phase 1b and Phase 2 continued access period begins after 
completion of the Phase 1b and Phase 2 parts,respectively ,and ends at the end of trial .  
During the continued access period,patients on study  treatm ent who con tinue to 
experience clinical benefit and no undue risks may conti nue to receive study  treatm ent 
until one of the cri teria for discont inuat ion is met.  The continued access period includes 
continued access follow-up.
oContinued access follow -up:  begins theday after the pati ent and the invest igator 
agree that the patient will no longer continue treatment in the continued access 
period and l asts approximately 30 days (Â±7days).  The continued access
follow-up visit occurs at or near the end of the continued access fo llow-up peri od.
8.1.4. Baseline and Study Treatment Period Assessments
Baseline radiographic assessment of disease will be performed within 28 days prior to 
enrollment in Phase 1b and randomizat ion in Phase 2 ; scans performed prior to the date of 
consent may be used provided they are within 28 days of rando mizat ion.
Imaging and tum or assessment will be performed every  6weeks (Â±7 day s), irrespect ive of 
treatm ent cycles, as calculated from enro llment (Phase 1 b) or randomizat ion (Phas e 2).  Im aging 
requi rements include computed tom ography  (CT)scan or magnet ic resonance imaging (MRI) of 
chest, abdomen, and pelvis .  Other areas may be scanned , when clinically indicated.  Digital 
images are to be sent to a third -party  organi zation for st orage.  It i s recommended that CT 
imaging of the abdo men/pelvis be performed with intravenous (IV)contrast, whenever possible.  
If this is not feasible/advisable secondary to hy persensi tivity or other condit ions, then 
gadolinium -enhanced MRI is preferred.  For patients with known serious allergic reactions to CT 
contrast m aterial , a CT of  the chest wi thout contrast and contrast -enhanced MRI of the 
abdo men/pelvis are encouraged.
I5B-MC-JGDL( c) Clinical Protocol Page 43
LY3012207The patientâ€™s first treatment will be administered within 72 hours (3 day s) following enro llment 
(Phase 1b) or randomizat ion (Phase 2), whenever possible (up to 3 add itional days â€™delay  of first 
dose of treatment will be permitted due to holidays, weekends, bad weather, or other unforeseen 
circumstances and will not cou nt as a protocol deviat ion).
Patients in both arms will receive any necessary  prem edicati on if needed (see Sect ion 9.1.1 ) prior 
to the infusio n of study  therapy  at each treatm ent cycle.
A treatment cy cle will  be defined as 3 weeks (21 da ys Â± 3 day s).  The start of study  treatm ent 
will be considered Cycle 1 Day  1.
Phase 1b :
ï‚·Olaratum ab (15 or 20 m g/kg IV infusio n) on Days 1 and 8 of every  3-week cycle over 
60minutes, fo llowed by  a 1-hour observat ion period for the first 2 cycles.If there is no 
evidence of an infusio n-related reacti on (IRR) after the D ay1 and D ay8 infusi ons of 
olaratum ab in the first 2 cy cles, no observation period is required for subsequent 
treatm ent cycles.   In the event that a Grade 1 or 2 IRR occurs after Cycle 2, the 1 -hour 
observat ion peri od will  be reinst ituted for a minimum of 2 cy cles.  The reinst ituted 
observat ion peri od m ay be suspended after 2 cy cles if the pat ient shows no further signs 
or symptoms of an IRR .
ï‚·Gemci tabine (900 m g/m2, IV infusi on) onDays 1 and 8 over 90 minutes (fixed -dose rate 
of 10mg/m2/minute ), after olaratumab infusio n
ï‚·Docetaxel (75 mg/m2IV infusio n) onDay 8over 60 minutes, after gemcitabine
Phase 2 :
Patients in the invest igational Arm A will receive:
ï‚·Olaratum ab on Days 1 and 8 of every 21 -day cycle over 60 minutes, fo llowed by  a 1-
hour observation period for the first 2 cycles. If there is no evidence o f an IRR after 
the Day1 and D ay8 infusi ons in the first 2 cycles, no observat ion peri od is requi red 
for subsequent treatm ent cy cles.  In the event that a Grade 1 or 2 IRR occurs after 
Cycle 2, the 1 -hour observat ion peri od will be reinstituted for a minimum o f 2 cycles.  
The reinst ituted observat ion peri od may  be suspended after 2 cycles if the patient 
shows no fu rther si gns or symptom s of an IRR .  The dose of olaratumab will be 
determined fro m the Phase 1b part of the study .  Depending on the safet y and PK 
profile of the Phase 1b dose levels, it is possible that an intermediate dosing regimen 
of 2 loading doses of 20mg/kg during Cycle 1 fo llowed by  15mg/kg in every 
subsequent cy cle coul d be ut ilized in Phase 2, as is being studied in the Phase 3 Study 
JGDJ.
ï‚·Gem citabine (900 m g/m2, IV infusi on) on Days 1 and 8 over 90 minutes (fixed -dose 
rate of 10 mg/m2/minute ), after olaratumab infusio n
ï‚·Docetaxel (75 mg/m2IV infusio n) on Day  8 over 60 minutes, after gemcitabine
I5B-MC-JGDL( c) Clinical Protocol Page 44
LY3012207Patients in the control Arm B will receive:
ï‚·Placebo (IV infusio n) on Days 1 and 8 of every 21 -day cycle over 60 minutes, 
followed by a 1- hour observation period for the first 2 cycles. If there is no evidence 
of an IRR after the D ay1 and D ay8 infusi ons in the first 2 cycles, no observat ion 
period is requi red for subsequent treatment cy
cles.  In the event that a Grade 1 or 2 
IRR occurs after C ycle 2, the 1 -hour observat ion peri od will be reinst ituted for a 
minimum o f 2 cycles.  The reinst ituted observat ion peri od m ay be suspended after 2 
cycles if the pati ent shows no further signs or symptoms of an IRR.
ï‚·Gem citabine (900 m g/m2, IV infusi on) on Days 1 and 8 over 90 minutes ( fixed -dose 
rate of 10 mg/m2/minute ), after olaratumab infusio n
ï‚·Docetaxel (75 mg/m2IV infusio n) on Day  8 over 60 minutes, after gemcitabine
Phase 1b and 2
Administrati on and dosing of all therapeut ic products will occur as described in Section 9.1.
Criteria for starting the next cy cle are defined in Section 9.4.1.2 .  Dose reductions for 
olaratum ab/placebo will be made in the event of specific treatment -related AEs, as described in 
Secti on9.4.1.2.2 .  Supportive care guidelines are detailed in Sect ion9.6.1 .
Patients will  be treated until there is documented radio logical PD, toxi city requi ring cessat ion of 
treatm ent, wi thdrawal  of consent, or until other withdrawal criteria are met.  In the event there is 
symptom atic deterioration result ing in treatment discontinuation, radiog raphic confirmat ion 
shoul d be perform ed.  For patients who discont inue treatment for any  reason other than 
radiographically  docum ented PD (for exam ple, symptom atic deterioration), radiographic 
assessments should cont inue as scheduled every 6 weeks (Â±7 days) as cal culated from  
rando mizat ion unt il objective radiographic evidence of PD.
8.1.5. Postdiscontinuation Follow -Up Period Assessments
Postdiscontinuati on short -term and l ong-term follow -up assessments will be conducted as 
described in the Study  Sched ule (Attachment 1 ).Adverse event (AE) informat ion will be 
collected until at least 30 days after the last dose of study  treatm ent.  Aft er the 30 -day short -term 
follow-up visit, only  new and ongoing SAEs deemed related to study treatment will be co llected.
Long -term follow-up will cont inue as lo ng as the patient is alive, and has not wi thdrawn to
follow-up, or the study  has not completed as defined in Section 8.1.6 .
For pati ents who discont inue study  treatm ent for any  reason wi thout obj ectively measured PD, 
imaging studies and tumor assessments are obtained every  6 weeks (Â±7 days), i rrespect ive of 
treatm ent cycles as calculated from rando mization, until documented progression.
For pati ents that discont inue study  treatm ent after obj ectively measured PD, the fo llowing 
inform ation will be co llected every 3months (Â±7 days) for the first y ear, then every  6 months 
(Â±14 day s) unt il the patientâ€™s death, or overall study co mpletion:
I5B-MC-JGDL( c) Clinical Protocol Page 45
LY30122071.details on all subsequent ant icancer treatment (start/stop dates and treatm ents administered)
2.first post -study treatment disease progression date
3.survival status
8.1.6. Study Completion and End of Trial
Phase 1b
The Phase 1b partof the study  will be considered complete following determinat ion of the 
recommended Phase 2 dose of olaratumab that may be safely  administered in combinat ion with 
gemcitabine plus docetaxel  
to patients with locally advanced or metastatic STS (Figure JGDL .2).
Phase 2
This study  will be considered com plete (that i s, the sci entific evaluation will be co mplete [study
completion]) fo llowing final analysis o fthe OS endpoint ( atleast 108OS ev ents in the 
olaratum ab-naÃ¯ve cohort )hasbeen performed and evaluated, as determined by Lilly
(Figure JGDL. 3).  Invest igators will continue to follow the study schedule for all patients until 
notified by Lilly that study  com pletion has occurred .
â€œEnd of trialâ€ refers to the da te of the l ast visi t or last scheduled proce dure for the last patient.
Upon study  com pletion, invest igators and patients may be unblinded to study treatment 
assignment for the Phase 2 part.  Patients receiving study  treatm entand experiencing ongo ing 
clinical benefit and no undue risks may cont inue to receive the study  treatment in the continued 
access period.  The continued access period begins after study  com pletion and will cont inue unt il 
the end of trial.
The end o f trial occurs after study  com pletion and after the last patient has discont inued study  
treatm ent and com pleted any applicable continued access follow
-up.
I5B-MC-JGDL( c) Clinical Protocol Page 46
LY3012207Figure JGDL .2. Phase 1b: Study period and continued access diagram .End of Trial for Patients 
on Phase 1b portionStudy 
CompletionPatients on 
Treatment
Patient on Study Treatment
Study PeriodContinued 
Access PeriodaPatient on 
Study 
Treatment
aLilly will notify sites when this begins and ends.  Short -Term 
Follow -Up Long -Term 
Follow -UpPatient 
Discontinues 
Study 
Treatment
Continued 
Access 
Period 
Follow -Up
Final Analysis for Phase 2 dose 
recommendation completeLast visit/
scheduled 
procedure for 
last patientPhase 1b
Patient 
Discontinues 
Study 
Treatment
I5B-MC-JGDL( c) Clinical Protocol Page 47
LY3012207Abbreviations:  iDMC = independent Data Monitoring Committee; OS = overall 
survival; PK = pharmacokinetic.
The iDMC safety reviews will occur when approximately 60 patients (approximately 
30patients from each arm) have received at least 2 cycles of treatment or discontinued 
all study  treatment due to any reasons prior to Day 8 in Cy cle 2.  An interim PK 
analy s
is will accompany  the iDMC safety review .  Subsequent iDMC meetings will 
occur app roximately  every  6 months thereafter until approximately 1year after 
completing enrollment .
Figure JGDL. 3. Phase 2: Study period and continued access diagram.
8.1.7. Continued Access Period
Lilly will notify invest igators when the continued access period begins and ends .
The continued access period will apply  to this study  only if at least 1 pati ent is still on study  
treatm entwhen study co mpletion occurs.
After study  com pletion, all pat ients who are on study  treatm entand who are eligible for 
continued access will be unblinded.  Patients receiving study  treatm entand experie ncing ongo ing 
clinical benefit and no undue risks may cont inue to receive study treatm entin the continued End of Trial for 
Phase 2Study 
CompletionPatients 
on 
Treatment
Patient on Study Treatment
Study Period Continued 
Access PeriodaPatient on 
Study 
Treatment
aLilly will notify sites when this begins and ends.  Short -Term 
Follow -Up Long -Term 
Follow -UpPatient 
Discontinues 
Study 
Treatment
Continued 
Accesss 
Follow -Up
Primary 
Analysis of OSLast visit/
scheduled 
procedure for 
last patientPhase 2
Patient 
Discontinues 
Study 
Treatment
I5B-MC-JGDL( c) Clinical Protocol Page 48
LY3012207access period until one of the cri teria for di scont inuation is met (Section 7.3).  During the 
continued access period, placebo will no longer be administered, and crossover will not be 
permitted.
During the continued access period, co ncom itant medicat ion,AEs, SAEs, and study  treatm ent
dosing will be reported on the CRF.  Serious adverse events will also be reported to Lilly  Global 
Patient Safet y (see Section 10.3.1 ) .  In the event that an SAE occurs, Lilly may request addit ional 
inform ation (such as local laboratory  resul ts, concomi tant m edicati ons, and hospitalizat ions) in 
order to evaluate the reporte d SAE. Blood sam ples f or PK and immunogenicit y analysis will be 
collected inthe event of an infusio n-related reacti on (IRR).
Invest igators will perform any other standard procedures and tests needed to treat and evaluate 
patients; however, the choice and timing of the tests will be at the investigatorâ€™s discret ion.Lilly
will not routinely co llect the results of these assessments.
Patients who are in short -term follow-up when the continued access period begins will cont inue 
in short -term follow-up unt il the 30 -day short -term fo llow-up visit is co mpleted.  Long -term 
follow-up does not apply.
Patients who are in long -term follow-up when the continued access period begins will be 
discontinued fro m long-term follow-up.
8.1.8. Committees
The following committees will be established to evaluate patientsâ€™ safety and/orefficac y of th e 
study  treatm ent.  There will be charters for these committees to fo llow.
Independent Data Monitoring Committee ( iDMC)
Phase 2 :
For the Phase 2 part, the independent Data Monitoring C ommittee (iDMC) will beestablished to 
conduct interim safet y analyses as specified in Section 12.2.14 and will fo llow an approved 
iDMC charter .  The iDMC may init iate a consultatio n with an appropri ate expert (if addit ional 
expert ise is needed regarding evaluat ion of any  safety  signals ).  The iDMC will communicate 
back to Lilly Senior Management Designee about their assessment .
The i DMC will also review adverse events of special interest (AESI s
)for olaratum ab, including
IRRs .
The first iDMC meet ing to review Phase 2 interim safet y data will occur when approximately  
60patients (approximately  30patients from each arm ) have received 2 cy cles of treatm entor 
discontinued all study  treatm ent due to any  reasons pri or to Day 8 in Cycle 2.  Subsequent iDMC 
meet ings will occur approximately  every 6 months there after.  Enrollment and treatment will 
continue during the iDMC safet y assessments.  In the event a safety  signal  is detected, addit ional 
meet ings may occur as needed. See Section 12.2.14 for addi tional details.
Addit ionally , the i DMC will perform  the interim efficacy  analysis according to specificat ions in 
iDMC charter and study  statist ical analysis plan .
I5B-MC-JGDL( c) Clinical Protocol Page 49
LY3012207Independent Review Committee (IRC)
Phase 2 :
An Independent Review C ommit tee m ay review the CT scans and MRI scans for tumor 
assessments from selected patients if necessary (for exam ple,based on inquiries fromregul atory
authori ties).   
8.1.9. Study Duration
From  first pati ent visi tin the Phase 1b part to last pati ent visi tin the Phase 2 part, the estimated 
study  durati on is 47 months.
8.2. Discussion of Design and Control
For the P hase 1b dose-escalation study , a nonrandomized, uncontrolled design is being used to 
ident ify the recommended dose of olaratum ab to be used in the Phase 2 part.
For the Phase 2 part, arandomized, controlled design is being used.  Randomization minimizes 
system atic bias in the select ion and assignment of patients to study  treatm ent and provides 
justificat ion for inferential statist ical methods to be used on data from this study .  Using a n 
appropriate concurrent con trol arm enables di rect stati stical estimat ion of benefits and harms due 
to study  treatm ent and minimizes bias in the assessment and interpretation of observed treatment 
effects. Patients will be stratified for differences in factors thought to be associated with clinical 
outcom es to further reduce the potential for bias and improve the power of the analyses
(Secti on9.3).  Assessment of bias is further minimized by the use o f a doubl e blind and placebo 
control .
Invest igational treatment administration in the Phase 2 partof this study  is doubl e -blind; that is, 
patients, invest igational sites, and the Sponsor s tudy team  do not have immediate access to 
treatm ent assi gnments for any  patients.  This design feature minimizes potential bias due to 
knowl edge of pat ientâ€™s treatment during evaluat ion of study  endpoints, at the patient level or 
aggregated across patients .
I5B-MC-JGDL( c) Clinical Protocol Page 50
LY30122079.Treatment
9.1. Treatments Administered
The fo llowing treatm ents will  be administered in this study  every  3-week (21 -day) Â± 3 day  cycle:
Phase 1b:
ï‚·Olaratum ab (15 or 20 m g/kg intravenous [ IV]infusion over 60 minutes on Days 1 and 8) 
plus gemcitabine (900 mg/m2, IV infusio nover 90 minutes [fixed -dose rate of 
10mg/m2/minute] on Days 1 and 8 )plus docetaxel ( 75 mg/m2IV infusio nover 
60minutes on Day  8)
Phase 2:
ï‚·Invest igational Arm A: Olaratum ab (15 or 20 m g/kg IV infusio nover 60 minutes on 
Days 1 and 8) plus gemcitabine (900 mg/m2, IV infusio n over 90 minutes [fixed -dose 
rate: 10 m g/m2/minute]on Day s 1 and 8) pl us docetaxel  (75mg/m2IV infusio n, over 
60minutes on Day  8)
ï‚·Control Arm B:  Placebo (equivalent vo lume IV infusio n over 60 minutes on Day s1 and 
8) plus gemcitabine (900 mg/m2, IV infusio n over 90 minutes on Days 1 and 8) plus 
docetaxel ( 75mg/m2 IV infusio nover 60 minutes on Day  8)
Patients will  cont inue to receive study  treatm ent unt il there is documented disease progression, 
unacceptable toxicit y, death, or other dis continuat ion criteria are met.
Table JGDL .1shows the treatment regimens.
I5B-MC-JGDL( c) Clinical Protocol Page 51
LY3012207Table JGDL .1. Treatment Regimens/Dosing Schedule
Study Drug Dose Route DayInfusion 
Duration (Â± 5 
minutes)Phase 1b
15 mg/kg 
Cohort Olaratumaba15 mg/kg IV Days1 and 8over 60 minutes
1-hour ( +5 minutes) 
observation periodb initial 2 cycles
Gemcitabinec900 mg/m2Days1 and 8 over 90 minutes
Docetaxeld75mg/m2Day 8 over 60 minutes20 mg/kg 
Cohort Olaratumaba20 mg/kg IV Days1 and 8 over 60 minutes
1-hour ( +5 minutes) 
observation periodb initial 2 cycles
Gemcitabinec900 mg/m2Days1 and 8 over 90 minutes
Docetaxeld75mg/m2Day 8 over 60 minutesPhase 2
Arm AOlaratumabaDose determined 
by the analysis in 
Phase 1b IV Days1 and 8over 60 minutes
1-hour ( +5 minutes) 
observation periodb initial 2 cycles
Gemcitabinec900 mg/m2Days1 and 8 over 90 minutes
Docetaxeld75mg/m2Day 8 over 60 minutesArm BPlaceboaequivalent volume IV Days1 and 8 over 60 minutes
1-hour ( +5 minutes) 
observation periodb initial 2 cycles
Gemcitabinec900 mg/m2 Days1 and 8 over 90 minutes
Docetaxeld75mg/m2Day 8 over 60 minutes
Abbreviations:  C1 = Cycle 1; eCRF = electronic case report form; IRR = infusion -related reaction; 
IV=intravenous; PO = orally.
aAdminister olaratumab as an infusion over 60 minutes (Â± 5 minutes) , not to exceed 25 mg/min . Note exceptions 
when the infusion times of olaratumab are longer than 60 minutes (Sec tion9.4.1.2.2.1 ). Premedicate all patients 
with the following medications (or equivalent) intravenously : a histamine H1 antagonist ( for example , 
diphenhydramine) and dexamethasone 30 to 60 minutes prior to the olaratumab doses on Days 1 and 8 of Cycle 
1.  For subsequent cycles, premedicate all patients with a histamine H1 antagonist ( for example , 
diphenhydramine) intrave nously  30to 60 minutes prior to each dose of olaratumab.  See also Section
 9.2.1 for 
more details.   Additional premedication may be provided at th e investigatorâ€™s discretion.  Premedication must be
provided in the setting of a prior Grade 1-2 olaratumab/placebo IRR, as detailed in Section 9.4.1.2.2.1 .  All 
premedication administered must be adequately documented in the eCRF.
I5B-MC-JGDL( c) Clinical Protocol Page 52
LY3012207Treatment Regimens/Dosing Schedule (concluded)
bA 1-hour ( +5 minutes) Observation Period is required after the administration of olaratumab/placebo during the 
initial 2 cycles.  Whenthe Observation Period is applicable , collect vital signs 4times:  1) within 15 minutes 
(Â±5minutes) prior to olaratumab/placebo infusion, 2) within 1 hour ( +5 minutes) after completion of the 
olaratumab/placebo infusion, 3) wit hin 1 hour (+ 5 minutes) after completion of the gemcitabine infusion, and 
4)within 1 hour ( +5 minutes) after completion of the docetaxel infusion.  If there is no evidence of an infusion -
related reaction during the initial 2 cycles of olaratumab/placebo, then no observation period is required for 
subsequent treatment cycles.  In the event that a Grade 1 or 2 IRR occurs after Cycle 2, the 1 -hour observation 
period will be reinstituted for a minimum of 2 cycles.  The reinstituted observation period may be su spended 
after 2 cycles if the patient shows no further signs or symptoms of an IRR. See Section 9.2.1.  For Cycles3+, 
obtain vital signs 3times: 1) within 15 minutes ( +5 minutes) prior to olaratumab/placebo infusion ,2) within 1 
hour ( +5 minutes) after completion of the gemcitabine infusion , and 3) within 1 hour ( +5 minutes) after 
completion of the docetaxel infusion.
cAdminister gemcitabine as an infusion over 90 minutes (Â± 5 minutes) (fixed -dose rate:10 mg/m2/minute).
Premedication for gemcitabine may be administered according to institutional guidelines and/or clinical practice .  
All premedication administered must be adequately documented in the eCRF .  Gemcitabine premedication, if 
needed, must not be administered before the end of olaratumab/placebo infusion or before completion of the 
observation period (if applicable).
dAdminister docetaxel as an in fusion over 60 minutes (Â± 5 minutes) after gemcitabine .  Premedication for 
docetaxel may be administered according to institutional guidelines and/or clinical practice .  All premedication 
administered must be adequately documented in the eCRF .  Docetaxel premedication must not be administer ed 
before the end of olaratumab/placebo infusion or before completion of the observation period (if applicable).  
Exception is given to dexamethasone premedication that is started 1 day prior to docetaxel per package insert.
Please see Sect ion 9.4for further details regarding dosing calculat ions of study  drugs.
The invest igator or his/her designee is responsible for the fo llowing:
ï‚·explaining the correct use of th e drugs and planned duration of each individualâ€™s 
treatm ent to the patient/site personnel/legal representative,
ï‚·verifying that instructions are fo llowed properly,
ï‚·maintaining accurate records of study  drug dispensing and collect ion,
ï‚·and returning all unused medicat ion to Lilly or its designee at the end of the study .
Note :  In some cases, sites may destroy  the m aterial  if, during the invest igator site select ion, the 
evaluator has verified and documented that the site has approp riate facilit ies and wri tten 
procedures to dispose clinical trial materials.
Patients will  be instructed to contact the investigator as soon as possible if they  have a com plaint 
or probl em with the study  drug so that the situation can be assessed .
9.1.1. Premedication
All premedication administered must be adequately documented in the electronic case report 
form (eCRF).
9.1.1.1. Olaratumab or Placebo
Infusio n-related reacti ons, including Grade 3 -5 IRR events, have been observed with 
olaratum ab.To date, Grade 3- 5 IRRs have occur redduring the first cycle of olaratumab 
treatm ent.  Therefore, premedicate all patients with the fo llowing medicat ions (or e quivalent)
I5B-MC-JGDL( c) Clinical Protocol Page 53
LY3012207intravenously : a histamine H1 antagonist ( for example , diphenhydramine) and dexamethasone 
30to 60 minutes prior to the olaratumab/placebo doses on Days 1 and 8 of Cycle 1.
For all subsequent cy cles, prem edicate all pat ients with a histamine H1 antagoni st (for example , 
diphenhydramine) intravenously 30 to 60 minutes prior to each dose of olaratumab/placebo.
Prem edicat ion with addi tional agents m ay be provided at invest igator discret ion.
All premedication administered must be adequatel y documented in the eCRF.
9.1.1.2. Gemcitabine
Prophylactic ant iemetics will be routinely  administered.   Additional ly, premedicat ion for 
gemcitabine may  be administered according to institut ional guidelines and/or clinical pract ice.  
All premedicati on administered must be adequately  documented in the eCRF.
Sites shoul d consul t the m anufacturerâ€™s instructions for gemcitabine for com plete prescribing 
inform ation (including warnings, precautions, contraindicat ions, and adverse reactions) and 
follow inst itutional procedures for the administration of gemci tabine.
9.1.1.3. Docetaxel
Prem edicat ion for docetaxel may be administered according to inst itutional guidelines and/or 
clinical practice.   Recommended premedicat ion for the docetaxel i s corticosteroi ds suc h as 
dexamethasone 8 mg orally twice a day  starting the day  prior to docetaxel and continuing for 
3days or at the di scret ion of the invest igator. Patients who develop peripheral edema as a side 
effect of docetaxel maybe treated with diuretics at the discretion of the invest igator.  Addit ional 
antiemetic premedicat ion may be emplo yed at the discretion of the invest igator.  All 
prem edicat ion administered must be adequately documented in the eCRF.
Sites shoul d consul t the m anufacturerâ€™s instructions for docetaxel for complete prescribing 
inform ation (including warnings, precautions, contraindicat ions, and adverse reactions) and 
follow inst itutional procedures for the administration of docetaxel .
9.1.1.4. Granulocyte -Colony Stimulating Factors
G-CSF use is recommended in all cycles for pati ents wi th a pri or history  of pelvic radiation .  For 
all other patients , G-CSF use is recommended per the guidelines outlined in Table JGDL. 2.
Patients wi th a pri or history  of pelvic radiation who require chemotherapy  dose reducti on despi te 
prophylact ic G-CSF are not required to have prophylact ic G-CSF in subsequent cy cles if per 
investigator assessment such chemotherapy  dose reducti ons adequately  address the ri sk of 
further myelo suppressio n.
As outlined in Sect ion9.6.1.1 ,
 prophylactic use of G -CSF shoul d consist of at least 5 day s of 
G-CSF ( 5 micrograms/kg/day subcutaneously ) beginning on Day 9, or a single dose of peg-G-
CSF (6 mg,subcutaneously ) on Day 9or 10 .
9.2. Materials and Supplies
Olaratum ab and pl acebo will be provi ded to the si tes by Lilly .
I5B-MC-JGDL( c) Clinical Protocol Page 54
LY3012207Olaratum ab/placebo will be supplied as a sterile preservative -free so lution for IV infusio n in 
single- use vials containing 500 mg/50 mL of olaratum ab(10mg/mL) or placebo .
Olaratum ab/placebo is formulated in 10 mM histidine, 100 mM glycine, 50 mM sodium 
chloride, 75 mM mannito l, and 0.02% polysorbate -20, pH 5.5. All excipients used in the 
formulation ofolaratumab/placebo drug product are of pharmacopeia grade.
Gemci tabine anddocetaxel will be provi ded by Lilly .  In the event that there are regional 
restri ctions or supply limitat ions, commercially available gemci tabine anddocetaxel may be 
purchased bythe sites.
Clinical study  materials will be l abeled according to the cou ntryâ€™s regul atory  requi rements.
9.2.1. Olaratumab/Placebo
Olaratum ab/Placebo Drug Product: The drug product must be stored under refrigerat ion at 2Â°C 
to 8Â°C (36Â°F -46Â°F) wi th protecti on from direct light.  Do not freeze and/or shake 
olaratum ab/placebo drug product.  Stabilit y studi es have dem onstrated that the drug product can 
withstand transient excursio n to room temperature (15Â°C -25Â°C) without adverse effect; however, 
storage at this temperature is not recommended.
Please refer to the pharmacy manual for olaratumab/placebo dosing so lution for infusio n. 
CAUTION:   Infusion -related reacti ons may  occur during or following olaratum ab/placebo
administration (see Section 9.4.1.2.2.1 for a definit ion of Grade 3 and 4 IRRs ).  During the 
administration of olaratumab /placebo , pati ents shoul d be in an area with resuscitat ion equipment 
and treatments necessary  for advanced lif e support and cardiopulmo nary resusci tation (CPR), 
such as bronchodilators, vasopressor agents ( for example , epinephrine), oxy gen, gl ucocorti coids, 
antihistamines, IV fluids, and so forth.  A 1- hour observat ion peri od is requi red after the 
administration o f the first and second cy cles of olaratum ab/placebo.  If there is no evidence of an 
IRR during the init ial 2 cycles of olaratum ab/placebo, then no observation period is required for 
subsequent treatment cy cles.  In the event that a Grade 1 or 2 IRR occurs after Cy cle 2, the 1 -
hour observation period will be reinst ituted for a minimum o f 2 cycles.  The reinst ituted 
observat ion peri od m ay be suspended after 2 cy cles if the pat ient shows no further signs or 
symptoms of an IRR.   See Section 9.4.1.2.2.1 for management of infusio n rate wi th Grade s1 and 
2 IRRs.
9.2.2. Gemcitabine
Gem citabine is a commerci ally available product and should be stored, reconstituted and 
discarded p er manufacturerâ€™s instructions.
Gemci tabine will be administered at a dose of 900mg/m 2(IV) over 90 minutes (fixed -dose rate 
of 10 m g/m2/minute) on Day s 1 and 8 of each 21-daytreatment cy cle.
9.2.3. Docetaxel
Docetaxel is a co mmercially available product.  Investigators should consul t the manufacturerâ€™s 
instructi ons for com plete packaging, labeling, storage, and stabilit y informat ion.
I5B-MC-JGDL( c) Clinical Protocol Page 55
LY3012207Docetaxel will be administered at a dose of 75mg/m2(IV) over 60 minutes on Day 8 of each 
21-daytreatm ent cy cle.
9.3. Method of Assignment to Treatment
Phase 1b:
Upon signing the inform ed consent form (ICF) , the si te will register the patient in the Interactive 
Web Response System (IWRS), which is web- based and accessible 24 hours a day . The IWRS 
registrati on consists of assigning the patient a unique study  identificat ion number. Patients who 
meet all criteria for enrollment will be assigned to receive study  treatm entthrough the IWRS 
system .No dose escalat ions (that is, to the next cohort) can occur without prior discussio n and 
agreem ent wi th the responsible Lilly CRP or CRS.
There i s no randomizat ion procedure for Phase 1b patients. Phase 1b pat ients will not participate 
in Phase 2.
Phase 2:
Upon signing the ICF, the si te will register the patient by  the IWRS, which is web -based and 
accessible 24 hours a day .  The IWRS registration consists of assigning the patient a unique 
study ident ification number for all patients .  Pati ents who meet all criteria will be rando mized
into 1 of  the 2 treatm ent arm s on a 1:1 basis , using the IWRS .
The I WRS will assign patients to treatment arms according to a stratified method of 
rando mization (that is, independent randomizat ion within each strat um), defined by  the 
following 5factors:
ï‚·Prior treatm ent wi th olaratumab (y es versus no)
ï‚·Number of prior systemic therapies for locally advanced/metastatic disease (0 versus â‰¥1)
NOTE:  Any therapy  administered in the adjuvant/neoadjuvant setting will not be 
considered as a prior line o f therapy  here.
ï‚·Histologi cal tum or type (leiomyosarcom a versus non-le io myosarcoma )
ï‚·ECOG PS(0 versus 1)
ï‚·Prior pelvic radiation (yes versus no)
After rando mizat ion, pati ents shoul d receive thei r first dose of treatment within 72 hours (3 day s) 
whenever possible (up to 3 addit ional days â€™delay  of first dose of treatment will be permitted due 
to holidays, weekends, bad weather, or other unforeseen circumstances and will not count as a 
protocol  deviat ion).
9.4. Selection and Timing of Doses
A cycle is defined as an interval of 21 days (up to 3 day sâ€™delay  of a cy cle will be permitted due 
to holidays, weekends, bad weather, or other unforeseen circumstances and will not count as a 
protocol  deviat ion).
The dose of olaratum ab/placebo administered will be determined by measuring the pati ent's 
weight in kil ograms on D ays1 and 8 of each cycle.  Also, see Section 9.2.1 for further details on 
I5B-MC-JGDL( c) Clinical Protocol Page 56
LY3012207olaratum ab/placebo.   The dose of gemcitabine or docetaxel administered will be determined by 
calculat ing the patient's body surface area (BSA) at the beginni ng of  each cycle.
If the patientâ€™s weight does not fluctuate by  ï‚³10% (increase or decrease) from the weight used to 
calculate the pri or dose, the olaratum ab/placebo or gemcitabine or docetaxel  dose will not need 
to be recalculated , unless deemed clinically meaningful .  A ï‚±5% variance in the calculated total 
dose (or for gem citabine and/or docetaxel a variance according to local inst itutional guidelines is 
also allowed ) will be allowed for ease of dose administration.
Day 8 administrati on of  gemci tabine and docetaxel must not be given prior to Day  8.
Patients will  receive treatm ent until evidence of progressive disease (PD), unacceptable toxicit y, 
death, or other withdrawal criteria are met (as described in Sect ion7.3).
9.4.1. Special Treatment Considerations
9.4.1.1. Dose -Limiting Toxicity Determination (Phase 1b Part)
Bone m arrow suppressi on occurs rel atively frequent ly wit h the gemcitabine and docetaxel 
regimen and can lead to complicat ions such as fever and neutropenia, infect ion, or bl eeding, 
which are generally considered DLT -level toxicit ies and thus can confound DLT determinat ion 
in the setting of co mbinat ion with olaratumab.  The criteria listed below will be used to 
determine the dose of olaratumab that can be added to gemcitabine and docetaxel without 
causing a significant increase in toxicit y over that expected with gemcitabine/doc etaxel alo ne.
In the Phase 1b part, DLT assessment will be performed.  A DLT is defined as events such as the 
following , graded according to the NCI -CTCAE version 4.0, whe n the event occurs within 
Cycle 1, and is considered to be related to study treatm ent by  the invest igator in conjuncture with 
the Sponsor :
ï‚·febrile neutropenia with documented Grade â‰¥3 infection or sepsis
ï‚·Grade 4 thrombocy topeni a, or Grade 3 thrombocy topeni a com plicate d by hemorrhage
ï‚·Grade 4 neutropenia last ing 7 days or longer 
ï‚·nonhematologic Grade â‰¥3 toxi city, except for toxicit ies such as nausea, vo miting, 
transi ent electroly te abnorm alities, or di arrhea which can be controlled with optimal 
medical management within 48 hours)
In addit ion to the DLT assessment period in Cycle 1, safet y data bey ond Cycle 1 m ay also be 
taken into consideration prior to a decisio n to escalation or determinat ion of the Phase 2 dose.
9.4.1.2. Dose Delays, Modifications, and Discontinuations
To begin dosing at each cy cle(Day  1), the fo llowing cri teria must be f ulfilled:
ï‚·ANC â‰¥1.5 Ã— 103cells/ÂµL ( â‰¥1500 cells/ÂµL; â‰¥1.5 Ã— 109/L), with no G -CSF in the prior 48 
hours
ï‚·Platelets â‰¥100 Ã— 103cells/ÂµL ( â‰¥100,000 cells/ÂµL; â‰¥100 Ã— 109cells/L) , with no platelet 
transfusio n in the prior 72 hours
ï‚·Hem oglobin â‰¥
8.0g/dL .  Note: For inclusio n criteria, hemoglobin â‰¥9.0 g/dL .
I5B-MC-JGDL( c) Clinical Protocol Page 57
LY3012207ï‚·Total  bilirubin below ULN .  In pati ents wi th Gilbertâ€™s Syndrome, total bilirubin should 
be ï€¼3 mg/dL.
ï‚·Serum  creatinine â‰¤1.5 times ULN .  If creatinine is above ULN, the patientâ€™s creat inine 
clearance is â‰¥45 m L/min (refer to Attachment 8 for the Cockcroft -Gault formula for 
creatinine clearance).
ï‚·AST and ALT â‰¤3.0x ULN, or â‰¤5 x ULN if the transaminase elevat ion is due to liver 
metastases
ï‚·Any treatm ent-related nonhem atologic toxicitythat is NCI-CTCAE, v 4.0Grade <2 or 
equivalent severit y to baseline , unless toxi city consists of l aboratory  abnormalit ies (for 
example, potassi um,magnesium , or phosphate ) that are managed per institutional
standards .
(For Grade 4 nonhem atologic toxicity deem ed related to ol aratumab/placebo ,
see Table JGDL.7.)
Delays:
In general, dose delays of one study  drug (ol aratumab/placebo ,gemcitabine ,or docetaxel ) due to 
toxicity guidances outlined in Secti ons 9.4.1.2.1 and 9.4.1.2.2 willnot necessitate delaysof the 
other study  drug .  However, close considerat ion must be made by the invest igator to administer 
all study  treatm ents per the schedule outlined in Section 9.1.
Treatment may be delayed for up to 14days to allo w a patient sufficient time for recovery  from 
study  drug -related toxici tyor non -study -drug-related even ts at the investigatorâ€™s discret ion (for 
example, an autom obile accident) .
Dose Modificat ions:
Any pat ient who requires a dose reduction for drug -related toxicit y will cont inue to receive the 
reduced dose for the remainder of the study , except in the situat ion described in Table JGDL. 2, 
footnote b .  For gem citabine or docetaxel , any pat ient who has had 2dose reducti onsand who 
experiences a toxicit y that woul d cause a thirddose reducti on m ust be discont inued fro m study  
treatm ent.  For olaratumab, a ny pat ient who has had 2dose reductions and who experiences a 
toxicity that woul d cause a thirddose reduction must be discont inued fro m study  treatm ent.
In the Phase 2 part, s ince all i nvest igators are blinded to treatment arms, they will treat all  
patients as if thepatientreceived study  drug versus placebo and will adjust doses accordingly.
In the event of an alterati onin olaratumab/placebo dose due to an olaratumab /placebo -related 
toxicity, gemci tabine or docetaxel need not be altered, and the planned gemci tabine or docetaxel
schedule should be maintained.
Similarly, olaratumab /placebo therapy  need not be altered for either gemci tabine -or 
docetaxel -related toxici ty.
The d osing algorithm on Day s1 and 8 for gemcitabine, docetaxel , o laratumab and G -CSF use, 
based on ANC and platelet count, are shown inTable JGDL. 2.  Treatment should not begin on 
Day 1 of any cycle until the ANC is ï‚³1500 cells/Âµl and the pl atelet count i s â‰¥100 ,000 cells/ Âµl.
I5B-MC-JGDL( c) Clinical Protocol Page 58
LY3012207Dose adjust ments required for hematologic and nonhematologic toxicit y due to gem citabine or 
docetaxel are presented in Table JGDL .4and Table JGDL. 5, respectively .   Dose adj ustments 
requi red for hem atologic and nonhematologic toxicit y due to ol aratum ab are presented in 
Table JGDL. 6and
 Table JGDL.7, respectively .
I5B-MC-JGDL( c ) Clinical Protocol Page 59
LY3012207Table JGDL. 2. Dosing Algorithm on Days1 and 8 for Gemcitabine ,Docetaxel ,Olaratumab ,and G -CSF Use Based on 
Absolute Neutrophil Count and Platelet Count
Treatment 
DayAbsolute 
Neutrophil 
Count
(cells/Âµl)Platelet 
Count
cells/Âµl)Gem D ose(mg/m2) Doc Dose (mg/m2) Olaratumab/Placebo G-CSF Usea
Day 1
(Olaratumab
/Placebo
Gem)â‰¥1500 and â‰¥100,000 900bNot Applicable Administer Not Applicable
Day 8 
(Olaratumab
/Placebo
Gem ,Doc)â‰¥ 1000 and â‰¥100,000 900b75bAdminister Not required
500 to 
<1000â‰¥75000 675c60cAdministerAdminister as outlined 
in Section 9.1.1.4 .
â‰¥500<100,000 
to 75000675c60cAdministerNot required unless 
ANC meets criteria
<500 Any Omit on Day 8dOmit on Day 8d Omit on Day 8 (also 
see Table JGDL. 6)Administer as outlined 
in Section  9.1.1.4 .
Any <75000 Omit on Day 8dOmit on Day 8d Omit on Day 8 (also 
see Table JGDL. 6)Not required unless 
ANC meets criteria
Abbreviations : ANC = absolute neutrophil count; Doc = docetaxel; G-CSF = granulocyte colony -stimulating factor; Gem = gemcitabine; Âµl = microlit er.
a Patients with a prior history of pelvic radiation should receive prophylactic G -CSF in all cycles.  G -CSF use is recommended per the guidelines outlined in 
Section 9.1.1.4 .  Patients with a prior history of pelvic radiation who require chemotherapy dose reduction despite prophylactic G -CSF are not required to 
have prophylactic G -CSF in subsequent cycles if per investigator assessment such chemotherapy dose reductions adequately address the risk of further 
myelosuppression.
bIfthere has been 1dose reduction for drug-related toxicity, thedose of gemcitabine is675mg/m2and the dose of docetaxel is 60mg/m2.If there have been 2
dose reductions for drug -related toxicity, the dose of gemcitabine is 500 mg/m2and the dose of docetaxel is 45 mg/m2. A
Day 8 dose reduction of 
gemcitabine or docetaxel because of Day 8 blood count parameters does not need to be cont inued on Day 1 of the subsequent cycle .
cIf there has already been 1dose reduction for drug -related toxicity, the dose of gemcitabine is500mg/m2and the dose of docetaxel is 45 mg/m2.  A Day 8 
dose reduction of gemcitabine or docetaxel because of Day 8 blood count parameters does not need to be continued on Day 1 of the subsequent cycle .
dAfter omission of gemcitabine and docetaxel on Day 8 due to ANC <500 cells/ ÂµLand/or platelet count of < 75,000 cells/ ÂµL, reduce dose of gemcitabine to the 
next appropriate dose level per  Table JGDL. 3for subsequent cycles.
I5B-MC-JGDL( c) Clinical Protocol Page 60
LY3012207Disconti nuati ons:
In the event of permanent discontinuation of o laratumab/placebo therapy  due to an 
olaratum ab/placebo -related toxi city, pati ents m ay continue on gem citabine and docetaxel  
treatm ent per protocol .  If either gemcitabine or docetaxel are perm anently discontinued due to 
toxicity, the pati ent shoul d discont inue act ive treatment with the gemcitabine/docetaxel 
combinat ionif it is unclear which individual agent is the cause o f the toxicit y.  If toxici ty is 
clearly  related to one agent or the other, for example neuropathy due to docetaxel, only that agent 
shoul d be discont inued .   The patient may cont inue treatment with olaratumab/placebo alone, at 
the discret ion of the invest igator , if gemcitabine and /ordocetaxel are permanently discont inued.  
Any changes in treatments being added to or removed fro m patient care will be recorded on the 
eCRF.
The fo llowing inform ation (in this sect ion and the fo llowing subsect ions) pertains to dose 
modificati ons and del ays for and mana gement of AE s of concern, which may  or m ay not be 
associ ated wi th gemci tabine and docetaxel therapy , including the following :
ï‚·Hem atologic toxici ty(see Sect ion 9.4.1.2.1.2 )
ï‚·Other nonhematologic toxicit y(see Secti on9.4.1.2.1.3 )
The fo llowing inform ation (in this sect ion and the fo llowing subsect ions) pertains to dose 
modificati ons and del ays for and management of AE s of concern, which may  or m ay not be 
associ ated wi th olaratum ab/placebo therapy , including the following:
ï‚·IRR (see Section 9.4.1.2.2.1 )
ï‚·Hem atologic toxici ty (see Sect ion 9.4.1.2.2.2 )
ï‚·Nonhematologic toxicit y (see Sect ion 9.4.1.2.2.3 )
9.4.1.2.1. Gemcitabine and Docetaxel
9.4.1.2.1.1. Dose Level Reductions
In the case of toxicit y related to myelo suppressio n and its complications, the relat ive roles of 
gemcitabine and docetaxel  are often impossible to separate, and thus it is expected such toxicit y 
woul d resul t in dose reductions of both agents. In cases where AEs, in the opinion o f the 
investigator, are more likely  due to one drug than another, adjust ment of one of the 
chemotherapy agents and not the other is permissible.   
Dose l evel reduct ions for gem citabine and 
docet axel are shown in Table JGDL. 3.
The infusio n time o f gemci tabine after i ts dose reducti on may  be maintained at 90 minutes 
(
Â±5min) or may be shortened to keep a rate of approximately  10mg/m2/minaccording to 
discreti on of  the invest igator. The infusio n start and stop times must be reco rded.
Table JGDL. 3. Dose Level Reductions for Gemcitabine and Docetaxel
Study Drug Starting Dose Dose Reduction 1 Dose Reduction 2
Gemcitabine 900 mg/m2675mg/m2500 mg/m2
Docetaxel 75 mg/m260mg/m245mg/m2
I5B-MC-JGDL( c) Clinical Protocol Page 61
LY30122079.4.1.2.1.2. Hematologic Toxicity
The d osing algorithm on Day s1 and 8 for gemcitabine, docetaxel , o laratumab and G -CSF use, 
based on ANC and platelet count, are shown inTable JGDL. 2.
General guidelines for dose modificat ionsfor other hematologic toxicit ies are shown in
Table JGDL .
4.
Table JGDL .
4. General Guidelines for Gemcitabine and Docetaxel Dose 
Modification Due to Other Hematologic Toxicity
Toxicity Required Dose Modification
Granulocyte nadirs lasting less than 7 days and with 
no complicationsNo dose modification needed
First occurrence of febrile neutropenia and/or 
documented Grade 4 neutropenia persisting â‰¥ 7 daysReduce gemcitabine to 675 mg/m2and docetaxel to 
60mg/m2.  Prophylactic G -CSF recommended in 
subsequent cycles.  If patient experiences of febrile
neutropenia and/or documented Grade 4 neutropenia in a 
subsequent cycle despite dose reduction and prophylactic 
G-CSF, a second dose reduction (to gemcitabine 
500mg/m2and docetaxel 45 mg/m2) is allowed.  If 
febrile neutropenia or documented Grade 4 neutropenia 
occur in further cycles, the patient should be 
discontinued from the gemcitabine and docetaxel 
combinatio n.
Grade 3 thrombocytopenia (platelet count 25,000/ÂµL
to Ë‚50,000 /ÂµL) associated with clinically significant
bleeding Reduce gemcitabine to 675 mg/m2and docetaxel to 
60mg/m2for all subsequent cycles.  If the event recurs in 
a subsequent cycle despite dose reduction, a second dose 
reductio n (to gemcitabine 500 mg/m2and docetaxel 
45mg/m2) is allowed.  If Grade 3 thrombocytopenia with 
clinically significant bleeding occurs in further cycles, 
the patient should be discontinued from the gemcitabine 
and docetaxel combination .
Grade 4 thrombocytopenia (pl atelet count 
<25,000/Âµ L)Reduce gemcitabine to 675 mg/m2and docetaxel to 
60mg/m2for all subsequent cycles. If the event recurs in 
a subsequent cycle despite dose reduction, a second dose 
reductio n (to gemcitabine 500 mg/m2and docetaxel 
45mg/m2) is allowed.  If Grade 4 thrombocytopenia 
occurs in further cy cles, the patient should be 
discontinued from the gemcitabine and docetaxel 
combinatio n.
Abbreviations:  ANC = absolute neutrophil count; G -CSFs = granulocyte colon y-stimulating factors.
9.4.1.2.1.3. Nonhematologic Toxicity
General guidelines for dose modificat ion for hepatic toxici ties rel ated to gemcitabine and 
docetaxel are shown in Table JGDL. 5.
I5B-MC-JGDL( c) Clinical Protocol Page 62
LY3012207Table JGDL. 5. Dosage Reduction Guidelines for Docetaxel and Gemcitabine Due 
to Hepatic Toxicities
Toxicity Required Dose Modification
On Day  1, bilirubin > ULN Delay Day 1 (except for patients with Gilbertâ€™s Syndrome, 
who must have a total bilirubin <3 mg/dL . See Sec tion
9.4.1.2 ).
On Day  8, if bilirubin is â‰¤ULN Administer docetaxel on Day 8.
On Day  8, if the bilirubin is > ULN Omit docetaxel on Day 8. For subsequent cycles , omit 
docetaxel until bilirubin returns to â‰¤ ULN (except for 
patients with Gilbertâ€™s Syndrome, who must have a total 
bilirubin <3 mg/dL) .
Grade â‰¥3 elevations in SGOT (AST), SGPT 
(ALT), o r alkaline phosphataseReduce gemcitabine to 675 mg/m2and docetaxel to 
60mg/m2for all subsequent cycles . In subsequent 
treatments ,delay  gemcitabine and docetaxel for a maximum 
of 2weeks, until recover y to Grade â‰¤1.  If recover y to 
Grade â‰¤1 does not occ ur, discontinue gemcitabine and
docetaxel.   A second dose reduction (to gemcitabine 
500mg/m2and docetaxel 45 mg/m2) is allowed if Grade â‰¥3 
elevations recur. 
Abbreviations: ALT = a lanine transaminase ; AST = aspartate transaminase ; SGOT = s erum glutamic oxaloacetic 
transaminase ; SGPT = serum glutamic pyruvic transaminase ; ULN = upper limit of normal .
Note:  Bilirubin refers to total bilirubin .
ForGrade â‰¥2 nonhematologic organ -related toxicities(excluding alopecia) , delay treatm ent until 
recover yto Gr ade â‰¤1 or pre -therapy  baseline . Treatment may be delayed for up to 14days to 
allow a patient sufficient time to recover from study drug -related toxi city. If recovery  to Grade 
â‰¤1 does not occur within this allowed time , discontinue gemcitabine and docetax el.If the patient 
continues to experience the same toxicities, a second dose reduction (per Table JGDL. 3) is 
allowed.  G em
citabine and docetaxel  treatm entshoul d be di scontinued if toxicit ies recur in spite 
of 2 dose reducti ons. In general, Grade 3 nonhematologic toxicit ies (excluding electroly te 
toxicities that respond to supplemental treatment )require dose reduction.   Permanent 
discontinuat ion of gemcitabine and docetaxel is indicated for Grade 3 organ -related toxici ty that 
recurs despite up to 2dose reduction s.  Docetaxel  shoul d be reduced for Grade 2 neurologic 
toxicity and permanent ly discont inued for Grade 3 neuro logic toxi city.  Gem citabine and 
docetaxel should be p ermanent ly discont inued for Grade 4 nonhematologic toxicit y unless 
previously discussed wit h the Lilly CRP/CRS.
Pulmo nary toxicity has been reported with the use of gemcitabine. In cases of severe lung 
toxicity, gemci tabine therapy  shoul d be discont inued immediately and appropriate supportive 
care m easures instituted.
Gem citabine and docet axel shoul d be perm anent ly discont inued for any o f the following:
ï‚·unexplained new or worsening dyspnea or evidence of severe pulmo nary 
toxicity
ï‚·severe hepatic toxicit y
I5B-MC-JGDL( c) Clinical Protocol Page 63
LY3012207ï‚·Hem olyticUremic Syndrome or severe renal impairment
ï‚·Capillary Leak Syndrome
ï‚·posterior reversible encephalopathy syndro me
9.4.1.2.2. Olaratumab/Placebo
9.4.1.2.2.1. Infusion -Related Reactions
As wi th other m onocl onal antibodies, hypersensit ivity react ions m ay occur during or following 
olaratum ab administration.
A 1-hour observat ion peri od is requi red after the administrati on of olaratum ab/placebo in the 
first and second cy cles.  If there i s no evidence of an IRR during the init ial 2 cycles of 
olaratum ab/placebo, then no observat ion peri od is requi red for subsequent treatment cy cles.  In 
the event that a Grade 1 or 2 IRR occurs after Cycle 2, the 1
-hour observat ion peri od will  be 
reinst ituted for a minimum of 2 cycles.  The reinst ituted observat ion peri od m ay be suspended 
after 2 cy cles if the pat ient shows no further signs or symptoms of an IRR.   During the 
observat ion peri od, pati ents treated with olaratumab /placebo shoul d be cl osely  monitored f or 
signs and symptoms indicat ive of an infusio n reactio n by the medical staff fro m the start of the 
infusio n unt il at least 1 hour after the end of th e infusion in an area where emergency  medical 
resuscitat ion equipment and other agents (epinephrine , predniso lone equivalents, etc. ) are 
available.
Olaratum ab/placebo infusio n reactions will be defined according to the NCI -CTCAE Version 4.0
definition of  infusio n
-related r eactions.
Symptom s occurring during or following infusio n of investigational therapy  may also be defined 
according to AE categories such as allergic react ion, anaphylaxis, or cy tokine rel ease syndrom e 
(NCI -CTCAE Version4.0section â€œImmune system disordersâ€). In the setting of symptoms or 
signs occurring during or fo llowing infusio n of investigational therapy , invest igators are 
encouraged to use the AE term s that describe the event, and mark â€œyesâ€ or â€œnoâ€ for 
hypersen sitivity/IRR event flag .
For pati ents who experience a Grade 1 or 2 IRR, the infusio n should be stopped and the patient 
treated with the following (or equivalent) medicat ions intravenously : a histamine H1 antagonist 
(for example ,diphenhydramine hydrochloride), glucocortico id (for exam ple,dexamethasone), 
acetaminophen, and oxy gen (as indicated ), according to standard medical pract ices.  After 
recovery , the infusio n rate shoul d be decreased 50% for the duration of the infusio n. Patients 
who have experienced a prior Grade 1 or 2 IRR to olaratum ab (or pl acebo) , should be 
prem edicated wi th the following (or equivalent) medicat ions: a histamine H1 antagonist ( for 
example , diphenhydramine) intravenously and glucocorti coid (for example , dexamethasone)
intravenously , 
acetaminophen, and any  other m edicati onsas appropri ate for prophylaxis of IRR , 
approximately  30to 60 minutes prior to all subsequent olaratum ab/placebo infusio ns.  In 
addition, the 1hour post infusio n observation period s hould be reinstated as per Section 9.2.1 .  If 
subsequent infusio ns are then tolerated with the use of premedicat ions as above and a 50% 
decrease in infusio n rate, the infusio n rate m ay be increased to a rate deemed appropriate by  the 
I5B-MC-JGDL( c) Clinical Protocol Page 64
LY3012207investigator, as long as it does not exceed 25mg/min.  For olaratumab -pretreated patients who 
experienced a Grade 1 or 2 IRR during their prior treatment regimen ( that is, prior to 
rando mizat ion in this study ), the infusio n rate that was last tolerated should be the infusion rate 
for both doses of olaratumab in Cycle 1.   If tolerated, in subsequent cycles ,the infusio n rate may 
be increased to a rate deemed appropriate b y the investigator, as long as it does not exceed 
25mg/min.
A Grade 3 or 4 IRR will require immediate treatment, including the use of epinephrine, 
bronchodilators, and/or glucocortico ids for symptomat ic bronchospasm ; IV flui ds and/or 
pressors f or hy potensi on; and immediate and permanent discont inuat ion of all study  treatm ent
with appropri ate supporti ve care.
If a patient experiences an IRR to olaratum ab/placebo , all attem pts shoul d be m ade to obtain an 
anti-olaratum ab/placeb o antibody and olaratum ab/placebo PK blood sam plesas close to the 
onset of the event as possible, at the resolut ion of the event, and 30 days (Â±3days)following the 
event.   The procedure for sample collection and handling is described in a separate procedural 
manual.
9.4.1.2.2.2. Hematologic Toxicity
Table JGDL. 6summarizes the olaratumab dose modificat ions required in case o f hematol ogic 
toxicities.
I5B-MC-JGDL( c) Clinical Protocol Page 65
LY3012207Table JGDL. 6. General Guidelines for Olaratumab/Placebo Dose Modification Due 
to Hematologic Toxicity Deemed Related to Olaratumab
Toxicity Required Dose Modification
Neutropenia
  ANC Grade 1 -3 No dose modification required
  ANC <500 cells/ ÂµL (Grade â‰¥4) No treatment administered; treatment cycle delayed
  At retreatment:
  If  â‰¥Grade 3 neutropenic fever/infection has 
occurredWithhold dose until ANC is â‰¥ 1000 cells/Âµ L; for a 15-
mg/kg dose level ,reduce dose to 12mg/kg ;for a 
20-mg/kg dose level ,reduce dose to 15 mg/kg.
  
If Grade 4 neutropenia lasting >1week has occurred Withhold dose until ANC is â‰¥ 1000 cells/Âµ L; for a15-
mg/kg dose level ,reduce dose to 12mg/kg ; for a 20-
mg/kg dose level ,reduce dose to 15 mg/kg .
  Grade 4 ANC without fever/infection lasting â‰¤ 
1weekAdminister the next olaratumab/placebo at full dose at
investigator â€™sdiscretio n with recommended use of 
prophylactic G -CSFs
  Second incidence of either:  
  1) â‰¥Grade 3 neutropenic fever/infection
  2) Grade 4 neutropenia lasting >1 weekFor a 15-mg/kg dose level ,discontinue 
olaratumab/placebo ; for the 20 -
mg/kg dose level ,a 
second dose level reduction to 1 0mg/kg .  
Modify/discontinue gemcitabine and docetaxel as per 
Table JGDL .4.
Abbreviations:  ANC = absolute neutrophil count; G -CSFs = granulocyte colon y-stimulating factors.
9.4.1.2.2.3. Nonhematologic Toxicity
Specific guidelines for dose adjustments in pat ients who experience olaratumab /placebo IRRs
may be found in Sect ion9.4.1.2.2.1 .
General guidelines for dose modificat ion for other nonhematologic toxicit ies related to 
olaratum ab/placebo are shown in Table JGDL.7.  
I5B-MC-JGDL( c) Clinical Protocol Page 66
LY3012207Table JGDL.7. General Guidelines for Dose Modification Due to Nonhematologic 
Toxicit ies Deemed Related to Olaratumab/Placebo
Reac tion Grade Required Dose Modification
Grade 1 No dose modification is required.
Grade 2 At the investigatorâ€™s discretion, the pat ient may  continue to receive olaratumab/placebo per 
protocol, provided that the event does not pose a serious health risk or is easily treated.
Grade 3 For a Grade 3 toxicity not adequately controlled with appropriate supportive care, the dose 
must be withheld until organtoxicity is â‰¤ Grade 1 or has returned to pretreatment baseline; 
then treatment may resume at a reduced dose of 12 mg/kg for the 15 -mg/kg dose level and 
reduced dose of 15mg/kg for the 20 -mg/kg dose level .  If to xicity  recurs after therapy 
resume s, a second dose reduction ( second dose reduction of 10 mg/kg for the 15 -mg/kg dose 
level and12mg/kg for the 20 -mg/kg dose level )is permitted.
Grade 4 The dose must be withheld until dose toxicity is â‰¤ Grade 1 or has returned to baseline.  
Permanent discontinuation should be considered for any patient experiencing Grade 4 
nonhematologic toxicity assessed as related to olaratumab/placebo. However, if resumption 
of dosing is deemed appropriate by the investigator, treatment may resume only after 
consultation with the Lilly study physician, with the dose reduced to 10 mg/kg for the 15 -
mg/kg dose level ; dose reduced to 15 mg/kg for the 20 -mg/kg dose level .  If Grade 4 toxicity 
recurs after therapy resumes, all study treatment will be discontinued.
9.5. Blinding
Phase 1b:
This partis an open -label study .
Phase 2:
This is thedoubl e-blind edpartof the study .
During enro llment and prior to the interim efficacy analysis , only a minimum number of Lilly 
personnel will see the rando mizat ion table and treatment assignments before the study  is 
complete.   Individuals (IWRS, clinical trials materials management, Global Pat ient Safet y, and 
data m anagement personnel) validat ing the database willnot have access to aggregate summary  
reports or statist ics.  PK and/or immunogenicit y data that coul d unblind the study  will not be 
reported to invest igative sites or other blinded personnel until the study has been unblinded.
Upon final analyses of the study , invest igators may unblind pat ients to study  treatm ent 
assignment.
Efficacy informat ion (as outlined in Sect ion 10.1)will not be shared with sites unt il the study is 
completed (see Secti on8.1.6 ).  Treatment assignment will be scrambled in the reporting database 
until the database lock for data analysis.  This will ensure unblinded aggregate efficacy results 
are not available unt il the time o f final data analysis.
If an invest igator, site personnel performing assessments, or patient is unblinded, the pat ient may 
be discont inued fro m study  treatm ent.  In cases where there are ethical reasons to have the 
patient rem ain on study  treatm ent, the invest igator must obtain specific approval fro m a Sponsor 
physician or designee for the patient to continue on study treatm ent.
I5B-MC-JGDL( c) Clinical Protocol Page 67
LY30122079.5.1. Emergency Unblinding
Phase 2 :
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of a pati entâ€™s treatm ent assignment is warranted.  Patient safet y must always be the first 
consideration in making such a determinat ion.  If the invest igator decides that unblinding is 
warranted, the invest igator should make every effo rt to con tact the Lilly CRP /CRS prior to 
unblinding a patientâ€™s treatment assignment unless this could delay emergency treatment of the 
patient.  If a pati entâ€™s treatment assignment is unblinded, Lilly must be notified immediately.
All events resul ting in an unblinding event must be recorded and reported through the IWRS. If 
the invest igator or patient beco mes unblinded in the IWRS, that patient willbe discont inued 
from study  treatm ent.
9.5.2. Inadvertent Unblinding
Every  effort will be m ade to blind both the patient and the invest igator to the ident ity of the 
treatm ent, but the inadvertent unblinding of a patient may occur.  A double -blind study  design is 
known to be imperfect in the oncoly tic setti ng because the pot ential for individual unblinding 
exists due to treatment -related si gns and symptom s.  If an invest igator, site personnel performing 
assessments, or patient is unblinded, the unblinding will not be sufficient cause (in and of itself) 
for that pati ent to be discont inued fro m study  treatment or excl uded from  any safet y or efficacy  
analyses.
Addit ionally , there m ay be ethical reasons to have the patient remain on the study  treatm ent.  F or 
patients to con tinue on study  treatm ent in the event of unblin ding, the invest igator must obtain 
specific approval fro m a Lilly CRP /CRS for the pati ent to continue in the study .
9.6. Concomitant Therapy
All conco mitant m edicat ions should be recorded throughout the patientâ€™s participat ion in the 
study .
Concomitant medicat ions and supportive care therapies must also be documented at the time o f 
discontinuat ion and at the 30 -day short -term follow-up visit.
With the exceptions listed in the sect ions below, no other chemotherapy, invest igational
medicat ions, other anticancer therapy , immunotherapy , horm onal cancer therapy , radi ation, 
surgery  for cancer, or invest igationalmedicat ions will be permitted while pa tients are on study  
treatm ent.
Bisphosphonate osteoclast inhibitors ( for example , zoledronic acid or pamidronate) for treatment 
of bone metastases will be permitted while pat ients are on study  treatm ent.  However, the 
osteocl ast inhibitor denosumab is a monoclonal antibody  and coul d confound safet y analysis in 
the study  if the pati ent experie nces a hypersensit ivity reacti on to denosum ab.  Therefore, 
concomitant use of denosumab will not be permitted.
I5B-MC-JGDL( c) Clinical Protocol Page 68
LY3012207Appropriate documentation for all forms of premedicat ions, supportive care, and concomitant 
medicat ions (for example , medicat ions such as sedatives, ant ibiotics, analgesics, ant ihistamines, 
corticosteroi ds, erythropoi etin;procedures such as paracentesis, thoracentesis; or blood products 
such as blood cells, platelets, fresh frozen plasma transfusio ns)must be captured on the eCRF .
9.6.1. Suppo rtive Care
Patients shoul d receive full supportive care, if necessary .  Pati ents will  receive supportive care as 
judged by  their treating physician.  If it is unclear whether a therapy  shoul d be regarded as 
supportive care, the investigator should consult the Lilly C RP.  Use of any  supportive care 
therapy  must be captured on the eCRFs.
9.6.1.1. Granulocyte -Colony Stimulating Factors
G-CSF use is recommended in all cycles for patients with a prior history o f pelvic radiation.  For 
all other patien ts, G-CSF use is recommended per the guidelines outlined in Table JGDL. 2.
Patients wi th a pri or history  of pelvic radia tion who requi re chem otherapy  dose reducti on despi te 
prophylact ic G-CSF are not required to have prophylact ic G-CSF in subsequent cy cles if per 
investigator assessment such chemotherapy  dose reducti ons adequately  address the ri sk of 
further myelo suppressio n.
Prophylactic use of G -CSF shoul d consist of at l east 5 day s of G -CSF ( 5 micrograms/kg/day  
subcutaneously) beginning on Day  9, or a single dose of peg -GCSF ( 6 mg, subcutaneously) on 
Day 9 or 10.
9.6.1.2. Transfusion of Blood Products
Transfusio ns of red blood cells, platelets, or other blood products are permitted at the 
investigatorâ€™s discret ion, but may not be used to meet hematologic criteria for inclusion in the 
study  (refer to Secti on7.1,
 Inclusio n Criterion [9]).
9.6.1.3. Antiemetic Therapy
Both prophylactic and symptom -directed ant iemetic therap
iesare recommended and should be 
used in accordance wit h institutional guidelines (when existent) and/or at investigatorâ€™s 
discreti on.
9.6.2. Prohibited Therapies
Addit ional concurrent chemotherapy , radiati on therapy , biologic response m odifiers, or other 
investigat ional or approv ed anticancer agents may  not be administered to patients on this study .  
Palliat ive radiat ion or surgery  to symptom atic sites of disease will not be permitted while on 
study .
9.6.2.1. Effect of CYP3A4 Inhibitors and Inducers on Do cetaxel
Docetaxel is a CYP3A4 substrate. In vitro studies have shown that the metabo lism of docetaxel 
may be modified by the conco mitant administration of compounds that induce, inhibit, or are 
metabo lized by cytochrome P450 3A4. Avoid concurrent use o f docetaxel with inhibitors and 
inducers of CYP3A4. Refer to Attachment 7 for a list ofcommo nCYP3A4 inducers and 
inhibitors .  Use of a drug that is listed in Attachm ent 7 when there is no appropriate clinical 
I5B-MC-JGDL( c) Clinical Protocol Page 69
LY3012207subst itute for that drug will not be considered a protocol vio lation.Close m onitoring for toxi city 
and a docetaxel dose reduction could be considered if systemic administration of a potent 
CYP3A4 inhibitor cannot be avo ided.
9.7. Treatment Compliance
The study  medicat ion will be administered only at the invest igational sites by  the authorized 
study  personnel.  As a result, treatment compliance is ensured.   Treatment compliance will be 
monitored by  drug accountabilit y records, and treatm ent administration data are recorded in the 
patientâ€™s medical record and eCRF.  An investigator is required to prepare, maintain, and record 
all observat ions and other data pertinent to the investigation on each individual treated in this 
clinical trial.  All data reported on the eCRF must be derived from source documents and be 
consiste nt with the source documents.
I5B-MC-JGDL( c) Clinical Protocol Page 70
LY301220710. Efficacy , Patient Reported Outcomes ,Resource 
Utilization , Safety  Evaluations, Sample Collection and 
Testing, and A ppropriateness of Measurements
Written inform ed consent m ust be obtained pri or to any  study -specific pretreatm ent eval uations.
Study  procedures related to efficacy, safet y, patient-reported outcome s, resource utilizat ion
measures, sample collect ion,and testing assessments and their timing are described in the 
sections below and shown in the Study  Schedule ( Attachm ent 1 ).
10.1. Efficacy Measures
10.1.1. Radiographic Assessments at Baseline an d during Study 
Treatment
Within 28 days before enrollment in Phase 1 b and randomizat ionin Phase 2 , baseline tumor 
measurements will be performed on each pat ient.  Computed tomography (CT), including spiral 
CT scans and MRI are the pre ferred me thods of measurement .
The CT portion of a positron emission tomography ( PET)-CT scan may be used as a method of 
response assessment if the site can document that the CT is o f ident ical diagnostic qualit y to a 
diagnosti c CT (wi th intravenous and oral contrast). A PET scan alone or as part of a PET -CT 
may be performed for addit ional analyses but cannot be used to assess response according to 
RECIST .
The m ethod of assessment used at baseline must be used consistent ly for tum or assessment and 
will be repeated every 6 weeks (Â±7 day s), as calculated from date of enrollment for Phase 1b or 
rando mizat ionfor Phase 2 . Patients will be evaluated for response according to RECIST, v 1.1 
guidelines (Eisenhauer et al. 2009) , as outlined in Attachm ent 5 .
A Lilly  designated imaging core lab willcollect and store all tumor assessment images on all 
enrolled patients throughout the study. An independent review of all or a randomly selected 
subset of pat ient scans may be performed by an independent panel of radio logists.
After the primary  analysis of OS and unt il study  complet ion, Lilly will cont inue to collect all 
further anticancer treatment , subsequent disease progression date, and survival data on all 
patients but m ay reduce data collect ion for other efficacy data.  Th e frequency and ty pes of  
efficacy  assessments (other than collect ion of OS data) will be at the discret ion of the 
investigator, based on the standard of care.  Lilly will notify  investi gators when this reduced data 
collect ion begins and ends.
During the continued access period, efficacy assessments (frequency and type of assessments) 
will be at the discretion of the invest igator, based on the standard of care , and these data will not 
be co llected or analyzed.
I5B-MC-JGDL( c) Clinical Protocol Page 71
LY301220710.1.2. Radiographic Assessments during the S tudy Period 
Postdiscontinuation Follow -Up
Postdiscontinuati on follow-up during the study  period will be conducted as described in the 
Study  Schedule ( Attachment 1 ).
For those patients who discont inue study  treatm ent wi thout obj ectively measured PD, the 
investigat ive sites will cont inue to monitor patients and periodically evaluate tumor response 
every 6 weeks (Â±7 days) as calculated from enrollment (Phase 1b) or randomizat ion(Phase 2) by 
the sam emethod used at baseline and throughout the study  until the pati ent has object ive disease 
progression, or until the final analysis of OS.  After the pati ent has obj ective di sease progressi on, 
radiologic tests are no longer required and the patient shoul d be followed up approximately  every 
3months (Â±7 day s) for the fi rst  year, then every 6 mo nths (Â±14 days) unt il the pat ientâ€™s death or 
overall study  com pletion.
After final analysis of OS, during the Continued Access Period, efficacy assessments (frequency 
and t ype of assessments) will be at the discretion of the investigator, based on the standard of 
care.
Lilly will cont inue to collect all further ant icancer treatments, init ialsubsequent disease 
progression date, and survival data through study  com pletion but may reduce data collect ion for 
other efficacy data.  Lilly  will notify  invest igators when this reduced data collect ion begins and 
ends.
10.1.3. Primary Efficacy Measure
In the Pha se 2 partof the study , the primary  efficacy  measure is OS.   Overall survival durat ion is 
measured from the date of rando mizat ion to the date of death due to any cause.  For each patient, 
prior to each data analysis, a reasonable effort will be made to obtain the most up to date status 
of the pati ent (date of death or last date known to be alive). For each patient who is not known to 
have died as of the data -inclusio n cutoff date for a particular analysis, OS will be censored for 
that analysis a t the date the pati ent was l ast known to be alive .  For any  patient who has 
withdrawn consent for further fo llow-up of  survival  data, OS will  be censored at the l ast date for 
which the patient consented to be fo llowed for the study .
10.1.4. Additional Efficacy Mea sures
In the Phase 2 partof the study , the following additi onal efficacy measures will be determined 
for each pat ient, with planned statist ical analyses specified in Sect ion
 12and in the statistical 
analysis plan ( SAP;a separate docum ent).  Specific definit ions of each of these measures (such 
as defining events and censoring for each t ime to event endpo int) will b e provi ded in the SAP.  
The secondary  efficacy measures will be collected at the times shown in the Study  Schedule 
(Attachm ent 1 ).
ï‚·progression -freesurvival (PFS)
ï‚·object ive response rate (ORR)
ï‚·disease control  
rate (DCR)
I5B-MC-JGDL( c) Clinical Protocol Page 72
LY3012207ï‚·time to first worsening of the mBPI -sf (Brief Pain Inventory  Short F orm Modified) 
â€œworst painâ€ score
ï‚·time to any progression (censoring for death without progression)
ï‚·time to any new metastases (censoring for death and for other type of PD)
ï‚·new-metastases -free survival (nMFS)
ï‚·time to any progression based so lely on increased sum  of target l esions
ï‚·Time to sustained worsening of the QLQ -C30 scale scores (for example, Global Healt h 
Status / Qualit y of Life score, Phy sical Funct ioning score, and Role Functioning score)
ï‚·time to first worsening of ECOG PS
ï‚·second PFS (PFS2) after end of study  treatm ent while on subsequent ant icancer therapies
10.2. Patient -Reported Outcomes/Resource Utilization
Patient reported pain will be assessed using the mBPI -sf (Cleeland et al . 1991).  Health -related 
qualit y of l ife will be assessed with the EORTC QLQ -C30 (Aaronson et al. 1993).  Health status 
will be assessed using the EQ -5D- 5L (Janssen et al. 2008).  The PRO measures will be co llected 
on Day  1 of every  cycle and at the 30 -day short term fo llow-up visit.  
Paper versions of the quest ionnaires will be used.  It is reco mmended that the instruments be 
administered together and in sequence order, at the beginning o f the visit prior to other study  
procedures, with the mBPI-sf presented fi rst, followed by  the EORTC QLQ -C30 and continuing 
with the EQ -5D- 5L.  Whenever possible, if administration is not possible prior to all other 
procedures, at least every  effort shoul d be made to administer at the same t ime point in e ach 
visit.Questionnaires should be administered to th e pati ent pri or to extensive interaction wit h site 
staff and m ust be com pleted pri or to study  drug administration.
Patient-reported questionnaires should be completed by pat ients when a language translat ion is 
available in which the pat ient is fluent or literate.
10.2.1. mBPI -sf
The m BPI-sf (Cleeland et al . 1991) i s an 11 -item instrum ent used as a mult iple-item measure of 
cancer pain intensit y.  In addi tion to pain intensit y (4 items), the mBPI -sf is designed for patients 
to record the presence of pain in general, pain relief, and pain interference with funct ion (general 
activit y, mood, abili ty to wal k, abilit y to perform norm al work, rel ations with others, sleep, and 
enjoyment of life).  T he mBPI -sf is administered per the Study  Schedule ( Attachment 1 ).  The 
recall period is the past 24 hours or last week and complet ion time is ty pically 5 to 7 minutes.
Responses for the mBPI -sf items are captured through the use of 11 -point numeric rating scales 
anchored at 0 ( no pain ordoes not interfere ) and ranged through 10 ( pain as bad as you can 
imagine orcompletely interferes ).  The focus of the analysis will be on the â€œworst painâ€.  â€œWorst 
painâ€ intensit y has been shown to meaningfully impact patientsâ€™ lives as indicated by  a strong 
correl ation with functional interference scores in various ty pes of c ancer (Daut et al . 1983; 
Serlin et al. 1995; Ger et al. 1999; McMillan et al. 2000; Shi et al. 2009).  Moreover, a study  by 
Stone et al. (2004) suggested that patientsâ€™ tendency to focus on the most severe level o f pain 
I5B-MC-JGDL( c) Clinical Protocol Page 73
LY3012207during a recall period may bias average recalled pain. Therefore, t he focus of the analysis will 
be on the â€œworst painâ€.
Analgesic use will be recorded on the eCRF.  Data on each individual prescript ion and 
over-the-counter analgesic medicat ion will be recorded on the Concomitant Medicat ions eCRF ,
including but not limited to drug name and mode of administration.  The use of analgesics should 
be reviewed with the patient during each visit.  Any  changes to analgesic use (new or stopped 
analgesics) will be recorded on the eCRF.  Analgesics will be classified into 1 of 6 categories, 
using an analgesic ladder approach with medicat ion category  based on a World Healt h 
Organizat ion scale outlined in Table JGDL.8.  A therapy category  will be assigned according to 
the maximum category  of therapy  routinely administered based on analgesic data for that cycle.
The m BPI-sf popul ation will include all pat ients who com pleted the baseline assessment 
(Cycle1 Day 1)followed by at least 1 mBPI -sf â€œwors t painâ€ assessment after 1 cy cle of study  
drug (Cycle 2 Day 1 or l ater).
Table JGDL
.8. World Health Organization Pain Scale
Code Description
0 No analgesia
1 Aspirin (for pain, not cardiovascular prophylaxis), acetaminophen, nonsteroidal anti -inflammatory drugs
2 Codeine, hydrocodone, pentazocine, oxycodone
3 Oral morphine, hydromorphone, methadone, transdermal fentanyl
4 Parenteral opiates
5 Neurosurgical procedures (blocks)
10.2.2. EORTC QLQ -C30
Broadly used in cancer trials, validated, and available in over 80 different languages, the EORTC
QLQ -C30 (Aaronson et al. 1993) is a reliable and validated tool. The EORTC QLQ -C30 v3.0 is
a self -administered, cancer -specific ques tionnaire wi th multidimensio nal scales. The EORTC
QLQ -C30 self -reported general cancer instrument consists of 30 items covered by  1 of 3 
dimensio ns:
ï‚·global heal th status/qualit y of life (2 items)
ï‚·funct ional scales (15 total items addressing eit her physical, role, emotional, cognit ive, or
social functioning)
ï‚·symptom  scales (13 total items addressing either fatigue, nausea/vomit ing, pain, dyspnea,
insomnia, appetite loss, constipat ion, diarrhea, or financial impact)
The EORTC QLQ -C30 questi onnaire is administered per the Study  Schedule ( Attachm ent 1 ).  
The recall period is the past week, complet ion time is ty pically 5 to 7 minutes, and the
questionnaire will be scored as described by the EORTC scoring manual (Fayers et al. 2001).   
The EORTC population will include all pat ients who com pleted the baseline assessment (Cycle 1
Day 1) followed by at least 1 EORTC assessment after 1 dose of study drug (Cy cle 2 Day  1 or
later).
I5B-MC-JGDL( c) Clinical Protocol Page 74
LY301220710.2.3. EQ-5D-5L
The EQ -5D- 5L is a standardized instrument for use as a measure of self -reported heal th status
(Herdman et al. 2011).  Specifically , this quest ionnaire is included in this trial to evaluate 
healt h-state utilit ies associated with advanced STS.  These utilit y measures are an important 
input for economic evaluat ions concerning the value of treatment intervent ions.
The EQ -5D- 5L is designed to be used in conjunct ion wi th other pati ent-reported measures.  
Patients will  com plete the 5 -dimensio n (mobility, self -care, usual act ivities, pain/discomfort, and 
anxiet y/depressi on), 5-level (no problem, slight, moderate, severe, or extreme problem) 
assessment according to the Stu dy Schedule ( Attachment 1 ).  A unique EQ -5D healt h state is 
defined by co mbining 1 level fro m each of the 5 dimensions. Addit ionally, patients will indicate 
their current health status by  marking on a visual analogue scale (VAS) ranging from 100 (best 
imaginable healt h state) to 0 (worst imaginable healt h state).
The recall period is â€œtoday .â€  The EQ -5D- 5L is designed for self -completion by responde nts and 
is cognit ively  simple, taking only  a few minutes to complete.
The EQ-5D- 5L populat ion will include all pat ients who completed the baseline assessment 
(Cycle 1 Day 1) followed by at least 1 EQ -5D-5L assessment after 1 dose of study  drug (Cycle 2 
Day 1 or later) .
EQ-5D- 5L responses may be incorporated into cost utilit y analyses, but will not be included in 
the clinical study  report.
10.2.4. Resource Utilization
Invest igators will be asked to document the use of best supportive care measures, concomitant 
medicat ions, transfusio ns, and treatment -related hospitalization days.  Such assessments are to be 
taken throughout the study  through the 30 -day short -term postdi scont inuat ion follow-up visit .
10.3. Safety Evaluations
Invest igators are responsible for monitoring the safety of pat ients who have entered this study  
and for al erting Lilly or its designee to any  event that seems unusual, even if this event may be 
considered a n unant icipated benefit to the patient.
The invest igator is responsible for the appropriate medical care of pat ients during the study
.
The invest igator remains responsible for fo llowing, through an appropriate he alth care opti on, 
AEs that are serious, considered related to the study, or that caused the patient to discont inue 
before complet ing the study.  The patient should be fo llowed unt il the event is resolved or 
explained.  Frequency  of follow-up evaluati on is left to the discretion of the invest igator.
The timing of all safet y evaluat ions is shown in the Study  Schedule ( Attachm ent 1 ).  
Table JGDL .9presents a summary  of AE and SAE reporting guidelines.  Table JGDL .
9also 
shows which database or system is used to store AE and SAE data.
I5B-MC-JGDL( c) Clinical Protocol Page 75
LY3012207Table JGDL .9. Adverse Event and Serious A dverse Event Reporting Guidelines
Period Types of AEs/SAEs to be ReportedCollection 
DatabaseLilly Safety 
System
Baseline (pretreatment) Preexisting conditions x
All AEs x
SAEs related to protocol procedures x x
Study treatment period All AEs x
All SAEs x x
30-day  short - term 
postdiscontinuation follow -up All AEs x
All SAEs x x
Long -term postdiscontinuation 
follow -up All SAEs related to protocol procedures 
or study treatmentx x
Continued access period All AEs x
All SAEs x x
Continued access follow -up All AEs x
All SAEs x x
After the patient is no longer 
participating in the study (that is, no 
longer receiving study treatment and 
no lo nger in follow -up)All SAEs related to protocol procedures 
or study treatment that the investigator 
becomes aware ofx
Abbreviations:  AEs = adverse events; SAEs = serious adverse events.
10.3.1. Adverse Events
Lilly has standards for reporting AEs that are to be fo llowed regardl ess of applicable regulatory  
requi rements that m ay be less stringent.  A clinical study  AE is any untoward medical event 
associated wi th the use of a drug in humans, whether or not it is co nsidered rel ated to that drug.
Lack of drug effect is not an AE in clinical trials, because the purpose of the clinical trial is to 
establish drug effect.
Any clinically  significant findings fro m electrocardi ogram s (ECGs), labs, or vi tal sign 
measurements that result in a diagnosis should be reported to Lilly or its designee.
Cases of pregnancy that occur during maternal or paternal exposures to study  drugs shoul d be 
reported.  Data on fetal outcome and breast -feeding are collected for regulatory reporting and 
drug safet y evaluat ion.
Study  site personnel  will record the occurrence and nature of each patientâ€™s preexist ing 
condi tions, including clinically  significant si gns and symptom s of the disease under treatment in 
the study .
After the informed consent form (ICF) is signed, before th e pati ent receives the first dose of 
study  treatm ent, site personnel will record the occurrence and nature of any  AEs and any  change 
in the preexist ing condit ion(s).  All AEs and SAEs related to protocol procedures are reported to 
Lilly or its desi gnee viaeCRF .
I5B-MC-JGDL( c) Clinical Protocol Page 76
LY3012207In addit ion, all AEs occurring after the patient receives the first d ose of study  treatm entmust be 
reported to Lilly or its designee via eCRF.
Invest igators will be instructed to report to Lilly or its designee their assessment of the potential 
relatedness of each AE to protocol procedure, study drugs via eCRF .
Patients will  be evaluated for AEs at each visit and will be instructed to call their physician to 
report any  AEs between visi ts.
The NCI -CTCAE v 4.0will serve as the reference document for choosing appropriate 
termino logy for, and grading the severit y of, all AEs and other symptom s(NCI 2009)
.  For AEs 
without m atching termino logy wi thin the NCI -CTCAE v 4.0criteria,the investigator will be 
responsible for select ing the appropriate system organ class and assessing severit y grade based
on the intensit y of the event.
In addit ion to collect ing the AE verbat im and the CTCAE severit y grade, AE verbat im text wil l 
also be m apped by Lilly or its designee to corresponding termino logy within the Medical 
Dictionary for Regulatory  Activities (MedDRA Â®) di ctionary.
If a patientâ€™s dosage is reduced or treatment is discontinued as a result of an AE, study  site 
personnel must clearly  report to Lilly or its desi gnee via eCRF the ci rcumstances and data 
leading to any  such dosage reduction or discont inuation of treatment.
10.3.1.1. Serious Adverse Events
An SAE is any  adverse event from  this study  that results in one of the fo llowing outcom es:
ï‚·death
ï‚·a life
-threatening experience (that is, immediate risk of dying)
ï‚·persistent or significant disabilit y/incapacit y
ï‚·initial or prol onged inpatient hospitalizat ion
ï‚·congenital ano maly/birth defect
ï‚·considered significant by  the invest igator for any other reason
Important m edical events that may not result in death, be life -threatening, or require 
hospi talizati on may  be considered seri ous adverse drug events when, based upon appropriate 
medical judgment, they  may jeopardize the patient and may require medical or surgical 
intervent ion to prevent one of the outcomes listed in this definit ion.
Serious adverse event collect ion begins after the patient has signed informed consent and has 
received study  treatm ents.  If a pati ent experi ences an SAE after si gning informed consent, but 
prior to receiving study  treatm ents, the event will not be reported as serious unless the 
investigator feels the event may  have been caused by  a protocol  procedure.
Data on SAEs that occur before the end of trial will be stored in the collect ion database and the 
Lilly Safety  System .
Study  site personnel  must al ert Lilly or its desi gnee of  any serious adverse event (SAE) within 
24 hours of invest igator awareness of the event via a Sponsor -approved method.  If study  site 
I5B-MC-JGDL( c) Clinical Protocol Page 77
LY3012207personnel contact Lilly or its designee by  telephone regarding an SAE, study  site personnel  must 
also immediately provide official notificat ion on study -specific SAE forms.
This 24 -hour notificat ion requirement refers to the init ial SAE informat ion and all fo llow-up 
SAE informat ion.
Planned surgeries should not be reported as SAEs unless the underlying medical condit ion has 
worsened during the course of the study .
Planned hospi talizat ions or procedures for preexisting condit ions that are already recorded in the 
patientâ€™s medical history  at the time of study  enro llment should not be considered SAEs.  
Hospitalization or prolongat ion of hospitalizat ion without a preci pitating clinical AE (for 
example, for t he administration of study treatm ent or other protocol -requi red procedure) shoul d 
not be considered SAEs.
Serious adverse events due to disease progressi on, including death, shoul d not be reported unless 
the invest igator deems them tobe possibl y related to the study  treatm ents.
The invest igator does not need to actively mo nitor pati ents f or AEs once the trial has ended, 
unless provided otherwise in the protocol ; however, i f an invest igator becomes aware of an SAE 
occurring after the patientâ€™s participat ion in the trial has ended, and the investigator believes that 
the SAE is related to a protocol procedure or study treatments , the invest igator should repo rt the 
SAE to the Sponsor, and the SAE will be entered in the Lilly Safety  System .
Inform ation on SAEs expected in the study  popul ation independent of drug exposure and that 
will be assessed by  the Sponsor in aggregate periodically du ring the course of the trial may be 
found in the IB.
10.3.1.2. Suspected Unexpected Serious Adverse Reactions 
Suspected unexpected serious adverse react ions (SUSARs) are serious events that are not listed 
in the Development Core Safet y Informati on (DCSI) in the IB and that the invest igator identifies 
as rel ated to the study  treatm ents or study  procedure.  United S tates 21 CFR 312.32 and 
European Unio n Clinical Trial Direct ive 2001/20/EC and the associated detailed guidances or 
national regulatory  requi rements in parti cipat ing countries require the reporting o f SUSARs.  
Lilly has procedures that will be fo llowed for the recording and expedited reporting of SUSARs 
that are consistent with glo bal regulat ions and associated detailed guidances.
10.3.1.3. Adverse Events of Special Interest (AESI)
Adverse events of special interest (AESIs) are events that have been ident ified as safet y signals 
during preclinical or early  clinical tri als or based on class effects of similar drugs.  These events 
will be mo nitored prospectively in the clinical developmental program.  Each event is defined by  
a careful assessment and grouping of individual related MedDRA preferred terms.
AESI for olaratumab /placebo
ï‚·Infusio n
-related reacti ons
I5B-MC-JGDL( c) Clinical Protocol Page 78
LY3012207Refer to Section 9.4.1.2 for speci altreatm ent considerati ons for dose del ay, modificati ons, and 
discontinuat ions from  olaratum ab/placebo and gemcitabine/docetaxel , incl uding adverse events 
of concern or special inte rest.
10.3.2. Other Safety Measures
10.3.2.1. Electrocardiograms
Twelve -lead ECGs will be collected according to the Study Schedule( Attachm ent 1 ).  Patients 
must be supine for approximately  5 to 10 minutes before ECG collect ion and remain supine but 
awake during ECG collect ion.
Electrocardiograms may be obtained at addit ional times , when deemed clinically necessary .  
Collect ion of more ECGs than expected at a particular time point is allowed when needed to 
ensure high qualit y records.
Electrocardiograms will be interpreted by  a qualified physician (the investigator or qualified 
designee) at the site as soon after the time of ECG collect ion as possible, and ideally while the 
patient is st ill present, to determine whether the patient meets entry criteria and for immediate 
patient management, should any  clinically relevant findings be identified.
Table JGDL.10 provi des the Fridericia â€™s QT correctio n formula.
Table JGDL.10. Fridericia â€™s QT Correction Formula
FormulaFridericia 
QTc F= QT /(RR)1/3
Abbreviations:  QT = ECG interval measured from the onset of the QRS complex to the offset of the T wave; QTcF 
= QT interval corrected for heart rate using Fridericiaâ€™s formula; RR = time between corresponding points on 2 
consecutive R waves on ECG.
After enro llment, if a clinically significant increase in the QT/corrected QT (QTc) interval fro m 
baseline (Table JGDL.10) , or other clinical ly significant quanti tative or qualitat ive change fro m 
baseline, i s present, the invest igator will assess the patient for symptoms (for example, 
palpitations, near syncope, syncope) and to determine if the patient can cont inue in the study .  
The invest igator or qualified designee is responsible for determining if any change in pat ient 
management is needed and must document his/her review of the ECG printed at the time of 
evaluat ion.
For Phase 1b, all digital ECGs w ill be electroni cally  transmi tted to a desi gnated central ECG 
laboratory .  
A cardio logist at the central ECG laboratory  will then conduct a full overread on the 
ECG (including all intervals); a report based on data from this analysis will be issued to the 
investigat ive site.  All data from the overreads will be placed in the Lilly database for analyt ical 
and study  report purposes.
When there are differences in ECG interpretation between the invest igator (or qualified 
designee) and the cardio logist at the central  ECG laboratory , the investigator (or qualified 
designeeâ€™s) interpretation will be used for study  entry  and immediate patie nt management.  
I5B-MC-JGDL( c) Clinical Protocol Page 79
LY3012207Interpretations from the cardio logist at the central  ECG laboratory  will be used for data analysis 
and report writ ing purposes.   The invest igator (or qualified designee) must document his/her 
review of the ECG printed at the time of evaluat ion, the final overread ECG report issued by  the 
central  ECG l aboratory , and any alert reports .
10.3.3. Safety Monitoring
The Lilly CRP/CRS will m onitor saf ety data throughout the course of the Phase 1b partof the 
study and blinded safety data throughout the course of the Phase 2 partof the study .
Lilly will review SAEs wit hin time frames mandated by co mpany procedures.  The Lilly
CRP /CRS will, as is appropriate, consult with the funct ionally  independent Gl obal Pat ient Safet y 
therapeuti c area physician or clinical scient ist, and review:
ï‚·trends in safety  data
ï‚·laboratory  analy tes 
ï‚·AESI (as defined in Sect ion10.3.1.3 )
If a patient experiences elevated ALT >5 Ã—ULN and elevated total bilirubin >2 Ã—ULN, clinical 
and laboratory  monitoring shoul d be ini tiated by  the invest igator. For pat ients entering the study  
with ALT >3 Ã—ULN, m onitoring shoul d be tri ggered at ALT >2 Ã—baseline.   Details for hepat ic 
monitoring depend upon the severit y and persistence of observed laboratory  test 
abnorm alities.To ensure patient safety and co mply with regulatory  guidance, the invest igator is 
to consul t with the Lilly CRP regarding co llection of specific reco mmended clinical information 
and fo llow-up laboratory  tests. See0.
For the Phase 2 partof the study , in the event that safet y monitoring uncovers an issue that needs 
to be addressed by  unblinding at the group l evel, only  members of the data m onitoring 
committee (an advisory  group for this study  formed to protect the integrit y of data; refer to 
Secti on12.2.14 )
 can conduct addit ional analyse s of the safet y data.
For the Phase 2 partof this study , in which survival is a primary endpo int, all deaths and SAE 
reports will be reviewed in a blinded manner by Lilly during the clinical trial.  These reports will 
be reviewed to assure completeness and accuracy but will not be unblinded to Lilly during the 
clinical trial.  If a death or other clinical AE is deemed serious, unexpected, and possibly related 
to study  treatments, only Lilly Global Patient Safety  representatives external to the study  team  
will be unblinded for regulatory  reporti ng and safety  monitoring purposes.  These measures will 
preserve the integrit y of the data collected during this trial and minimize any potential for bias 
while providing for appropriate safet y monitoring.
10.3.4. Complaint Handling
Lilly collects product complaints on study  treatm entused in clinical trials in order to ensure the 
safet y of study  participants, m onitor qua lity, and to facilitate process and product improvements.
Com plaint s related to docetaxel and/or gemcitabine are reported direct ly to the manufacturers of 
those drugs/devices in accordance with the package insert.
I5B-MC-JGDL( c) Clinical Protocol Page 80
LY3012207For blinded studies, all product complaints associated with material packaged, labeled, and 
released by Lilly or its designee will be reported.
The invest igator or his/her designee is responsible for handling the fo llowing aspects o f the 
product complaint process in accordance wit h the instructions provided for this study :
ï‚·recording a complete descript ion of the product complaint reported and any associated 
AEs using the study -specific co mplaint form s provided for this purpose
ï‚·faxing the com pleted product complaint form wit hin 24 hours to Lilly or its desi gnee
If the invest igator is asked to return the product for invest igation, he/she will return a copy  of the 
product complaint form with the product.
10.4. Sample Collection and Testing
Attachm ent 1 lists the schedule for sample collect ions in this study.
Attachm ent 2 lists the specific tests that will be performed for this study  and whether these will 
be perform ed at a central or local laboratory.
10.4.1. Samples for Study Qualification and Health Monitoring
Blood and urine samples will be collected to determine whether patients meet 
inclusio n/excl usion criteria and to m onitor pati ent heal th.  Eligibilit y for inclusio n in this clinical 
trial will be based on l ocal clinical  laboratory  results (not transcribed onto eCRFs) and duplicate 
samples will be submitted to the central laboratory.   Treatment decisio ns may be based upon 
resul ts of tests perform ed locally. If local laboratory  tests are used for this purpose, then a 
duplicate specimen must be submitted to the central laboratory . Discrepancies between local and 
central  laboratory  that may have an impact on eligibilit y or treatm ent deci sions will  not be 
considered protocol deviat ions.
Invest igators must document their review of each laboratory  safety  report.
Laboratory /analy te resul ts that coul d unblind the study  will not be reported to invest igative sites 
or other blinded personnel until the study  has been unblinded.
Samples co llected for specified laboratory tests will be destroyed wit hin 60 days of receipt of 
confirmed test results.  Tests are run and confirmed prompt ly whenever scient ifically 
appropriate.  When scientific circumstances warrant, however, it is acceptable to retain samples 
to batch the tests run, or to retain the samples until the end of the study  to confirm  that the resul ts 
are valid.  Certain samples may be retained for a longer period, if necessary, to comply wit h 
applicable laws, regulat ions, or l aboratory  certificati on standards.
10.4.2. Biomarker Samples for Storage and Research
Biomarker research is performed to address questions of relevance to drug disposit ion, target 
engagement, pharmacodynamics, mechanism o f action, variabilit y of pat ient response (including 
safet y), and clinical outcome.  Sample collect ion is incorporated in to clinical studies to enable 
examinat ion of these questions through measurement of bio molecules including 
I5B-MC-JGDL( c) Clinical Protocol Page 81
LY3012207deoxy ribonucleic acid ( DNA ), ribonucleic acid ( RNA ), proteins, lipids, and other cellular 
elements.
As part of Lil lyâ€™s ongoing efforts to understand the relat ionship between cancer, genet ics, and 
response to therapy , this study  will analyze bio markers relevant to olaratumab, gem citabine, 
docetaxel ,and/or STS. The study  will analyze the correlat ion between bio markers and clinical 
outcom e and m ay be used for related research methods or validat ion of diagnostic tools or 
assays.
Samples for bi omarker research will be co llected at times specified in Attachment 6 , where local 
regul ations allow.
Where local regulat ions and ERBs allow, the fo llowing samples will be co llected for biomarker 
research as summarized below, specified in the Study  Schedule, and discussed in detail in the 
following subsect ions:
ï‚·whole blood sam ple for geneti c research (see Section10.4.2.1 )
ï‚·tumor tissue (newly obtained or archived) (see Section10.4.2.2 )
ï‚·plasma for bi omarkers (see Section10.4.2.3 )
10.4.2.1. Whole Blood Sample for Genetic Research
A blood sam ple will be collected for pharmacogenetic analysis as specified in t he Sampling 
Schedule (Attachment 6 ), where local regulat ions allow .
Samples will  notbe used to conduct unspecified dise ase or popul ation genet ic research either 
now or in the future.  Samples will be used to investigate variable response to study  treatm ent 
and to investigate genetic variants though t to pl ay a rol e in STS.  Assessment of variable 
response may include evalua tion of  adverse events or differences in efficacy.  These studies may 
include but are not limit ed to PDGFR ï¡, PDGFR ï¡ligands, and genes funct ional in the tumor 
microenvironment to evaluate their association wit h observed response to study  treatm ent.
All samples will be coded with the patientnumber.  These samples and any data generated can 
be linked back to the patient only by the study site personnel.  Sam ples will  be retained for a 
maximum o f 15 years after the last patient visit for the study, or for a shorter period if local 
regul ations and/or ERBs /IRBs impose shorter time limits, at a facilit y selected by  the Sponsor.  
This retentio n peri od enables use of new techno logies, response to regulatory  quest ions, and 
investigat ion of variable response that may not be observed unt il later in drug development or 
when the drug is commercially available.
Molecular techno logies are expected to improve during the 15 -year storage period and therefore 
cannot be specifically  named.  However, exist ing techno logiesinclude who le geno me or exo me 
sequencing, geno me wide association studies, candidate gene studies, and epi geneti c analyses.  
Regardless of the techno logy utilized, data generated will be used only  for the specific research 
scope described in this sect ion.
I5B-MC-JGDL( c) Clinical Protocol Page 82
LY301220710.4.2.2. Tumor Tissue for Biomarker Research
Previously obtained archived f ormalin-fixed paraffin- embedded tissue will be requested both for 
a central  pathol ogy review to confirm the diagnosis of STS and histol ogic subty pe, and for 
exploratory  biomarker research .
Collect ion of m andatory  archived tum or tissue sample ornewly obtained biopsy is required in 
order to participat ein this study unless restri cted by  local regulat ions.  If an archived specimen is 
not available, submissio n of a newly obtained biopsy (obtained at b aseline) is required for 
participat ion in this study .
The availabilit y of tum or tissues is important to better characterize the relat ionship of tumor 
biology and response evaluat ion in this study .  As such, this study  is requesting submissio n of 
tumor tissue (newly biopsied or archived) to support correlat ive studies.
Formalin -fixed paraffin -embedded tum or tissue shoul d be provi ded as a block or unstained 
slides.  Due diligence should be used to make sure that tumor specimen (n ot a norm al adjacent or 
a tum or margin sample) is provided.  Pathology  notes accom panying archival tissue may  also be 
requested. The report must be coded with the patient number.  Personal identifiers, including the 
patientâ€™s name and init ials must be removed fro m the inst itutional pathol ogy report pri or to 
submissio n. Archival blo cks will  be secti oned and returned to the study  site. Archival s lides and 
tissue samples co llected on -study  will not be returned .
Tumor tissue will  be examined for bio markers that may include, but are not limited to, those 
related to STS, study  treatm ent and/or the mechanism of act ion of olaratumab .
Samples will  be retained for a m axim um of 15 y ears after the last patient visit for the study , or 
for a shorter peri od if local regulations and/or ERBs /IRBs impose shorter time limits, at a facilit y 
selected by  the Sponsor.  This retention period enables use of new techno logies, response to 
regul atory  questi ons, and invest igation of variable response that may not be observed unt il later 
in drug development or when the drug is co mmercially available.
Techno logies are expected to improve during t he 15 -year storage period and therefore cannot be 
specifically named.  However, exist ing approaches including mutation profiling, copy  number 
variabilit y, gene expressio n, and/or immunohistochemistry  may be perform ed on these ti ssue 
samples to assess poten tial associ ations wi th these bi omarkers and clinical outcomes.
10.4.2.3. Plasma Samples for Biomarker R esearch
Plasma sam ples f or non -pharmacogenet ic biomarker research will be collected at the times 
specified in the Sampling Schedule ( Attachment 6 ),where local regulat ions allow.
Samples will  be examined for bio markers related to cancer, variable response to study  treatm ent, 
the mechanism of act ion of  study  treatm ent, and/or for research -related m ethods, or validating 
diagnosti c tool s or assays.
Potenti al pharmacodynamics and/or circulating markers may  include, but are not limited to ,
PDGF -AA, PDGF -BB, and PDGF -CC.
I5B-MC-JGDL( c) Clinical Protocol Page 83
LY3012207All biomarker samples will be coded with the patient number.  These samples and any  data 
generated can be linked back to the patient only by t he study site personnel.
Samples will  be retained for a m aximum  of15 years after the last patient visit for the study , or 
for a shorter peri od if local regulations and ERBs /IRBs impose shorter time limits, at a facilit y 
selected by  the Sponsor.  This retention period enables use of new techno logies, response to 
regul atory questi ons, and invest igation of variable response that may not be observed unt il later 
in drug development or when the drug is co mmercially available.
10.4.3. Samples for Immunogenicity Research
Blood sam ples f or immunogenicit y testing will  be collected to determine ant ibody  producti on
against olaratumab. To interpret the results of immunogenicit y, blood sam ples will  be collected
at the sam e time po ints as the blood samples designated to measure the serum concentrations of
olaratum ab (as noted in Section 10.4.4 ).
In the event of an olaratumab/placebo IRR, unscheduled blood samples will be co llected for 
additional immunogenici tyand PK analysis. These addit ional samples will be co llected as close 
as possible to the onset of the event, at the point of resolution fro m theevent, and 30 day s (Â± 3 
days) after onset of the event (as noted in Attachment 6).
Immunogenicit y will be assessed by  a validated assay  designed to detect anti -drug antibodies 
(ADA) inthe presence of the olaratumab. Antibodies may be further characterized and/or 
evaluated for their abili ty to neutralize the activit y of olaratum ab. Immunogenicit y may be 
further characterized by performing addit ional related assay s. The serum samples collected for
immunogenicit y testin g will  be stored at a facilit y designated by  the Sponsor.
Immunogenicit y informat ion that would unblind the study  will not be reported to invest igative
sites or blinded personnel unt il the study has been unblinded.
Samples may be stored for a maximum of 15 y ears f ollowing l ast pati ent visi t for the tri al at a
facilit y selected by  the Sponsor to enable further analysis of immune responses to olaratumab.   
The durati on allows the Sponsor to respond to regulatory  requests relate d to ol aratum ab.
10.4.4. Samples for Drug Concentration Measurements 
Pharmacokinetics
At the visit s and t imes specified in the Pharm acokinet ic and Immunogenicit y Sampling Schedule 
(Attachm ent 6 ), venous blood samples will  be collected to determine the serum concentrati ons of  
olaratum aband pl asma concentration sof gemci tabine and docetaxel .  A maximum o f 5samples 
may be collected at addit ional time points during the study ,if warranted and agreed upon 
between both the investigator and Lilly .  Instructi ons for the collection and handling of blood 
samples will be provided by  the Sponsor .  Itis preferred that the blood samples be obtained fro m 
a peripheral locat ion.  Bl ood sam ples will be allowed fro m central  access devices ,but a sam ple 
drawn fro m a centra l catheter of any t ype for PK must take precautions to prevent obtaining a 
dilute dsample.  If m ultiple sampl es are obtained centrally , the PK sample shoul d be the l ast 
I5B-MC-JGDL( c) Clinical Protocol Page 84
LY3012207specimen drawn to reduce the potential for a diluted or improperly drawn sample.   The actual 
date and time ( 24-hour clock time ) of each sampling will be recorded.
These s amples will be analyzed at laborator iesdesignated by  the Sponsor.  Serum concentrations 
of olaratum abwill be assayed using a validated enzyme
-linked immunosorbent assay (ELISA) 
method .  Gem citabine (with its major m etabo lite, dFdU) and docetaxel concentrati ons in plasma 
will be analyzed using validated liquid chro matography wit h tandem mass spectrometry  
(LC/MS/MS) a ssays.
Drug concentration informat ion that wouldunblind the study  will not be reported to invest igative 
sites or blinded p ersonnel until the study has been unblinded.
The PK samples will be stored at a facilit y designated by  the Sponsor.   The remaining serum  and 
plasma f rom the samples collected for pharmacokinet ics may be pool ed and used for exploratory  
metabo lism work and other exploratory PK/pharmacodynamic work as deemed appropriate.
Bioanaly tical samples collected to m easure olaratumab, gem citabine ,and docetaxel
concentration will be retained for a maximum of 1 year fo llowing l ast pati ent visi t for the study .
10.5. Appropriateness of Measurements
The m easures used to assess safet y and efficacy in this study  are consistent wi th those used in 
most convent ionaloncol ogy trials.
I5B-MC-JGDL( c) Clinical Protocol Page 85
LY301220711. Data Quality  Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
ï‚·provi de instructi onal materi al to the study  sites, as appropriate
ï‚·sponsor start -up training to instruct the invest igators and study  coordinators.  This sessio n 
will give instruction on the protocol, the completion of the CRFs, and study  procedures.
ï‚·make periodic visit s to the study  site
ï‚·be available for consultation and stay  in contact with the study  site personnel by  mail, 
telephone, and/or fax
ï‚·review and evaluate CRF data and use standard computer edits to detect errors in data 
collect ion
ï‚·conduct a qualit y review of the database
In addit ion, Lilly or its representatives will periodically check a sample of the pati ent data 
recorded against source documents at the study  site.  The study  may be audi ted by  Lilly or its 
representatives, and/or regulatory  agencies at any  time.  Invest igators will be given notice before 
an audit occurs.
To ensure the safet y of participants in the study , and to ensure accurate, complete, and reliable 
data, the invest igator will keep records of laboratory tests, clinical notes, and patient medical 
records in the patient files as original source documents for the study .  If requested, the 
investigator will provide Lilly , applicable regul atory  agencies, and applicable ERBs with direct 
access to original source documents.
11.1. Data Capture S ystem
An electronic data capture sy stem  will be used in this trial.  The site mai ntains a separate source 
for the data entered by  the si te into the Sponsor -provided electronic data capture sy stem .
Case report form data will be encoded and stored in a clinical trial database.  Data managed by a 
central  vendor, such as laborat ory test data or ECG data, will be stored electronically in the 
central  vendorâ€™s database system.  Data will subsequent ly be transferred from the central vendor 
to the Lilly generic labs system.
Any data for which the paper documentat ion provided by  the patient will serve as the source 
docum ent will be i dentified and documented by  each si te in that si teâ€™s study  file.  Paper 
docum entati on provi ded by  the patient may include, for example, a paper diary  to collect PRO 
measures (for example, a rating scale), a daily dosing schedule, or an event diary.
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint m anagement sy stem .
I5B-MC-JGDL( c) Clinical Protocol Page 86
LY301220712. Sample Size and Statistical Methods
12.1. Determination of Sample Size
Phase 1b
The primary  object ive of the Phase 1b partis to determine a recommended Phase 2 dose of 
olaratum ab that m ay be safely administered in combinat ion with gemci tabine (900 m g/m2)and 
docetaxel (75 m g/ m2)to pati ents wi th locally advanced or metastati c STS . Section 8.1.1
outlines the study  design for the Phase 1b portion.  Approximately , a total  of 
45patients will  
ensure that at l east 1 5patients will be treated at the 15-mg/kg and 30 pati ents at the 20-mg/kg 
cohort (see also Section 8.1.1 .).
Phase 2
Based on the outcome of the Phase 1b part, the dose selected for the Phase 2 part of Study JGDL 
will be eit her 15 m g/kg, 20 m g/kg,or 2loading doses of 20 mg/kg during Cycle 1 fo llowed by 
15mg/kg in every  subsequent cycle. Thedosing regimen for olaratumab will remain Day s1 and 
8 of a 21- day cycle regardl ess of the dosing strategy  adopted.
The primary  object ive of the Phase 2 partis to compare olaratumab plus gemci tabine and 
docetaxel (experimental arm) versus place bo pl us gemci tabine/ docetaxel  (control  arm) in term s 
of OS
,in patients with locally advanced or metastatic STS ,who have not previously been treated 
with olaratum ab (the â€œo laratumab-naÃ¯ve â€cohort) .
The Phase 2 part of the study will screen approximately 2 00olaratumab-naÃ¯ve patients to 
rando mize 166 olaratumab-naÃ¯ve patients in 1:1 randomizat ion (83 pati ents in the experimental 
arm and 83 patients in the control arm).  The primary ITT sample size of 166 was selected 
assuming the final analysis of OS will occur when at least 108 OS events in rando mized 
olaratumab-naÃ¯ve patients have been observed (35% censoring).
The final total of 108OS events (deaths) in olaratumab -naÃ¯ve pat ients provides 80% statist ical 
power for a two
-sided log-rank test at a 0. 20significance level (assuming the true OS HR is 
0.665).  An OS HR of 0. 665corresponds approximately to an increased median survival fro m 15 
months (est imated fro m published clinic al data in various t ypes of pat ients with advanced or 
metastati c STS) in placebo pl us gemcitabine and docetaxel to 22.5 months for olaratum ab plus 
gemcitabine and docetaxel .
In the event that OS is statist ically significant at the two -sided 0.20 alpha level, OS will also be 
compared to the m ore stringent two -sided 0.05 level.  In the event that OS is statistically 
significant at a two -sided 0.05 al pha l evel, then PFS will also be formally tested at a two -sided 
0.05 l evel. In the event that PFS is statistically significant at a two -sided 0.05 al pha level , then 
ORR will also be formally tested at a two -sided 0.05 level. This stati stical â€œgate -keepingâ€ 
amongOS,PFS,and ORR ensures that an overall 0.05 alpha level is maintained, in the event 
that oneor moreendpo ints are statistically significant at the 0.05 level.
Akey secondary objective of the study  will be to com pare OS between the experi mental  arm and 
the control arm in pat ients with locally advanced or metastati c STS ,who have previously been 
I5B-MC-JGDL( c) Clinical Protocol Page 87
LY3012207treated with o laratumab (the â€œo laratumab -pretreatedâ€ cohort) .   The Phase 2 part of the study will 
screen approximately 114 olaratum ab-pretreated patients to randomize 90olaratu mab-pretreated 
patients in 1:1 randomizat ion.
The sample size of 90 patients in the secondary cohort of â€œo laratumab -pretreatedâ€ patients was 
selected based on both statist ical and quali tative considerati ons.  See Secti on 12.2.14 for further 
discussio n of the rationale.
There will be aninterim efficacy  analysis planned for the Phase 2 partof the study .All available 
data on patient characterist ics, efficacy , and safet y outcom es will  be included for consi derat ion 
as part of the interim efficacy analysis. The primary  efficacy hypothesis will be tested at the 
interim efficacy  analysis using a no minal alph a level  of 0.00001.  The final analysis of the 
primary  efficacy  hypothesis will therefore be adjusted and tested at a nominal alpha level o f 
0.19999.
See Secti on
 12.2.14 and the studyâ€™s Statist ical Analysis Plan (a separate document) for further 
details regarding the interim efficacy analysis.
12.2. Statistical and Analytical Plans
12.2.1. General Considerations
Statistical analysis o f this study  will be the responsibilit y ofLilly .
All tests of treatment effects will be conducted at a 2 -sided al pha level of 0.05, unless otherwise 
stated.  All CIs will be given at a 2 -sided 95% level, unless otherwise stated .
Any change to the data analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol.   Before unblinding of the aggregate 
database, minor modifications or clarificat ions to the data analysis methods may be described 
and just ified in the SAP.  Any other change to the data analysis methods described in the 
protocol , and the j ustificat ion for making the change, will be described in the clinical study  
report.
If study  data vi olate key  stati stical assumpt ionsofan analysis method, alternat ive statist ical 
methods m ay be used.
Unless specifically described otherwise, all baseline, efficacy, safety , 
and heal th outcom es
analyses will be performed separately for the olara tumab-naÃ¯ve and olara tumab-pretreated 
cohorts.
Addit ional exploratory  analyses of the data will be conducted as deemed appropriate.
12.2.2. Analysis Population s
Phase 1b
Safety population: All enro lled patients who receive any quantit y of study  treatment , 
regardl ess of t heir eligibilit y for the study , will  be included in the safet y analysis. Safety 
I5B-MC-JGDL( c) Clinical Protocol Page 88
LY3012207evaluat ion will be performed based on the actual init ial therapy a patient has received, 
regardl ess of any other cohort to which he or she was assigned.
Efficacy eval uation will be performed based on the cohort assigned, regardless of the actual 
dose l evel of therapy  received.
DLT -evaluable Population : The DLT -evaluable popul ation will include all enrolled 
patients who com plete Cy cle 1 or di scontinue due to a DLT prior to complet ing Cycle 1 
treatm ent.
Phase 2
TheIntent -to-Treat (ITT) population include sall randomized pat ients.In ITT populat ion,
patients will be allocated to treatment groups as rando mized, and not by actual treatment 
received. This populat ion will be used for baseline, efficacy, and heal th outcom e analyses.
Safety population:   will include all rando mized pati ents who received any  quant ity of study  
treatm ent, regardless o f their eligibili ty for the study . The safet y evaluation will be 
perform ed based on the actual study  treatm ent a pati ent has received, regardless o f the arm  to 
which he or she was rando mized. The safet y populat ion will be used for all dosing/exposure, 
adverse events, and resource utilizat ion analyses.
12.2.3. Patient Disposition
A detailed description o f patient di sposi tion will be provi ded.  It will include a summary  of the 
number and percentage of patients entered into the study , enrolled in the study , and treated as 
well as n umber and percentage of patients completing the study , or discont inuing (overall and by 
reason for discont inuat ion).  A summary  of all important protocol deviat ions will be provided.
12.2.4. Patient Characteristics
Descript ion of pat ient characterist ics at baselin e, such as pat ient demographics , baseline disease 
characterist ics, preexist ing condit ions, and pri or therapi es,will be reported using descript ive 
statist ics.
12.2.5. Concomitant Therapy
Concomitant medicat ions will  be summarized for the safet y populati on.
12.2.5.1. Postdiscontinuation Therapy
The numbers and percentages of patients reporting postdiscont inuat ion therapies will be 
provi ded overall, by  type of  therapy  (surgery , radiotherapy , or system ic therapy ), and by  drug 
name.
12.2.6. Treatment Compliance
The number of dose omissio ns, reducti ons, and delays, the number of cycles received, and dose 
intensity will be summarized for all treated patients per treatment arm.
I5B-MC-JGDL( c) Clinical Protocol Page 89
LY301220712.2.7. Primary Outcome and Methodology
Phase 1b
The Phase 1b is a dose -escalat ion study .The primary  safet y endpo intis DLT. For each dose 
cohort, the numbers o f DLT will be assessed based on DLT -evaluable popul ation.
Phase 2
The primary  efficacy  outcome for the Phase 2 part of the study is OS inthe olaratumab -naÃ¯ve 
cohort of the ITT populat ion. The final analysis o f OS will be based on the stratified log -rank 
test, stratified by  3 of the 4 randomizat ion factors: number of prior systemic therapies for locally
advanced or metastati c disease (0 versus â‰¥1), histological tumor ty pe (leiomyosarcom a versus 
non-leiomyosarco ma), and ECOG PS (0 versus 1).
Overall survival curves, the median wit h 95% CI and survival rates at various time points for 
each treatment group will be est imated using the Kapl an-Meier m ethod (Kapl an and Meier 
1958).  The HR will be est imated using a stratified Cox regression model (Cox 1972) , stratified 
the sam e as the log-rank test described above.
12.2.8. Other Analyses of Efficacy
12.2.8.1. Progression -Free Survival
Phase 2
A precise definit ion of events and censoring for PFS will be d efined in the SAP. Progression -free 
survival will be analyzed using the Kaplan -Meier meth od, 
and compared based on a log -rank 
test, stratified by  the same stratificat ion factors used in the analysis o f the primary  endpoint OS.
PFS will be co mpared between the 2treatm ent groups based on l og-rank test, stratified by the 
same stratificat ion factors used in the analysis of the primary  endpoint OS.  PFS survival curves, 
the median with 95% CI ,and survival rates at various time points for each treatment group will 
be est imated using the Kaplan -Meier m ethod (Kaplan and Meier 1958).   The HR will be 
estimated using a stratified Cox regressio n model,stratified b y randomization strata .
12.2.8.2. Additional Efficacy Analyses
Addit ional analyses of the m easures defined in Section 10.1.4 , as well as any other pre -planned 
efficacy  analyses ,will be d efined in the SAP.   In the event that efficacy is observed to be very 
similar between the olaratumab- naÃ¯ve and o laratum ab-pretreated cohorts, it may  be reasonable to 
concl ude a uniform  efficacy across cohorts; in that case, additional efficacy  analyses m ay be 
perform ed pooling these 2popul ations, in order to obtain pooled estimates of efficacy 
param eters.
12.2.9. Pharmacokinetic andImmunogenicity Analyses
12.2.9.1. Pharmacokinetics
Pharmacokinet ic analyses will be conducted on patien ts who have received at least 1 dose of the 
study  drug and have had sufficient postdose samples collected to allow estimat ionof PK 
param eters .
I5B-MC-JGDL( c) Clinical Protocol Page 90
LY3012207In the Phase 1b part, PK parameter estimates will be co mputed by standard nonco mpartmental 
methods of analysis for olaratum ab, and for gem citabine, dFdU ,and docetaxel . The m aximum  
concentration (C max), time o f Cmax(tmax), area under the concentration -time curve (AUC), 
half-life ( t1/2), volume of distribution at steady  state (Vss), clearance (CL), and other relevant 
param eters that can be calculated from the data will be reported from the senonco mpart mental 
analyses.
In the Phase 2 part, PK pa rameters for olaratumab (CL, exposure, Vss, and t1/2) and inter -
individual PK variabilit ywill be computed using nonlinear mixed effect modeling implemented 
inNONMEM .  The versio n of any  software used for the analysis will be do cumented and the 
program will meet the Lilly  requi rements of  software validation. Gem citabine, dFdU, and 
docetaxel plasma levels will be reported using descript ive methods.
If warranted by  the data,PK/pharmacodynamic analyses using OS, PFS, and/or other appropriate 
clinical endpo ints willalso be conducted to characterize the exposure- response relationship in 
this study .
12.2.9.2. Immunogenicity
Incidence of treatm ent-emergent (TE) anti-olaratumab ant ibodies and any rela ted assays will be 
tabul ated.  The potential impact of immunogenicit y on ol aratum ab exposure will be evaluated in 
the popul ation PK m odeling exercises where immunogenicit y will be evaluated as a covariate.  
In addit ion, graphical assessments will be conduc ted, as appropri ate, to com pare drug exposure 
between TEADA -negat ive and TEADA -positive patients at correspondent visits, or before and 
after TE-ADA development for patients who developed TE-ADA.  However, for patients who 
test posit ive for ADA, thei r AD A titers will be listed over time and associated PK information 
(for example, plasma concentration) will be listed in subsequent cycles for each patient .
In the event of an IRR, the immunogenicit y and olaratum ab serum  concentrati ons will  be 
tabul ated.
12.2.10. Exploratory Translational Research Analyses
Biomarker assay  resul ts will be summarized and correlated with clinical outcomes.
12.2.11. Analyses of Patient -Reported Outcomes (PROs)
Patient-reported outcomes are measured through the f ollowing:
â€¢ mBPI -sf (Brief Pain Inventory  [Short F orm] Modified)
â€¢ EORTC QLQ -C30 (The European Organization fo r Research and Treatment of Cancer 
Qualit y of Life Quest ionnaire Core 30)
â€¢ EQ 5D -5L (EuroQol 5 -Dimensio n 5-Level)
For each instrument (mBPI -sf, EORTC QLQ -C30, and EQ -5D- 5L), percentage ofcompliance 
and reasons for non -compliance will be summarized by  treatm ent arm  and time point , for the ITT 
popul ation. Percentage ofcompliance will be calcul ated as the number of completed 
assessments divided by  the number of expected assessments .
I5B-MC-JGDL( c) Clinical Protocol Page 91
LY3012207Data will be separately summarized descript ively. Analyses will be performed separately by 
cohort (ol aratum abnaÃ¯ve and o laratumab -pretreated). The m ain efficacy measure for the pain 
endpo int will be the time to first worsening of the mBPI -sf â€œworst painâ€ score. Time to first 
worsening in pain will be described using the method of Kaplan -Meier and analyses will b e 
made between the 2 arms by  a log-rank test.  â€œWorseningâ€ will be defined as either a â€œworst 
painâ€ increase of â‰¥2 points post -baseline (Farrar et al. 2001; Rowbotham 2001) or an analgesic 
drug class increase of â‰¥1 level.  However, other approaches to defi ning clinically  meaningful  
worsening in pain might be considered.  Further details will be provided in the SAP.
Addit ionally , time to sustained worsening of QLQ -C30 scale scores (see Section 10.2) will be 
analyzed using Kaplan -Meier and Cox methods. Further statistical analysis to be performed for 
PROs will be defined and detailed in the SAP.
12.2.12. Safety Analyses
All safet y summaries and analyses will be based upon the Safet y Popul ation as defined in 
Secti on12.2.2 .Analyses will be performed for olaratum ab-naÃ¯ve and o laratumab -pretreated
cohorts separately as well as pooled between these cohorts .
All safet y analyses are based on the Safet y popul ation unless specified otherwise.
ï‚·Adverse events (AEs) , including TEAEs, will be summarized by MedDRA System 
Organ Class/preferred term, classified from verbat im terms.  The incidence and 
percentage of patients with at least one occurrence of a preferred term will be included, 
according to the most severe NCI -CTCAE Versi on 4.0 grade.  Causalit y (relat ionship to 
study  drug), acti on taken, and outcom e will be summarized separately .  Durati on of  AEs 
will be determined and included in the list ings.
ï‚·Study  drug exposure will be summarized for each arm using the fo llowing vari ables: 
number of infusio ns, number of cy cles, durati on of study  treatm ent, cum ulative dose, 
dose intensit y,and rel ative dose intensit y.
ï‚·Laboratory  resul ts will be classified according to the NCI -CTCAE, Versi on 4.0 criteria. 
Incidence of laboratory  abnorm alities will be summarized.
ï‚·Hospitalizations due to AEs, transfusio ns, and concomitant drugs will be summarized.
ï‚·Vital signs
ï‚·ECG
In the Phase 1b part, DLT
swill be summarized by  cohort in the pati ents who are evaluable for 
DLT assessments and listed by pat ient.  For Phase 1 b and Phase 2, the incidences of TEAEs by 
maximum CTCAE grade that occurred during the study  treatm ent peri od or wi thin 
approximately  30 days after the deci sion is made to discont inue study  treatm entwill be 
summarized .  Addi tionally,for Phase 1b and Phase 2 the following (but not limit ed to) 
safet y-relate d outcom es will be summarized:  study treatment discont inuat ion due to TEAEs, 
deaths during the study  treatment peri od or wi thin 30 days after the deci sion is made to 
I5B-MC-JGDL( c) Clinical Protocol Page 92
LY3012207discontinue study  treatm ent, treatm ent-emergent SAEs during the study  treatm ent peri od or 
within 30 days after the decisio n is made to discontinue study  treatm ent, hospi talizati ons, and 
transfusio ns during the study  treatm ent peri od or wit hin 30 days after the decisio n is made to 
discontinue study  treatm ent.
12.2.13. Subgroup Analyses
Subgroup analyses of PFS and OS will be performed and will be detailed in the SAP.
12.2.14. Interim Analyses
There will be safet y interim reviews for both Phase 1b and Phase 2 parts.  
Phase 1b
The safet y review for Phase 1b will be conducted by  Lilly  clinical research personnel.   Patient 
safet y will be assessed pri or to dose escal ation to ensure nothing precl udes administrati on of  a 
larger dose to future study  patients. In addit ion to reviewing AEs and laboratory  measurements, 
available PK/ pharmacodynamic profiles of olaratumab will be reviewed per cohort. Based on 
these interim result s, modificat ions (for example , reducti ons in dose i ncrement or changes in 
dosing schedule) to the d ose-escalat ion strategy  or other design elements may be made to ensure 
patient safet y. The study  invest igators and the Lilly CRP /CRS will make the determinat ion 
regarding dose escalat ion based upon their review of the safet y/tolerabilit y data and the PK d ata 
from the previous cohorts.
In addit ion, an interim safet y review will be conducted prior to proceeding to Phase 2 including 
safet y, PK, and pharmacodynamics . All relevant data including data beyond Cycle 1 will be 
reviewed to determine the recommended Phase 2 dose of olaratum ab. The decision to proceed to 
Phase 2 will be made fo llowing discussio ns between the invest igators and Lilly clinical research 
personnel.
Phase 2
An independent data monitoring co mmit tee (i DMC) will be established to conduct safet y interim 
reviews .  The m embership, rol es, and responsibilit ies of the iDMC are defined in the iDMC 
Charter (that is, a s eparate i DMC charter document).
There will be no prespecified rules for stopping or modifying the trial due to safet y concerns.  
The i DMC members will review unblinded interim safet y data to determine whether there are 
sufficient safet y concerns to j ustify modifying the study  or the terminat ion of study  treatm ent 
and/or e nrollment.
Study  sites will receive informat ion about interim results ONLY if they need to know for the 
safet y of their pati ents. Unblinding details are provided in the blinding section of the protocol 
(Secti on9.5).
The first iDMC meet ing to review interim data will occur when approximately 60patient s 
(approximately 30patients fro m each arm ) have received atleast 2 cycles of treatment or 
discontinued all study  treatm ent due to any  reasons pri or to Day 8 in Cycle 2.  Pwill be provided 
I5B-MC-JGDL( c) Clinical Protocol Page 93
LY3012207to the i DMC upon request. Subsequent iDMC meetings will occur approximately every 6 
months thereafter until approximately  1year after com pleting enrollment .  Enrollment and 
treatm ent will continue during the iDMC safety  assessments.  In the event a safet y signal is 
detected, additional meet ings may occur as needed.  Details as to the process and co mmunicat ion 
plan will be provided in the iDMC Charter.
As described in Section 12.1, an interim efficacy analysis is also planned for the Phase 2 part of 
the study .  The iDMC will be responsible for init ial conduct of the inter im efficacy analysis 
according to the specificat ions of the iDMC charter and statistical analysis plan. If there is an 
evidence of interim efficacy to warrant a sponsor internal review of the data, r esults of this 
interim efficacy  analysis may provide informat ion to help inform the init iation of new studies, 
but will not be used to modify the design and conduct of this current trial.
The interim efficacy analysis will occur a fter observing approximate ly40 OS events am ong the 
olaratum ab-pretreat edcohort of the ITT populat ion.  Due to the larger size of the olaratumab -
naÃ¯ve cohort, it is expected that there will be at least another 40 OS events in the olaratumab -
naÃ¯ve cohort at the time of this analysis.  The decisio n to perform interim efficacy analyses after 
40 OS events in each cohort was based on both statist ical and qualitat ive considerations.  An 
observat ion ofa very  strong effi cacy in one o f these cohorts , based on 40events, should be 
sufficient to consider further development for that co hort.  For example, an observed OS 
HR<0.60 woul d imply  at least an 80% (Bay esian noninformat ive) probabilit y that the true HR is 
less than 0.80. The evidence will be stronger if both cohorts show similar efficacy , allowing f or 
pooling of the cohorts.   Wit h 80 pooled events , an observed pooled OS HR< 0.67 woul d imply  at 
least a 79% probabilit y that the true pooled HR is less than 0.80.  Other efficacy and safet y 
outcom es will  be evaluated, so these scenarios for the interim OS HR are included here merely 
as a reference , to illustrate the kind of evidence that might lead to the init iation of addit ional 
studi es.  For further details, refer to the studyâ€™s Statist ical Analysis Plan (a separate document).
A second interim efficacy  analysis may  optionally be perfor med depending on the expected 
timing of the final analysis and the results of the first interim efficacy analysis.  If a second 
interim efficacy  analysis is performed, it will be conducted applying a no minal alpha level of 
0.00001 to the primary OSanalysi s in o laratumab -naÃ¯ve pat ients.
I5B-MC-JGDL( c) Clinical Protocol Page 94
LY301220713. Informed Consent, Ethical Review, and Regulatory  
Considerations
13.1. Informed Consent
The invest igator is responsible for ensuring that the patient understands the potential risks and 
benefits of participating in the study, including answering any questions the patient may have 
throughout the study  and sharing in a timely manner any  new informat ion that m ay be rel evant to 
the pati entâ€™s willingness to continue his or her participat ion in the trial.
The ICF will be used to explain the potential risks and benefits of study  parti cipat ion to the 
patient in simple terms before the patient is entered into the study , and to docum ent that the 
patient is sat isfied with his or her underst anding o f the risks and benefits of participat ing in the 
study  and desires to parti cipate in the study .
The invest igator is responsible for ensuring that informed consent is given by each patient or , 
where permitted by  local law or re gulation, by the patient's legal representative.  This includes 
obtaining the appropriate signatures and dates on the ICF prior to the performance of any 
protocol  procedures and prior to the administration of study  drugs .
A legal representative must give informed consent for a child to participate in this study.  In 
addition to inform ed consent given by the legal representative, the ERB may  require the child to 
give docum ented assent, if capable.
As used in this protocol, the term â€œinformed consentâ€ includes all consent and assent given by 
patients or thei r legal representatives.
13.2. Ethical Review
Lilly or its representatives must approve all ICFs before they  are used at the in vestigative sites .  
All ICFs must be co mpliant with the ICH guideline on GCP.
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Lilly before the 
study  may begin at the investi gative si tes.
The ERB should include or consult with experts who are knowledgeable in pediatric ethical, 
clinical, and psychosocial issues.
The study  siteâ€™s ERB sshoul d be provi ded wi th the fo llowing:
ï‚·the current IB and updates during the cou rse of the study
ï‚·the ICF
ï‚·the assent form
ï‚·relevant curri cula vi tae
13.3. Regulatory Considerations
This study  will be conducted in accordance wit h:
I5B-MC-JGDL( c) Clinical Protocol Page 95
LY3012207ï‚·consensus ethics principles derived fro m internat ional ethics guidelines, including the 
Decla ration of  Helsinki and Council for International Organizat ions of Medical Sciences 
International Ethical Guidelines 
ï‚·International Conference on Harmonisation (ICH) GCP Guideline (E6)
ï‚·ICH Gui deline ,Clinical Invest igation of Medicinal Products in the Pediatric Popul ation 
(E11)
ï‚·applicable laws and regulations.
The investigator or designee will prompt ly submi t the protocol  to applicable ERB(s).
Some of the obligat ions of Lilly will be assigned to a third-party  organi zation.
An identificat ion code assigned by the invest igator to each patient will be used in lieu of the 
patientâ€™s name to protect the patientâ€™s ident ity when reporting AEs and/or other trial -related data.
13.3.1. Country -Specific Protocol Addend a
Revisio ns to the protocol are made to comply wit h local law and regulatory requirements and to 
address feedback received from co mpetent authority reviews.  Where applicable, these changes 
are outlined in a country -specific protocol addendum associated with this proto col.  Parti cipat ing 
investigators or their designee will prompt ly submit the country -specific protocol addendum to 
applicable ERBs/IRBs in accordance with their local procedures.  After reading the addendum, 
each investigator will sign the protocol addendu m signature page, send a copy  of the signed page 
to a Lilly representative, and subsequent ly comply wi th any local requi rements contained in the 
relevant addendum.
13.3.2. Investigator Information
Physicians with a specialt y in medical onco logy will parti cipate as invest igators in this clinical 
trial.
13.3.3. Protocol Signatures
The Sponsorâ€™s responsible medical officer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately describes the pl anned design and conduct of the 
study .
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly representative.
13.3.4. Final Report Signature
The clinical study  report coordinat ing invest igator will sign the final clinical study report for this 
study , indicat ing agreement that, to the best of his or her knowledge, the report accurately 
describes the conduct and results of the study . 
The Lilly responsible medical officer and statist ician will sign/approve the final clinical study  
report for this study , confi rming that, to the best of his or her knowledge, the report accurately  
describes the conduct an d resul ts of the study .
I5B-MC-JGDL( c) Clinical Protocol Page 96
LY301220714. References
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, 
Fleishman SB, de Haes JCJM, Kaasa S, Klee MC, Osoba D, Razavi D, Rofe PB, Schraub S, 
Sneeuw KCA, Sullivan M, Takeda F .The European Organisat ion for Research and Treatment 
of Cancer QLQ -C30: aqualit y-of-life instrument for use in internat ional clinical trials in 
oncol ogy. J Natl Cancer Inst . 1993;85(5) :365- 376.
[ACS] American Cancer Societ y. 
Sarcoma: adult soft tissue can cer. 2014. Available fro m URL: 
http://www.cancer.org/acs/groups/cid/documents/webcontent/003138 -pdf.pdf .
Andrae J, Gallini R, Betsho ltz C. Role of platelet -derived growth factors in physio logy and 
medicine. Genes Dev . 2008;22(10):1276-1312.
Cancer Therapy  Evaluat ion Program, Co mmo n Termino logy Criteria for Adverse Events, 
Versi on 4.0, DCTD, NCI, NIH, DHHS. 2009. Publish date: 29 May  2009.
Cleeland CS. Pain assessment in cancer. In: Osoba D(ed). Effect of Cancer on Qualit y of Life, 
Chapter 21. CRC Press, Boc a Raton FL, 1991.
Cockcroft DW, Gault MD. Prediction of creat inine clearance fro m serum  creat inine. Nephron . 
1976;16:31 -41.
Cox DR. Regression models and life -tables. J Royal Stat Soc Ser B . 1972;74(2):187 -220.
Dâ€™Angelo SP, Tap WD, Schwartz GK, Carvajal RD. Sarcoma immunotherapy : past approaches 
and future direct ions. Sarcoma . 2014;2014:391967.
Daut RL, Cleeland CS, Flanery  RC. Devel opment of  the Wisconsin Brief Pain Questionnaire to
assess pain in cancer and oth er diseases. Pain . 1983;17(2):197 -210.
Eisenhauer EA, Therasse P, Bogaert J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, 
Gwy ther S, Mooney  M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Laco mbe D, Verweij J. 
New response evaluat ion criteria in so lidtumours: revised RECIST guideline (versio n 1.1). 
Eur J Cancer . 2009;45(2) :228-247.
Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in 
chronic pain intensit y measured on an 11
-point numerical pain rat ing scale. Pain.
2001;94(2):149 -158.
Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf o f the 
EORTC Qualit y of Life Group. The EORTC QLQ -C30 Scoring Manual (3rd Edition). 
Published by: European Organisation for Research and Treatment of Canc er, Brussels 2001.
Ger LP, Ho ST, Sun WZ, Wang MS, Cleeland CS. Validat ion of the Brief Pain Inventory  in a 
Taiwanese popul ation. J Pain Symptom Manage. 1999;18(5):316 -322.
Hensley ML, Blessing JA, Degeest K, Abulafia O, Rose PG, Homesley  HD. Fixed -dose rate 
gemcitabine plus docetaxel  as second -line therapy for metastatic uterine leio myosarcoma: a 
Gyneco logic Oncol ogy Group phase II study .Gynecol Oncol . 2008 a;109(3):323-328.
Hensley  ML, Blessing JA, Mannel R, Rose PG. Fixed -dose rate gemcitabine plus doc etaxel as 
first-line therapy for metastatic uterine leio myosarcom a: a Gynecol ogic Oncol ogy Group 
phase II tri al. Gynecol Oncol . 2008 b;109(3):329-334.
I5B-MC-JGDL( c) Clinical Protocol Page 97
LY3012207Hensley  ML, Wathen JK, Maki  RG, Arauj o DM, Sutton G, Pri ebat DA, George S, Soslow RA, 
Baker LH. Adjuvant t herapy for high -grade, uterus -limited leio myosarcom a: resul ts of a phase 
2 trial (SARC 005). Cancer . 2013;119(8):1555-1561.
Herdm an M, Gudex C, Llo yd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development 
and preliminary  testing of the new five -level version of EQ -5D (EQ -5D- 5L). Qual Life Res . 
2011;20(10):1727 -1736.
Janssen MF, Birnie E, Haagsma JA, Bonsel GJ. Com paring the standard EQ -5D three- level 
system  with a five -level versio n. Value Health . 2008;11(2):274 -284.
Jemal A, Center MM, Ward E,Thun MJ. Cancer occurrence. Methods Mol Biol . 2009;471:3â€“29.
Judson I, Verweij J, Gelderblo m H, Hartm ann JT, SchÃ¶ffski P, Blay JY, Kerst JM, Sufliarsky  J, 
Whelan J, Hohenberger P, Krarup
-Hansen A, Alcindor T, Marreaud S, LitiÃ¨re S, Hermans C, 
Fisher C, Ho gendoorn PC, dei Tos AP, van der Graaf WT; European Organisat ion and 
Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin alo ne versus 
intensified doxorubicin plus ifosfamide for first -line treatment of advanced or metastatic so ft-
tissue sar coma: a rando mised controlled phase 3 trial. Lancet Oncol . 2014;15(4):415 -423.
Kaplan EL, Meier P. Nonparametric estimat ion of inco mplete observat ions. J Amer Stat Assoc . 
1958;53:457 -481.
LiA, Xi a X, Yeh J, Kua H, Liu H, Mishina Y, Hao A, LiB. PDGF -AA pr omotes osteogenic 
different iation and migrat ion of mesenchymal stem cell by down -regul ating PDGFRÎ± and 
derepressing BMP -Smad1/5/8 signaling. PLoS One .2014;9(12):e113785.
Linch M, Mi ah AB, Thway  K, Judson IR, Benson C. Systemic treatment of soft -tissue sarco ma -
gold standard and novel therapies. Nat Rev Clin Oncol . 2014;11(4): 187â€“202.
Loizos N, Xu Y, Huber J, Liu M, Lu D, Finnerty  B. Targeting the platelet derived growth factor
receptor Î± with a neutralizing human mo nocl
onal antibody  inhibits the growth of tumor 
xenografts: implicat ions as a potential therapeut ic target. Mol Cancer Ther . 
2005;4(3):369 -379.
Maki  RG, Wathen JK, Patel  SR, Pri ebat DA, Okuno SH, Samuels B, Fanucchi M , Harm on DC, 
Schuetze SM, Reinke D, Thall PF, Benjamin RS, Baker LH, Hensley ML. Rando mized phase 
II study  of gemci tabine and docetaxel  com pared wi th gemci tabine al one in pat ients with 
metastati c soft ti ssue sarcomas: results of Sarcoma Alliance for Resear ch Through 
Collaboration Study  002. J Clin Oncol . 2007;25(19):2755-2763.
McMillan SC, Tittle M, Hagan S, Laughlin J. Management of pain and pain -related symptom s in 
hospi talized veterans wi th cancer. Cancer Nurs . 2000;23(5):327 -336.
National Cancer Intelli gence Newtork. Bone and soft tissue sarcomas UK incidence and 
survival: 1996 to 2010 [online], http://www.ncin.org.uk/view?rid=2353 (2013).
NgF, Boucher S, Koh S, Sastry KS, Chase L, Lakshmipathy U, Choong C, Yang Z, Vemuri MC, 
Rao MS, Tanavde V. PDGF, TG F-beta, and FGF signaling is important for different iation and 
growth of mesenchymal stem cells (MSCs): transcriptional profiling can ident ify markers and 
signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and 
osteogeni clineages. Blood . 2008;112(2):295 -307.
I5B-MC-JGDL( c) Clinical Protocol Page 98
LY3012207Pauti er P, Fl oquet A, Penel N, Piperno -Neum ann S, Isambert N, Rey  A, Bom pas E, Ci offi A, 
Delcambre C, Cupisso l D, Collin F, Blay JY, Jimenez M, Duffaud F. Randomized mult icenter 
and stratified phase II study  of gemci tabine al one versus gem citabine and docetaxel  in pat ients 
with metastati c or relapsed leio myosarcom as: a Federati on Nati onale des Centres de Lutte 
Contre l e Cancer (FNCLCC) French Sarcoma Group Study  (TAXOGEM study ).Oncologist .
2012;17(9):1213 -1220.
Ravi V, Patel  S, Benjamin RS. Chemotherapy  for sof t
-tissue sarco mas. Onco logy (Williston 
Park). 2015;29:43 -50.
Rowbotham MC. What is a "clinically meaningful" reduction in pain? Pain. 2001;94(2):131 -132.
Seddon B, Scurr M, Jones RL, Wood Z, Propert- Lewis C, Fis her C, Flanagan A, Sunkersing J, 
A'Hern R, Whelan J, Judson I. A phase II trial to assess the activit y of gemcitabine and 
docetaxel as first line chemotherapy treatment in patients with unresectable leio myosarcom a.
Clin Sarcoma Res . 2015a; 5:13.
Seddon BM ,Whelan J, Strauss SJ, Leahy MG, Woll PJ, Cowi e
F, Rotherm undt CA, Wood Z, 
Forsy thS, Khan I, Nash S, Patterson P, Beare S. GeDDiS: A prospective rando mised 
controlled phase III trial o f gemcitabine and docetaxel com pared wi th doxorubi cin as first -line 
treatment in previously  untreated advanced unresectable or metastatic soft tissue sarcomas 
(EudraCT 2009 -014907- 29).2015b. Presented at American Societ y of Clinical  Oncol ogy 
annual meet ing, 2015 b. Associ ated wi th Abstract 10500.
Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, 
moderate or severe? Grading pain severit y by its interference with funct ion. Pain.
1995;61 (2):277â€“284.
Shah GD, Loizos N, Youssoufian H, Schwartz JD, Rowinsky EK. Rat ionale for the development 
of IMC -3G3, a fully human immunoglobulin G subclass 1 monoclonal ant ibody  targeting the 
platelet-derived growth factor receptor alpha. Cancer . 2010;116(4 Suppl ):1018 -
1026.
Sharma S, Taky ar S, Manson SC, Powell S, Penel N. Efficacy and safet y of pharm acological  
intervent ions in second -or later-line treatment of patients with advanced so ft tissue sarco ma: a 
systemic review. BMC Cancer . 2013;13:385.
Shi Q, Wang XS, Mendoza TR, Pandya KJ, Cleeland CS. Assessing persistent cancer pain: a
comparison of current pain ratings and pain recalled fro m the past week. J Pain Symptom 
Manage. 2009;37(2):168 -174.
Stone AA, Broderick JE, Shiffman SS, Schwartz JE. Understanding recall o f weekly pain fro m a 
momentary  assessment perspective: absolute agreement, between -and within -person 
consistency, and judged change in weekly pain. Pain . 2004;107(1- 2):61 -69.
Tap WD, Jones RL, Van Tine BA, Chmie lowski B, Elias AD, Adkins D, Agulnik M, 
Cooney MM, Livingston MB, Pennock GK, Ham eed MR, Shah GD, Qin A, Shahir A, Croni er 
DM, Ilaria RL, Conti I, Cosaert J, Schwartz GK. Olaratumab and doxorubicin versus 
doxorubi cin alo ne for treatment of soft -tissue sarcom a:  an open -label phase 1b and 
rando mized phase 2 trial. Lancet . 2016; 388:488 -497. (suppl; Present ed at American Societ y of 
Clinical Onco logy annual  meeting, 2015b. Associated with Abstract 10501).
I5B-MC-JGDL( c) Clinical Protocol Page 99
LY3012207Tempero M, Pl unkett W, Rui z Van Haperen V, Hainsworth J, Hochster H, Lenzi R, 
Abbruzzese J.Rando mized phase II comparison o f dose -intense gemcitabine: thirty-minute 
infusio n and fixed dose rate infusio n in pat ients with pancreat ic adenocarcino ma. J Clin Oncol .
2003;21(18) :3402 - 3408.
I5B-MC-JGDL( c) Clinical Protocol Page 100
LY3012207Attachment 1. Protocol JGDL Study  Schedule
I5B-MC-JGDL( c) Clinical Protocol Page 101
LY3012207Study Schedule, Protocol I5B-MC-JGD L
Perform  procedures as indicated.   All screening /baseline evaluati ons are perform ed wi thin 14 days prior to enrollment in Phase 1b or 
rando mizat ionin Phase 2 , unless otherwise specified.  Upon signing the informed consent form, the si te will register the patient in the 
Interactive Web Response Sy stem  (IWRS).  The pati ent will be enrolled in Phase 1b or randomized in Phase 2 via IWRS after mee ting 
inclusio n/excl usion criteria.  After enrollment in Phase 1b or randomizat ion in Phase 2, pati ents should receive their first dose of 
treatm ent wi thin 72 hours (3 day s) whenever possible.
Baseline Schedule (Phase 1b and Phase 2)
Study Period Baseline
Cycle BL
Visit 0
DurationUp to 14 days
(except where noted)
Relative Day from Enrollment in 
Phase 1b/ Randomization in 
Phase 2 â‰¤14 â‰¤7
Procedure 
CategoryProtocol 
Section sProcedure Comments
Study Entry/ 
Enrollment7, 13.1 Informed Consent /Assent (if applicable)X (within 28 days
of enrollment in Ph ase 1b or 
randomization in Phase2, 
unless otherwise specified)Written informed consent (or assent, if applicable) must be obtained prior to any 
study-specific screening evaluations.  For screening purposes, required assessments 
performed prior to the date of consent may be used provided they are noted 
exceptions .
7.1, 7.2, 
9.3Inclusion/Exclusion Evaluation and IWRS XUpon signing the informed consent form , the site will register the patient in the 
IWRS .  The patient will be enrolled in Phase 1b or randomized in Phase 2 via IWRS 
after meeting inclusion/exclusion criteria.  After enrollment in Phase 1b or 
randomization in Phase 2, patients should receive their first dose of treatment within 
72 hours (3days) whenever possible.
Medical 
History10.3.1 Medical History XAny preexisting and pretreatment toxicity (treatment or disease related) should be 
documented and recorded as part of the pretreatment medical history.  Disease 
characteristics at initial diagnosis and at study entry will be collected.
All adverse events must be recorded after signing the informed consent.
7 Demography X Date of birth, sex, and race/ethnicity will be collected at baseline.
7 Prior Treatment Therapies of Underlying Disease XPrior treatment includes any treatment for underlying disease, including maintenance 
therapy.  Start and stop dates should be documented as well.  Previous therapy must 
be completed â‰¥ 3weeks ( 21days) prior to first dose of study drug .
Physical 
Examination7 Physical Examination X Physical examination at baseline includes heigh t, weight, and BSA measurement.
7.1
Att. 4ECOG Performance Status X Refer to Attachment 4 for details.
Vital signs X Vital signs include blood pressure, pulse, respiratory rate and temperature.
Concomitant 
Medications9.6 Concomitant MedicationsX (within 30 days
of C1D1)Concomitant medications will be recorded, including any taken within 30 days prior 
to start of study treatment.
I5B-MC-JGDL( c) Clinical Protocol Page 102
LY3012207Baseline Schedule (Phase 1b and Phase 2)
Study Period Baseline
Cycle BL
Visit 0
DurationUp to 14 days
(except where noted)
Relative Day from Enrollment in 
Phase 1b/ Randomization in 
Phase 2 â‰¤14 â‰¤7
Procedure 
CategoryProtocol 
Section sProcedure Comments
Lab/
Diagnostic 
Tests7.1
Att. 2Hematology XScreening evaluations done within 7 days prior to enrollment in Phase 1b or 
randomization in Phase 2, do not have to be repeated .
7.1
Att. 2Serum Chemistry XScreening evaluations done within 7 days prior to enrollment in Phase 1b or 
randomization in Phase 2, do not have to be repeated.
7.1
Att. 2Coagulation Profile XScreening evaluations done within 7 days prior to enrollment in Phase 1b or
randomization in Phase 2 do not have to be repeated.
Att. 2 Urinalysis XScreening evaluations done within 7 days prior to enrollment in Phase 1b or
randomization in Phase 2 do not have to be repeated. Includes a routine urinalysis 
(UA), and if clinically indicated a microscopic analysis.  If routine analysis indicates 
â‰¥2+ proteinuria, then thepatient must have â‰¤1000 mg of protein in 24 -hour urine or 
urine protein/creatinine ratio â‰¤ 1 on spot urine (up to 3 business days is allowed if 
the weekend) .
7.1
Att. 2Pregnancy Test XSerum Î² -HCG pregnancy test ( women of childbearing potential only) within 7 days 
prior to enrollment in Phase 1b or randomization in Phase 2.  If the serum pregnancy 
test performed for inclusion purposes is positive, confirm by repeating and 
performing a urine pregnancy test. The results of this test will not be collected on 
the eCRF.
7.1
Att. 2Follicle -stimulating Hormone (FSH) XPerformed only at screening in menopausal women that have experienced 
spontaneous amenorrhea for 6 to 12 months.  To be done for women only when 
needed to confirm postmenopausal status.
10.4.2.2
Att. 6Mandatory Tumor Tissue XMandatory archived tumor tissue or tumor tissue from biopsy (if adequate archived 
samples are unavailable) for biomarkers and tumor type (refer to Section 10.4.2.2 for 
details).
10.3.2.1 ECG X (within 28 days
of enrollment in Phase 1b or 
randomization in Phase 2 )A single 12 -lead ECG is to be obtained within 28 da ys prior to enrollment in 
Phase 1b or randomization in Phase 2 (refer to Section 10.3.2.1 for details) .
Efficacy
Assessment10.1.1
Att. 5Imaging Studies (CT/MRI)
Tumor Assessments ( according to RECIST v1.1)X (within 28 days
of enrollment in Phase 1b and 
randomization in Phase 2 )Within 28 days prior to enrollment in Phase 1b or randomization in Phase 2 (refer to 
Section 10.1.1 for details). Scans performed prior to the date of consent may be 
used provided they are within 28 days of enrollment (Phase 1b) and randomization
(Phase 2).
Patient Disposition XAt the time that the patient is discontinued from Study Participation, information 
regarding the patient status will be collected.
Abbreviations:  Î² -HCG = beta human chorionic gonadotropin; BL = baseline; BSA = body surface area; C1D1 = Cycle 1 Day 1; CT = computed tomograp hy; CTCAE = Common Terminology Criteria 
for Adverse Events; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; eCRF = electronic case report form; FSH = f ollicle -stimulating hormone; IWRS = interactive web -
response system; MRI = magnetic resonance imaging; PRO = patient -reported outcome; RECIST = Response Evaluatio n Criteria In S olid Tumors; v =version.
I5B-MC-JGDL( c) Clinical Protocol Page 103
LY3012207Study Schedule, Protocol I5B -MC-JGD L
Perform  procedures as indicated. Please refer to appropriate protocol sect ions for more detailed instructions.
Treatment Period Schedule (Phase 1 b and Phase 2)
Study Period Treatment Period
Comment Procedure 
CategoryProtocol 
Section sRelative Day within Cycle 
(21 day cycle âˆ’3 days)1a8a
Physical 
Examination9.4,
10.3.1Physical Examination X XPhysical examination during treatment period includes weight and BSA measurement.  Patients 
should be weighed at D1 and D8 of each cycle and BSA calculated.
Att. 4 ECOG Performance Status X Complete prior to treatment infusion. 
10.3.1 Vital signs X XVital signs include blood pressure, pulse, respiratory rate ,and temperature.
Please refer to Table JGDL .1footnote b for the times when vital signs should be collected.
Lab/
Diagnostic TestsAtt. 2 Hematology X XLaboratory assessments may be done within 3days prior to D1 and D8 of each cycle.  See 
Attachment 2 for details.
Att. 2 Serum Chemistry X XLaboratory assessments may be done within 3days prior to D1 and D8 of each cycle.  See 
Attachment 2 for details.
Att. 2 Coagulation Profile XPerform within 3days prior to D1 of every other cycle or as clinically indicated.  See 
Attachment 2 for details.
Att. 2 Pregnancy Test XSerum or urine pregnancy test on D1 of every cycle or per local practice (whichever is of 
shorter duration).  If the pregnancy test performed on D1 of the cycle is positive, confirm with a 
serum pregnancy test (pregnancy test results are not recorded on the eCRF).
10.4.4 PK SamplesSee Attachment 6 for 
specific time pointsWhole blood samples collected and processed into serum (olaratumab) or plasma
(gemcitabine/docetaxel) .  If a patient experiences an IRR to olaratumab, blood samples for 
immunogenicity and PK analysis will be taken at the following time points:  (1) as soon as 
possible after the onset of the IRR, (2) at the resolution of the IRR, and (3) 30 (Â± 3 days) days 
after onset of the IRR event.
10.4.3 Immunogenicity SamplesSee Attachment 6 for
specific time pointsWhole blood samples collected and processed into serum. If a patient experiences an IRR to 
olaratumab , blood samples for immunogenicity and PK analysis will be taken at the following 
time points:  (1) as soon as possible after the onset of the IRR, (2) at the resolution of the IRR, 
and (3) 30 (Â± 3 days) days after onset of the IRR event.
10.4.2.1Pharmacogenetic (DNA) Whole 
Blood SampleSee Attachment 6 for 
specific time point .Whole blood sample collected.  It is highly recommended to draw the whole blood sample prior 
to the first dose (C1D1 at predose); however, it can be collected later during the study if 
necessary.
10.4.2.3 Plasma sample for biomarkersSee Attachment 6 for 
time points .Whole blood samples collected and processed into plasma .
10.3.2.1 ECG XIn Phase 1b , twelve -lead ECGs are to be performed as single ECGs within 3 days prior to Day 1 
of every cycle ,until PD or treatment discontinuation, whichever comes first.
Patient reported 
outcomes 10.2PRO Assessments (mBPI -sf, 
EORTC QLQ C30, EQ -5D-5L)XThe Patient Reported Outcome (PRO) measures will be coll ected on Day 1 of every cycle
(Phase 2 only) .
Efficacy
Assessment10.1.1
Att. 5Imaging Studies (CT/MRI)
Tumor Assessments ( according to 
RECIST v1.1)XImaging studies and tumor assessments are be obtained every 6 weeks (Â±7 days), irrespective of 
treatment cycles as calculated from enrollment in Phase 1b or randomization in Phase 2, until 
documented progression for patients with CR, PR, or SD, and/or for patients who have 
discontinued study treatment due to toxicity or reasons other than PD.  Refer to Section 10.1.1
for details.
I5B-MC-JGDL( c) Clinical Protocol Page 104
LY3012207Study Period Treatment Period
Comment Procedure 
CategoryProtocol 
Section sRelative Day within Cycle 
(21 day cycle âˆ’3 days)1a8a
Adverse Events 
Collection/
CTCAE Grading10.3.1 Toxicity Assessment X XAll AEs considered at least possibly -related to study treatment will be followed until reso lution, 
stabilization, return to baseline, or until deemed irreversible.
Concomitant 
Therapy9.6 Concomitant Medications X XConcomitant medications will be recorded throughout the treatment period, including those 
taken during the 30 days after the last dose of all study treatment.
Premedication9.1.1.1 , 
9.1.1Administer premedication prior to 
olaratumab or placebo .X XPremedicate all patients with the following (or equivalent) medications intravenously : a 
histamine H1 antagonist (e .g., diphenhyd ramine) and dexamethasone 30 â€“60 minutes prior to 
the olaratumab/placebo doses on Days 1 and 8 of Cycle 1.  For subsequent cycles, premedicate 
all patients with a histamine H1 antagonist (e .g., diphenhydramine) intravenously 30 -60 
minutes prior to each dose of olaratumab or placebo.
Study Treatment9.2.1 Administer olaratumab or placebo . X XAdminister until progressive disease (PD), unacceptable toxicity, death, or other withdrawal 
criteria are met.  No crossover will be permitted in the Phase 2 part.
9.2.2 Administer gemcitabine . X XAdminister until progressive disease (PD), unacceptable toxicity, death, or othe r withdrawal 
criteria are met.
9.2.3 Administer docetaxel . XAdminister until progressive disease (PD), unacceptable toxicity, death, or other withdrawal 
criteria are met.
Patient DispositionAt the time that the patient is discontinued from any component of the study treatment or Study 
Participation, information regarding the patient status will be collected.
aStudy procedures will be performed prior to study drug administration, except where noted (such as vital signs).  In case of dose interruption, these evaluations will also be done at minimum 
frequency every 21 days (Â±3 days).
Abbreviations:  BSA = body surface area; C1D1 = Cycle 1 Day 1; CT = computed tomography; CTCAE = Common Terminology Criteria for Adverse Events; D =Day; D/C = discontinuation; 
ECG =electrocardiogram; ECOG = Eastern Cooperative Oncology Group; eCRF = electronic case report form; IRR = infusion -related reaction; MRI = magnetic resonance imaging; PD = progressive 
disease; q3c = every 3 cycles; RECI ST = Response Evaluation Criteria in Solid Tumors.
I5B-MC-JGDL( c) Clinical Protocol Page 105
LY3012207Study Schedule, Protocol I5B -MC-JGD L
Perform  procedures as indicated.
Post-Treatment Discontinuation Schedule
Study Period Post-discontinuation Follow -Up
Short -Term Follow -Up Long -Term Follow-Up
Visit 801 802-8XX
Duration 30 Â±7 days See footnote for duration
Procedure 
CategoryProtocol 
SectionProcedure Comments
Physical 
Examination 9.4,10.3.1 Physical examination X Physical examination will include weight.
Att. 4 ECOG performance status X
10.3.1 Vital signs X Includes blood pressure, pulse, respiratory rate, and temperature.
Lab/
Diagnostic 
TestsAtt. 2 Hematology X See Attachment 2 for details.
Att. 2 Serum chemistry X See Attachment 2 for details.
Att. 2 Coagulation profile X See Attachment 2 for details.
Att. 2 Urinalysis XIncludes a routine urinalysis (UA), and if clinically indicated a microscopic 
analysis.  If urine dipstick or routine analysis indicates proteinuria â‰¥2+, obtain 
urine protein/creatinine ratio on spot urine or a 24-hour urine collection (to 
assess protein) must be obtained (up to 3 business days is allowed if the 
weekend) .
Att. 2 Pregnancy test XSerum or urine pregnancy test.  If the pregnancy test is positive, confirm with 
a serum pregnancy test (pregnancy test results are not recorded on the eCRF).
Additional pregnancy tests may be done after short -term follow- up if required 
by local regulation .
10.3.2.1 ECG XIn Phase 1b only, t welve -lead ECGs are to be performed as single ECGs for 
all patients at the short â€“term follow- up.
10.4.4 PK sample XSee Attachment 6 .In addition, if a patient experiences an IRR to 
olaratumab/placebo, blood samples for immunogenicity and PK analysis will 
be taken at the short -term follow- up after the IRR.
10.4.3 Immunogenicity sample XSee Attachment 6 .  In addition, if a patient experiences an IRR to 
olaratumab/placebo, blood samples for immunogenicity and PK analysis will 
be taken at the short -term follow- up after the IRR.
10.4.2.3 Plasma sample for biomarkers X SeeAttachment 6 .
Patient 
Reported 
Outcomes10.2PRO Assessments (mBPI -sf, 
EORTC QLQ C30, EQ -5D-
5L)XThe Patient Reported Outcome (PRO) measures will be collected at the 30 -day 
short -term follow- up visit.
Efficacy 
Assessments10.1.1 , 
Att. 5Imaging/Tumor Assessments 
(according to RECIST v1.1)X (if applicable) XFor patients who discontinue study treatment for any reason without 
objectively measured PD, imaging studies and tumor assessments are be 
obtained every 6 weeks (Â±7 days), irrespective of treatment cycles as 
calculated from enrollment in Phase 1b or from r andomization for Phase 2, 
until documented progression.
I5B-MC-JGDL( c) Clinical Protocol Page 106
LY3012207Post-Treatment Discontinuation Schedule
Study Period Post-discontinuation Follow -Up
Short -Term Follow -Up Long -Term Follow-Up
Visit 801 802-8XX
Duration 30 Â±7 days See footnote for duration
Procedure 
CategoryProtocol 
SectionProcedure Comments
8.1.3Survival Information ,All 
Subsequent Anti -Cancer 
Treatments ,and Associated 
Disease Progression DateXFor patients enrolled in Phase 1 b and randomized in the Phase 2 partthat
discontinue study treatment after objectively measured PD the following 
information will be collected every 3months (Â±7 days) for the first year, then 
every 6 months (Â±14 days) until the patientâ€™s death, or overall study 
completion :  details on all subse quent anticancer treatment (start/stop dates 
and treatments administered ; first post -study treatment disease progression 
date; and survival status.
Adverse Events 
Collection/
CTCAE 
Grading10.3.1 Toxicity assessment XAll AEs considered at least possibly -related to study treatment will be 
followed until resolution, stabilization, return to baseline, or until deemed 
irreversible.  After the 30 -day short -term follow- up visit, only new and 
ongoing SAEs deemed related to study treatment will be collected.
Concomitant 
Medication 
Notation9.6 Concomitant medications X
Patient Disposition X XAt the time that the patient is discontinued from Study Participation, 
information regarding the patient status will be collected.
Abbreviations:  AE = adverse event; CT = computed tomography; CTCAE = Common Terminology Criteria for Adverse Events; ECG = e lectrocardiogram; ECOG =Eastern Cooperative Oncology 
Group; LCSS = Lung Cancer Symptom Scale; PD = progressive disease; PRO =patient-reported outcome; QoL = quality of life; RECIST = Response Evaluation Criteria in Solid Tumors; 
SAE =serious adverse event.
Short-term follow -upbegins the day after the patient and the investigator agree that the patient will no longer continue study treatment and lasts approximately 30 days (Â±7 days).  The date of this 
agreement is to be reported on the CRF as the date of Discontinuation from study treatment.
Long -term follow -up:begins the day after short -term follow -up is completed .
ï‚· Follow -up for progression: Patients that discontinue study treatment for reasons other than progression will be followed eve ry 6 weeks (Â±7 days) until PD.
ï‚· Follow -up for survival:  Patients will be followed every 3months (Â±7 days) for the first year, then every 6 months (Â±14 days) until the patientâ€™s death or overall study completion.
I5B-MC-JGDL( c) Clinical Protocol Page 107
LY3012207Study Schedule, Protocol I5B -MC-JGD L
Perform  procedures as indicated.
Continued Access Period Schedule
Study PeriodContinued Access 
Treatment PeriodContinued Access 
Follow -Up Period
Cycle X-Y Follow -Up
Visit 501-5XX 901
Duration 1day 30 Â±7 days
Procedure 
CategoryProtocol 
SectionProcedure Comments
Physical 
Examination9.4 Physical examination X Weight .
Adverse Events 
Collection/CTC
AE Grading10.3.1 Toxicity assessment X XAll AEs/SAEs will be followed for up to 30 days after the patient 
and investigator agree that the patient will no longer continue 
study treatment.
Concomitant 
Therapy 9.6 Concomitant Medications X XConcomitant medications will be recorded throughout the 
treatment period, including those taken during the 30 days after 
the last dose of all study treatment.
Lab/Diagnostic 
TestsAtt. 6 Immunogenicity/Pharmacokinetics X XIf a patient experiences an IRR to olaratumab during the 
Continued Access Period, blood samples for immunogenicity 
and PK analysis will be taken at the follo wing time points:  
(1)as soon as possible after the onset of the IRR, (2) at the 
resolution of the IRR, and (3) 30 days (Â±3 days) after the IRR.
Premedications 9.1.1.1Administer premedication prior to 
olaratumab treatment .XPremedicate all patients with a histamine H1 antagonist (e .g., 
diphenhydramine) intravenously 30 -60 minutes prior to each 
dose of olaratumab.
Study 
Treatment9.2.1 Administer olaratumab . XAdminister on Days 1 and 8, until evidence of progressive 
disease, unacceptable toxicity, death, or other withdrawal criteria 
are met.
9.2.2 Administer gemcitabine . XAdminister on Days 1 and 8, until evidence of progressive 
disease, unacceptable toxicity, death, or other withdraw al criteria 
are met.
9.2.3 Administer docetaxel . XAdminister on Day 8, until evidence of progressive disease, 
unacceptable toxicity, death, or other withdrawal criteria are met.
Abbreviations:  AE = adverse event; CTCAE = Common Terminology Criteria for Adverse Events; eCRF = electronic case report form; IRR = infusion -related reaction; PK = pharmacokinetics ; 
SAE =serious adverse event .
Continued access follow -upbegins the day after the patient and the investigato r agree that the patient will no longer continue study treatment in the continued access period, and lasts until the 
continued -access follow -up visit is completed, approximately 30 days (Â±7 days) later.
I5B-MC-JGDL( c) Clinical Protocol Page 108
LY3012207Attachment 2. Protocol JGDL Clinical Laboratory  Tests
All laboratory  evaluat ions are to be performed wit hin 14 days prior to randomizat ion or study  
drug administration unless otherwi se specified (refer to Attachment 1) .  Eligibilit y for inclusio n 
in this clinical trial will be based on local clinical laboratory  resul ts (not transcribed onto 
eCRFs); duplicate samples will be submi tted to the central  laboratory .  For pati ent and study  site 
convenience and safet y, treatm ent deci sions m ay be based upon resul ts of tests performed 
locally.  If l ocal laboratory  tests are used for thi s purpose, then a duplicate specimen must be 
submi tted to the central  laboratory .  Discrepancies between local and central laboratory  that m ay 
have an impact on eligibilit y or treatm ent decisi ons will  not be considered protocol deviations.  
On-study  clinical  laboratory  tests assay ed for pati ent safet y (such as hematology , serum  
chemistry , coagulati on, and pregnancy tests) are to be collected prior to study  treatm ent
I5B-MC-JGDL( c) Clinical Protocol Page 109
LY3012207Clinical Laboratory Tests
Hematologya,bClinical Chemistrya,b
Hemoglobin Serum Concentrations of the following:
Hematocrit Sodium
Erythrocy te count (RBC) Potassium
Mean cell volume Total bilirubin
Mean cell hemoglobin concentration Alkaline phosphatase
Leukocytes (WBC) Alanine aminotransferase (ALT)
Neutrophils Aspartate aminotransferase (AST)
Lymphocy tes Gammaglutamyl transfera seg
Monocytes Blood urea nitrogen (BUN)
Eosinophils Creatinine
Basophils Uric acidg
Platelets Calcium
Glucose, random
Coagulation TestaAlbumin
Partial thromboplastin time (PTT or aPTT)
Prothrombin time (PT or INR )Total protein
Chloride
Thyroid-stimulating hormoneg
Urinalysisa,cDirect bilirubin
LDH
Specific gravity
pH Pregnancy testa,e
Protein
Glucose Follicle -stimulating hormone (FSH) a,f
Ketones
Blood Exploratory Biomarker Testsd
Refer to Section 10.4.2 .Urine leukocyte esterase
Otherd
Immunogenicity samples
PK samples
I5B-MC-JGDL( c) Clinical Protocol Page 110
LY3012207Abbreviations:  CRP = clinical research physician; D = Day; INR = international normalized ratio; LDH =lactate 
dehy drogenase ; PK = pharmacokinetics; WOCBP = women of childbearing potential .
aAssay ed by local or investigator -designated laboratory .
bDuplicate samples will also be a ssayed by Sponsor -designated laborator y.
cIf urinary  protein is â‰¥2+ at evaluations, a 24 -hour urine collection (to assess protein) must be collected , or 
alternatively, a urine protein/creatinine ratio on spot urine .  Note: UPC ratio of spot urine is an estimation of the 
24-hour urine protein excretion â€“a UPC ratio of 1 is roughly equivalent to a 24 -hour urine protein of 1000 mg.  
UPC ratio is calculated using one of the following formulae:
ï‚·[urine protein]/[urine creatinine] â€“if both protein and creatinine are reported in mg/dL 
ï‚·[(urine protein) x 0.088]/[urine creatinine] â€“if urine creatinine is reported in mmol/L .
dAssay ed by a Sponsored -
designated (central) laboratory . Refer to Attachment 6 .
eSerum pregnancy test will be performed at screening in females of childbearing potential only (if the baseline 
serum test is positive, a repeat serum and urine pregnancy test will be done; if those results are positive, the 
investigator is to consult with the Lilly CRP regarding if dosing should occur and which follow -up laborato ry 
tests are performed).  While on -study, urine pregnancy test will be performed in females of childbearing potential 
only on D1 of ever y cycle or per local practice (whichever is of shorter duration) and at short -term follow -up 
visit.  If the serum pregnancy test performed for inclusion purposes is positive confirm by repeating the serum 
and performing a urine pregnancy test.  If the urine pregnancy test performed on D1 of each cycle is positive, 
confirm with a serum pregnancy test.
fPerformed only at screening in menopausal women that have experienced spontaneous amenorrhea for 6 to 12 
months.  To be done for women only when needed to confirm postmenopausal status.
g   Performed locally at screening only, repeat not required but should be obtained if clinically appropriate.
I5B-MC-JGDL( c) Clinical Protocol Page 111
LY3012207Attachment 3. Protocol JGDL Hepatic Monitoring Tests 
for Treatment -Emergent A bnormality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow up with patients in consultat ion with the Lilly clinical research physician.
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrombin Time
WBC Prothrombin Time, INR
Neutrophils
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Recommended Autoimmune Serology :
AST Anti- nuclear antibody a
GGT
CPK Anti-smooth muscle antibody a
Anti actin antibody a
Abbreviations:  ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatine phosphokinase; 
GGT = gamma -glutamyl transferase; IgG =immuno globin G; IgM = immunoglobin M; INR = international 
normalized ratio; RBC = red blood cell; WBC = white blood cell.
aAssay ed by Lilly -designated laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability.
I5B-MC-JGDL( c) Clinical Protocol Page 112
LY3012207Attachment 4. Protocol JGDL ECOG Performance Status
ECOG Performance Status
Activity Status Description
0 Fully  active, able to carry  on all pre -disease performance 
without restri ction
1 Restricted in physically strenuous activit y but 
ambulatory  and able to carry  out work of a light or 
sedentary  nature, e.g., light house work, office work
2 Ambulatory  and capable o f all selfcare but unable to 
carry  out any  work activit ies. Up and about more than 
50% of waking hours
3 Capable of only limited selfcare, confined to bed or chair 
more than 50% of waking hours
4 Com pletely disabled. Cannot carry  on any selfcare. 
Totally confined to bed or chair
5 Dead.
Source:  Oken et al. 1982.
I 5 B -M C -J G D L( c) Cli ni c al Pr ot o c ol P a g e 1 1 3 
L Y 3 0 1 2 2 0 7 At t a c h m e nt 5. Pr ot o c ol J G D L R E CI S T Crit eri a 1. 1 
C CI 
I 5 B -M C -J G D L( c) Cli ni c al Pr ot o c ol P a g e 1 1 4 
L Y 3 0 1 2 2 0 7 C CI 
I 5 B -M C -J G D L( c) Cli ni c al Pr ot o c ol P a g e 1 1 5 
L Y 3 0 1 2 2 0 7 C CI 
I 5 B -M C -J G D L( c) Cli ni c al Pr ot o c ol P a g e 1 1 6 
L Y 3 0 1 2 2 0 7 C CI 
I 5 B -M C -J G D L( c) Cli ni c al Pr ot o c ol P a g e 1 1 7 
L Y 3 0 1 2 2 0 7 C CI 
I 5 B -M C -J G D L( c) Cli ni c al Pr ot o c ol P a g e 1 1 8 
L Y 3 0 1 2 2 0 7 C CI 
I 5 B -M C -J G D L( c) Cli ni c al Pr ot o c ol P a g e 1 1 9 
L Y 3 0 1 2 2 0 7 C CI 
I5B-MC-JGDL( c) Clinical Protocol Page 120
LY3012207Attachment 6. Protocol JGDL Pharmacokinetic, 
Immunogenicity , and Translational Research 
Sampling Schedule
It is essent ial that the exact infusio n start and stop times (actual clock readings), as well as 
infusio n parameters (such as, ty pe of  infusio n pump, flow rate se ttings) are recorded.  The exact 
time of co llection of each venous blood sample will be based on the clock used to record 
infusio n times.  It is essent ial that the pharmacokinetic blood samples not be withdrawn fro m the 
same site as the drug infusio n.
For samples co llected within the first 24 hours of study  drug administration , sample collect ion 
times may  vary  Â±10% or as specified in the PK sampling schedule.
I5B-MC-JGDL( c) Clinical Protocol Page 121
LY3012207Pharmacokinetic Sampling Schedule â€“Phase 1b
Sample 
NumberCycle Day Dosing Sampling TimeOlara tu
mab
PKa, eGem 
PKbDoce 
PKc IKd, e
1
11Prior to olara tumabfX X
Olara tumab (1 hr)
2 â‰¤5 min post -olara tumab X
Obs (1 hr)
3 60 Â± 10 min post -olara tumab X
44 hrÂ± 25minpost-
olara tumabX
5 2 24 Â± 3 hr post -olara tumab X
6 5 Anytime X
7
8Prior to olara tumabfX X
Olara tumab (1 hr)
8 â‰¤5 min post -inf X
Obs (1 hr)
9 60 Â± 10 min post-olara tumab X
Gem (1 .5hr)
10 â‰¤5 min post -gem X
Doce taxel (1 hr)
11 â‰¤5 min post -doce X X
12 60 Â± 10 min post doce X X X
13 3 hr Â± 15 min post-doce X X
14 9 24 Â± 3 hr post -olara tumabfX X X
15 10 Anytime X
16 12 Anytime X
17 15 Anytime X
18
21Prior to olara tumabfX X
Olara tumab (1 hr)
19 â‰¤5 min post -inf X
20
8Prior to olara tumabf
Olara tumab (1 hr)
21 â‰¤5 min post -inf X
22
31Prior to olara tumabfX X
Olara tumab (1 hr)
23 â‰¤5 min post -olara tumab X
24 60 Â± 10min post -olara tumab X
254 hrÂ± 25minpost-
olara tumabX
26 2 24 Â± 3 hr post -olara tumab X
27 5 Anytime X
28
8Prior to olara tumabfX
Olara tumab (1 hr)
29 â‰¤5 min post -olara tumab X
30 60 Â± 10 min post -olara tumab X
314 hrÂ± 25minpost-
olara tumabX
32 9 24 Â± 3 hr post -olara tumab X
33 12 Anytime X
34 15 Anytime X
35-5 and then every 
other cycle1 Prior to olara tumabfX X
80130-day follow -up 
visitAnytime X X
Abbreviation s:  Doce = docetaxel; Gem = gemcitabine; IK = immunogen icity; IRR = Infusion related reaction; PK = pharmacokinetic ;Obs=observation .
aSamples of approx. 3mL of whole blood will be drawn without anticoagulant for measurement of olaratumab in serum. 
bSamples of approx. 2mL of whole blood will be drawn into plastic tubes with anticoagulant for measurement of gemcitabine in plasma.
cSamples of approx. 3 mL of whole blood will be drawn int o plastic tubes with anticoagulant for measurement of docetaxel in plasma .
dFor the immunogenicity assay, approx. 10mL of whole blood will be drawn.
eIf a patient experiences an IRR to olaratumab/placebo, blood samples for immunogenicity and PK analysis will be taken at the following time points:  
(1) as soon as possible after the onset of the IRR, (2) at the resolution of the IRR, and (3) 30 days (Â±3 days) after the IRR .
fPretreatment PK samples may be collected up to 60 minutes prior to the olaratumab infusion and must be prior to administering any premedication.
I5B-MC-JGDL( c) Clinical Protocol Page 122
LY3012207Pharmacokinetic Sampling Schedule â€“Phase 2
Sample 
NumberCycle Day Dosing Sampling TimeOlara
tuma
b
PKa, eGem 
PKbDoce 
PKc IKd, e
1
11Prior to olara tumab /placebofX X
Olara tumab (1 hr)
2 â‰¤5 min post -olara tumab /placebo X
3
8Prior to olara tumab dose/placebofX X
Olara tumab (1 hr)
4 â‰¤5 min post -olara tumab /placebo X
Obs (1 hr)
Gem (1 .5hr)
5 â‰¤5 min post -gem X
Doce taxel (1 hr)
6 â‰¤5 min. post -doce taxel X X
7
21Prior to olara tumab /placebofX X
Olara tumab (1 hr)
8 â‰¤5 min post -olara tumab /placebo X
9
8Prior to olara tumab /placebofX
Olara tumab (1 hr)
10 â‰¤5 min post -olara tumab /placebo X
11
31Prior to olara tumab /placebofX X
Olara tumab (1 hr)
12 â‰¤5 min post -olara tumab /placebo X
13
8â‰¤Prior to olara tumab /placebofX
Olara tumab (1 hr)
14 â‰¤5 min post -olara tumab /placebo X
15-5 and then 
every other 
cycle1 Prior to olara tumab /placebofX X
80130-day 
follow -up 
visitAnytime X X
Abbreviation s:  Gem = gemcitabine; IK = i mmunogen icity; IRR  = Infusion related reaction ; PK = pharmacokinetic; Obs = observation .
aSamples of approx. 3 mL of whole blood will be drawn without anticoagulant for measurement of olaratumab in serum.
bSamples of approx. 2mL of whole blood will be drawn into plastic tubes with anticoagulant for measurement of gemcitabine in plasma.
cSamples of approx.3 mL of whole blood will be drawn into plastic tubes with anticoagulant for measurement of docetaxel in plasma.
dFor the immunogenicity assay, approx. 10mL of whole blood will be drawn.
eIf a patient experiences an IRR to olaratumab/placebo, blood samples for immunogenicity and PK analysis will be taken at the following time 
points:  (1) as soon as possible after the onset of the IRR, (2) at the resolution of the IRR, and (3) 30 days (Â±3 days) afte r the IRR.
fPretreatment PK samples may be collecte d up to 60 minutes prior to the olaratumab infusion and must be prior to administering any 
premedication.
Biomarker Research Sampling Schedule
Sample 
Number Cycle Day Sampling TimePlasma for 
BiomarkersaWhole 
bloodbTumor 
Tissuec
1 1 1 Predose X X X
3 1 P rior to olaratumab /placebo infusiondX
80130-day follow -up 
visitAnytime X
aRefer to Section 10.4.2.3 for details on whole blood for plasma collection.
bRefer to Section 10.4.2.1 for details on whole blood for DNA collection.   It is highly recommended to draw the whole blood 
sample prior to the first dose (Cycle 1 Day 1 at predose); h owever, it can be collected later during the study if necessary.
cRefer to Section 10.4.2.2 for details on tumor tissue collection.
dPretreatment samples may be collected up to 60 minutes prior to the olaratumab/placebo infusion.
I5B-MC-JGDL( c) Clinical Protocol Page 123
LY3012207Attachment 7. Protocol JGDL List of Common CYP3A 4 
Inhibitors and Inducers of Docetaxel
CYP3A4 Inducers Strong CYP3A4 Inhibitors Moderate CYP3A4 Inhibitors
Aminoglutethimide Clarithromycin Amiodarone
Bosentan Chloramphenicol Amprenavir
Carbamazepine Cobicistat Aprepitanta
Efavirenz (in liver only) Conivaptan Atazanavir
Fosphenytoin Cremophor EL Cimetidine
Nafcillin Cyclosporine Ciprofloxacin
Nevirapine Delavirdine Clotrimazole
Oxcarbazepine Diclofenac Darunavir
Pentobarbital Diltiazem Darunavir and ritonavir
Phenobarbital Elvitegravir and ritonavir Desipramine
Phenytoin Enoxacin Doxycycline
Primidone Fosamprenavir Dronedarone
Rifabutin Grapefruit juice Efavirenz
Rifampin Indinavir Erythromycin
Rifapentine Indinavir and ritonavir FK1706
St. John's wort Itraconazole Fluconazole 
Ketoconazole Fluvoxamine
Lopinavir and ritonavir Haloperidol
Mibefradil Imatinib
Miconazole Metronidazole
Nefazodone Norfloxacin
Nelfinavir Protease inhibitors
Nicardipine Quinidine
Posaconazole Schisandra sphenanthera extract
Quinidine Sertraline
Ritonavir Tetracycline
Saquinavir Tofisopam
Telithromycin Verapamil
Theophylline
Troleandomycin
Voriconazole
aAprepitant is allowed when given according to local practice and institutional guidelines and if no alternative 
antiemetic is recommended.
I5B-MC-JGDL( c) Clinical Protocol Page 124
LY3012207Attachment 8. Protocol JGDL Creatinine Clearance 
Formula
Note:   This formula is to be used for calculat ing creatinine clearance (CrCl) fro m local 
laboratory results only.
For serum creatinine 
concentration in 
mg/dL:
CrCl =
(mL/min) (140 â€“ agea) ï‚´(wt)  ï‚´  0.85 (if female) , orï‚´1.0 
(if male)
72ï‚´serum creatinine (mg/dL )
For serum creatinine concentration in ï­mol/L:
CrCl   =
(mL/min)(140 â€“ agea) ï‚´(wt)  ï‚´0.85 (if female) , orï‚´1.0 
(if male)
0.81ï‚´serum creatinine (ï­mol/L )
a A ge in y ears, weight (wt) in kilograms.
Reference:  Cockcroft and Gault 1976.
I5B-MC-JGDL( c) Clinical Protocol Page 125
LY3012207Attachment 9. Protocol JGDL Amendment ( c) Summary
APhase 1b (Open- Label) / Phase 2 (Randomized, 
Double -Blinded) Study  Evaluating Gemcitabine and 
Docetaxel With or Without Olaratumab in the 
Treatment of A dvanced Soft Tissue Sarcoma
Overview
Protocol  I5B-MC-JGDL ( b) â€œA Phase 1b (Open -Label) / Phase 2 (Randomized, Double -Blinded) 
Study  Evaluat ing Gemcitabine and Docetaxel Wit h or Wi thout Ol aratum ab in the Treatm ent of 
Advanced Soft Ti ssue Sarcom aâ€ has been amended.  The new protocol is indicate d by 
amendment ( c) and will be used to conduct the study  in place of any preceding version o f the 
protocol .
The overall changes and rationale for the changes made to this protocol are as fo llows: 
ï‚·The protocol synopsis, definit ions, Figure JGDL.1 and Sect ions 7.1 and 8.1.2 were modified 
to allow for expansion o f olaratum ab of inclusio n criteria by enrolling 90 additional patients 
that have previously received o laratumab (olaratumab pre -treated) in the Phase 2 part of the 
study .  Secti on 6. 2 is updated with asecondary  objective regarding this pat ient populat ion.  
The r ationale for adding these pati ents i s toevaluate for a signal for strategi c planning of 
future studies including this patient subset (refer to section 5.2 and 5.5.3) .   
ï‚·The protocol synopsis ,Sections 8.1.8 and 12.2.14, and SAP have been m odified to add an 
interim efficacy  analysis to the Phase 2 part of the study .  This analysis will be triggered after 
40 OS events in the olaratumab pre-treated patients .
ï‚·In Section 5.4 the number of patients previously treated with olaratumab in clinical trials is 
updated per the most recent IB.   
ï‚·Inclusio n criterion [9] regarding patients receiving ant i-coagul ant therapy  was updated for 
consistency across clinical trials wit h olaratumab.
ï‚·Exclusio n criterion [23] was added regarding the olaratum ab pre -treated populat ion for 
safet y.
ï‚·Criteria to begin subsequent treatment cy cles was cl arified in Section 9.4.1.2.  In this same 
section, clarificat ion was added to allowable treatment delays.
ï‚·A second dose reduction in gemcitabine and docetaxel will be allowed with this amendment.  
Clarificat ions are also made on dose alterations for toxicit ies of gemcitabine and docetaxel.  
These changes are noted in Tables JGDL.2, JGDL.3, JGDL.4, and JGDL.5 and Section 
9.4.1.2.  In addit ion, in this same sect ion it is clarified that treatment may cont inue with one 
chemotherapy agent if the other is discontinued for toxicit y.
ï‚·Secti on 9.4.1.2.2 i s updated wi th inform ation on modificat ion of infusio n rates for patients 
with Grade 1 and 2 IRRs.  It is also updated for instructions on olaratumab pre -treated 
patients wi th prior IRR.
I5B-MC-JGDL( c) Clinical Protocol Page 126
LY3012207ï‚·Tables JGDL.6 and JGDL.7 are updated for dose modifications of olaratumab for toxicit ies.  
These changes are for consistency across all o laratumab protocols.
ï‚·In Table JGDL.10 the criteria for QT interval assessment is changed to the Fridericiaâ€™s QT 
correcti on formula, for consistency across olaratumab protocols.
ï‚·Alterations in LDH, gammaglutamyl transferase, and TSH have not been foundto be related 
to olaratum ab.  Accordingly , inAttachm ent 2, these labs are no l onger requi red subsequent to 
baseline evaluat ion.    
ï‚·PROs are not needed to be done in long -term follow-up period (Visit 802 -8XXX) for Phase 
1b/2.  Accordingly, the Post-Treatment Discont inuation Schedule has been updated. 
ï‚·Other edits for clarit y andconsistency were made.
I5B-MC-JGDL( c) Clinical Protocol Page 127
LY3012207Revised Protocol Sections
Note: Deletions have been ident ified by strikethroughs .
Addit ions have been identified by  the use of double underscore .
2. Synopsis
Study Rationale:
Recent ly, tThe platelet -derived growth factor receptor alpha (PDGFR ï¡ï€©antibody  olaratumab in 
combinat ion with doxorubi cin dem onstrated a si gnificant improvement in an interim analysis of
overall survival (OS) over d oxorubicin alo ne in patients with advanced so ft tissue sarco ma (STS) 
(Tap et al . 201 65).  Since so me patients may not be appropriate candidates for doxorubicin -based 
chemotherapy, or have received prior anthracycline treatment, exploring olaratumab 
combina tions wi th other chemotherapeut ic agents that are often used in STS treatment is of 
considerable interest.  Study I5B-MC-JGDL is a mult icenter Phase 1b /2 study  ofolaratumab in 
combinat ion with gemci tabine and docetaxel  in patients wi th advanced or metastatic STS, not 
amenable to treatm ent wi th surgi cal resect ion or radi otherapy  with curative intent.   The first part 
(Phase 1b) of the study  will consist of an open -label , single- arm, dose -escalat ion assessment of 
the safet y and tol erabili ty of olaratum abadministered at 15mg/kg(Days 1 and 8) or20mg/kg
(Days 1 and 8 ) with gemci tabine (900 mg/m2[fixed dose rate :  10 m g/m2/minute] Days 1 and 8) 
and docetaxel (75 mg/m2Day 8), of  a 21 -day cycle.   After the dose of olaratumab in co mbinat ion 
with gemci tabine and docetaxel has been determined fro m the analysis of the Phase 1b part, the 
Phase 2
, randomized, double -blinded, placebo -controlled partof the study  will open to 
enrollment.   
Approximately 166 256 patients will  be randomized in Phase 2 in a 1:1 ratio to Arm  
A (ol aratum ab pl us gemci tabine and docetaxel) or Arm B (placebo plus gemcitabine and 
docetaxel).
Clinical Protocol Synopsis:  Study I5B -MC -JGDL
Number of Planned Patients:
Phase 1b:
Enrolled:  Approximately 45 55 patients
Phase 2:
Entered:  Approximately 200 314
Randomized:  256 166 Length of Study:   approximately 44 47 months
Planned last patient visit:  August November 2020
Planned interim safety analy sesare performed to monitor the safety data in the Phase 2 part of the study :.
1. Approximately 60 patients in Phase 2 have completed at least 2 cycles of treatment:  required 
safety, and PKdata if needed.
2. Every 6 months thereafter until approximately 1 year after completing enrollment :  required safety
andPKdata if needed .
Planned interim efficacy analyses in the Phase 2 part of the study: 
1. After 40 OS events in olaratumab -pretreated patients.   
I5B-MC-JGDL( c) Clinical Protocol Page 128
LY3012207Objectives:   
The primary objective of t he Phase 2 part is to compare the OS in olaratumab -naÃ¯ve patients with locally advanced 
or metastatic STS treated with olaratumab plus gemcitabine and docetaxel versus placebo plus gemcitabine and 
docetaxel.
A secondary objective of the Phase 2 part is to compare OS in olaratumab -pretreated patients with locally advanced 
or metastatic STS treated with olaratumab plus gemcitabine and docetaxel versus placebo plus gemcitabine and 
docetaxel.
The secondary objectives of the Phase 2 p art are to compare olaratumab plus gemcitabine and docetaxel versus 
placebo plus gemcitabine and docetaxel in both olaratumab - naÃ¯ve and olaratumab -pretreated groups, for the
follow ing:
The exploratory objective s for both Phase 1b and Phase 2 is are:
Study Design:   This trial is a Phase 1b open -label, dose -escalation part followed by a randomized, double -blind, 
placebo -controlled Phase 2 study of olaratumab plus gemcitabine and docetaxel in patients with locally advanced or 
metastatic STS, not amenable to treatment with surgical resection or radiotherapy with curative intent.  In the Phase 
1b part, 2 cohorts (15 mg/kg or 20 mg/kg) will be studied to determine the olaratumab dose that may be safely 
administered in combination with gemcitabine and docetaxel.   After th e dose of olaratumab in combination with 
gemcitabine and docetaxel has been determined from the Phase 1b part, the Phase 2 part of the study will open to 
enrollment.  In Phase 2, approximately 166 256 patients will be randomized 1:1, in a double -blinded ma nner, to Arm 
A (olaratumab plus gemcitabine and docetaxel) or Arm B (placebo plus gemcitabine and docetaxel).  Randomization 
will be stratified by prior treatment with olaratumab (yes versus no), number of prior systemic therapies for locally 
advanced or m etastatic disease (0 versus â‰¥1), histological tumor type (leiomyosarcoma versus non -
leiomyosarcoma), Eastern Cooperative Oncology Group performance status (ECOG PS) (0 versus 1), and prior 
pelvic radiation (yes versus no).  Patients will continue treatmen t until there is documented disease progression, 
unacceptable toxicity, death, or other discontinuation criteria are met.
Diagnosis and Main Criteria for Inclusion and Exclusions:   Patients at least 16 years of age, ECOG PS 0 to 1, 
gemcitabine ,anddocetaxel , and olaratumab naÃ¯ve, with histologically confirmed, locally advanced, unresectable or 
metastatic STS, and not amenable to curative treatment with surgery or radiotherapy.  Patients with gastrointestinal 
stromal tumor or Kaposiâ€™s sarcoma will b e excluded.  Patients previously enrolled in Study I5B -MC -JGDJ or any 
other blinded study with olaratumab are not eligible to participate in this trial.   
Reference Therapy, Dose, and Mode of Administration:
For the Phase 1b and 2 parts :
Gemcitabine is a commercially available product and should be stored, reconstituted, and discarded per 
manufacturerâ€™s instructions .  Gemcitabine isadministered at a dose of 900 mg/m 2over approximately 90 minutes 
(fixed dose rate:  10mg/m2/minute ) on Days 1 and 8 of each 21-day cycle.
Docetaxel :is a commercially available product A commercial preparation of docetaxel will be used and should be 
prepared and administered according to the manufacturerâ€™s instructions.  In the Phase 1b and Phase 2 parts,
dDocetaxel will be isadministered at a dose of 75 mg/m2(IV) over approximately 60 minutes on Day 8 of each 21 -
day cycle.
For the Phase 2 part :
Placebo:   injection for IV use, supplied in single -use vials, administered to patients as an IV infusion over 
approximately 60 minutes on Days 1 and 8 of each 21 -day cycle
Planned Duration of Treatment:
Long -term follow -up (postdiscontinuation): Patients that di scontinue study treatment for reasons other than 
progression will be followed every 6 weeks (Â±7 days) until progr essive disease ( PD), thereafter ever y 2 3months 
(Â±7days)for the first 2years, then every 6 months (Â±14 days )until the patientâ€™s de ath or o verall study completion.
I5B-MC-JGDL( c) Clinical Protocol Page 129
LY3012207Statistical Methods:
Statistical:
Efficacy:   Phase 2: The primary objective is to compare OS in olaratumab -naÃ¯ve patients with locally advanced or 
metastatic STS treated with olaratumab plus gemcitabine and docetaxel versus placebo plus gemcitabine and 
docetaxel.  Investigative sites will screen approximately 200  patients to randomize  166 Patients will be randomized
in1:1 randomizatio nto the two treatment arms. (83 patients in the experimental arm and 83 patients in the control 
arm) .  The intent ion-to-treat (ITT) sample size of 166 for olaratumab -naÃ¯ve patients (83 in the experimental arm and 
83 in the control arm) was selected assumin g the final analysis of OS will occur after 108 OS events have been 
observed (35% censoring).
The final total of 108OS events in the olaratumab -naÃ¯ve patients (deaths) provides 80% statistical power for a two -
sided log -rank test at a 0. 20significance lev el (assuming the true OS hazard ratio [ HR] is 0.665).  An OS HR of 
0.665corresponds approximately to an increased median survival from 15 months (estimated from published 
clinical data in various types of patients with locally advanced or metastatic STS) in placebo plus gemcitabine and 
docetaxel to 2 2.5 months for olaratumab plus gemcitabine and docetaxel.
An additional 90 olaratumab -pretreated patients (45 in the experimental arm and 45 in the control arm) will be 
randomized to compare the same regimens as asecondary objective.
The primary efficacy outcome for the Phase 2 part of the study is OS in the olaratumab -naÃ¯ve cohort of the ITT 
populatio n.  Analysis of OS will be based on the stratified log rank test, stratified by the 3 of the 4 randomization 
strata; that is, number of prior systemic therapies for locally advanced or metastatic disease (0 versus â‰¥1), 
histological tumor type (leiomyosarcoma versus non -leiomyosarcoma) , and ECOG PS (0 versus 1) .
Overall survival curves, the median w ith 95% confidence interval ( CI)and survival rates at various time points for 
each treatment group will be estimated using Kaplan -Meier method (Kaplan and Meier 1958).  The HR will be 
estimated using a stratified Cox regression model, stratified by the af orementioned 3 randomization strata. All ITT 
populatio n will be included in the analysis of this endpoint.   There is no interim efficacy analysis planned for the 
Phase 2 part.   The same OS analyses will also be performed separately for the olaratumab -pret reated cohort of the 
ITT population.
Interim analysis
There will be safety interim reviews for both Phase 1b and Phase 2 parts.  In addition, an interim efficacy analysis is 
planned for the Phase 2 part of the study.
The safety review for Phase 1b will be conducted by Lilly clinical research personnel.  The study investigators and 
the Lilly clinical research physician/clinical research scientist (CRP/CRS) will make the determination regarding 
dose escalation based upon their review of the safety/tolerabili ty data and the PK data from the previous cohorts. In 
addition, an interim safety review will be conducted prior to proceeding to Phase 2 including safety and PK .
An independent data monitoring committee (iDMC) will be established to conduct Phase 2 safe ty interim reviews.  
The first iDMC meeting to review interim data will occur when approximately 60 patients (approximately 30 
patients from each arm) have received at least 2 cycles of treatment or discontinued all study treatment due to any 
reasons prior to Day 8 in Cycle 2.  Subsequent iDMC meetings will occur regularly thereafter .
An interim efficacy analysis is planned for the Phase 2 part of the study.  After observing 40 OS events among the 
olaratumab -pretreated cohort of the ITT population, interim analy sis will occur.  Any  positive interim efficacy 
results may be used for planning of additional separate clinical studies, but will not be used to modify the design and 
conduct of this current trial.
I5B-MC-JGDL( c) Clinical Protocol Page 130
LY30122074. Abbreviations and Definitions
Term Definition
Olaratumab naÃ¯ve
Olaratumab pretreatedA study  participant who has never received olaratumab prior to enrollment or 
randomization
A study  participant who has previously received commercially available olaratumab, as 
defined by the inclusion criteria
5.2 Olaratumab Background
In norm al mesenchymal bi ology,PDGF/PDGFR signaling has a significant role in mesenchymal 
stem cell different iation, growth of mesenchymal cells, angiogenesis, and wound healing 
(Andrae et al. 2008; Ng et al. 2008; Li et al. 2014).   
PDGF/PDGFRÎ± signaling has been 
implicated in the pathogenesis o f multiple cancers, including osteosarcoma, chondrosarcoma, 
prostate cancer, breast cancer, ovarian cancer, and others.  In malignant disease, the 
PDGF/PDGFRÎ± axis prom otes tumor growth and prol iferat ion through both autocrine and 
paracrine mechanisms.   PDGFRÎ± is expressed on stromal cells, as well as the cancer cells 
themselves, wi thin certain tum ors.  Furthermore, studies have shown that PDGF/PDGFRÎ± 
signaling affects tumor vasculature through p aracrine mediat ion of vascular endothelial growth 
factor production (Shah et al. 2010).   Addit ional inform ation is available in the olaratumab 
investigatorâ€™s brochure (IB).
5.3 Study Rationale 
The posi tive efficacy  resul ts seen wi th olaratum ab in combinat ion with doxorubi cin in 
Study JGDG (Tap et al . 201 65)warrant further study  of olaratumab with gemci tabine plus 
docetaxel, another active treatment regimen, for patients with advanced or metastatic STS.
Study  I5B-MC-JGDL will eval uate the efficacy  and safet y of olaratum ab, in combinat ion with 
docetaxel and gemcitabine (fixed dose rate:  10 m g/m2/minute) in pat ients with locally advanced 
or metastati cSTS.  The study  will allow this evaluati on in both ol aratum ab-naÃ¯ve and 
olaratum ab-pretreated populat ions.  Ol aratumab -naÃ¯ve pat ients are those who may be ineligible 
for treatm ent wi th doxorubi cin or for whom gemcitabine/docetaxel is more appropriate as init ial 
chemotherapy than doxorubicin.
5.4 Rationale for Selection of Dose
Olaratumab:
The current dose -selection strategy  for this study  is based on the integrated safet y, efficacy , and 
pharmacokinet ics (PK)data for olaratumab across previous Phase 1 and Phase 2 studies.   In 
2Phase 1 d ose-escalation trials ( Studies I5B-IE-JGDCand I5B-IE-JGDF ) and in the 2 Phase 2 
monotherapy  studi es (Studi es I5B-IE-JGDE and I5B-IE-JGDH ), single -agent ol aratum ab has 
consistent ly been well tol erated ,with no dose-limiting toxicit ies (DLTs )observed up to a dose of 
20 m g/kg administered every  2weeks and up to a dose of 15 mg/kg administered o nDays1 and 
8 of a 21- day cycle.   When used in co mbinat ion with liposomal doxorubicin in Study  I5B-IE-
JGDA (olaratum ab dose of 20 mg/kg every  2 weeks), and wi th paclitaxel plus carbopl atin in 
I5B-MC-JGDL( c) Clinical Protocol Page 131
LY3012207Study  I5B-IE-JGDB (olaratumab dose of 15 mg/kg Day s1 and 8 every  3 weeks), a higher rate of 
toxicities such as neutropenia and infect ions was observed versus the comparator agents . As of 
30June 20152016, 691 patients have been enro lled into the olaratumab clinical program and 497
790 patients have received olaratumab through Phase 1, Phase 2, and Phase 3 studies .  In Study  
JGDG , although there was a higher incidence of some known doxorubicin toxicit ies such as 
mucosit is, nausea/vomit ing, and diarrhea, these were monitorable, predominantly Grade â‰¤2, and 
did not l ead to a higher incidence of treatment discontinuat ion.  Overal l, these toxicit ies are 
consistent with the toxicit y profile of the combinatio n agents used and are considered 
monitorable and acceptable for the patient populat ions studied.
Gemcitabine and Docetaxel:
Fixed -dose rate gemcitabine (900 mg/m2over 90 minutes [ fixed dose rate of 10 m g/m2/min], 
Days 1 and 8, plus docetaxel 100 mg/m2on d D ay eight8) yielded high object ive response rates 
among pat ients with advanced l eiomyosarcoma in both the second- line, and first -line setting 
(Hensley et al. 2008a, 2008b).  However, to increase the tolerabilit y of this chemotherapy  
regimen a docetaxel dose of 75 mg/m2, which is lower than 100 mg/m2,has been selected for this 
study .  Som e of the toxi city seen in previ ous clinical  experience (fat igue, asthenia, a nd fluid 
retention) was m ore ty pical of the docetaxel counterpart, suggesting that this docetaxel dose 
modificati on coul d improve the tol erabili ty of this regimen.  Thi s is consistent with the 
75-mg/m2 docetaxel  dose chosen in recent Phase 3 GeDDiS trial ( Seddon et al. 2015b).  
Therefore, t his Phase 1b/2 trial invest igates the efficacy  and safet y of olaratumab in co mbination 
with gemci
tabine (900 m g/m2over 90 minutes [ fixed -dose rate of 10 m g/m2/min]) and docetaxel  
(75mg/m2)for the treatm ent of locally advanced or m etastati c STS that is not amenable to 
treatm ent wi th surgical  resecti on or radi otherapy  with curative intent.
5.5.3 Rationale for Amendment (c)
As doxorubi cin in co mbination wit h olaratum ab becom es more comm on in clinical pract ice for 
advanced or metastatic STS, addit ional evaluation in o laratumab -pretreated patients is warranted 
in order to understand the effect of olaratumab as continuat ion therapy  with regimens such as 
gemcitabine/docetaxel  that are custom arily administered after max imal doxorubicin dosing.  
Addit ionally , the concept of continuing a bio logic treatm ent wi th a change in chemotherapy  
backbone is supported by  evidence of on -going treatment effect of trastuzumab and bevacizumab 
in multiple lines of therapy  in HER2 posi tivebreast cancer and metastatic colon cancer, 
respectively .  Furtherm ore, resistance to antibody  therapy in cancer is via separate mechanisms
than chemotherapy  resistance, supporting the theory  that continued benefit from olaratumab is 
possible after progres sive disease on other chemotherapy regimens.  Finally, due to potential 
effect on PDGFRÎ± expressing stromal cells, continued olaratumab exposure may lead to 
favorable changes in the tumor microenvironment irrespect ive of change in chemotherapy 
regimen.  Th e evaluat ion of olaratumab in co mbination with gemcitabine and docetaxel in 
olaratum ab pre -treated patients will be a secondary object ive. Ninet y patients will be added as 
this is deemed to be an adequate number to observe a signal for strategic planning o f future 
studi es.  The protocol  amendment also adds an interim efficacy  analysis o f all study  outcom es to 
allow for timely Phase 3 development strategies.
I5B-MC-JGDL( c) Clinical Protocol Page 132
LY30122076.1 Primary Object ive
Phase 1b
The primary  object ive of the Phase 1b partis to determine a rec ommended Phase 2 dose of 
olaratum ab that m ay be safely administered in combinat ion with gemci tabine and docetaxel to 
patients wi th locally advanced or m etastati c STS.
Phase 2
The primary  object ive of the Phase 2 partis to compare the OS in olaratuma b -naive patients with 
locally advanced or metastatic STS treated with olaratumab plus gemcitabine and docetaxel 
versus placebo plus gemcitabine and docetaxel.
6.2 Secondary Objectives
Phase 2
A secondary  object ive of the Phase 2 part is to compare OS in ol aratum ab-pretreated patients 
with locally advanced or metastatic STS treated with olaratumab plus gemcitabine and docetaxel 
versus placebo plus gemcitabine and docetaxel.
The secondary  objectives of the Phase 2 partare to compare olaratum ab pl us gemci tabine and 
docetaxel versus placebo pl us gem
citabine and d ocetaxel in both ol aratum ab-naÃ¯ve and 
olaratum abpre-treated groups , for the fo llowing:
7. Study Population
Eligible pat ients will have a histological diagnosis of locally advanced or m etastati c STS, by 
local pathol ogy review, not am enable to treatm ent wi th surgical  resecti on or radi otherapy  with 
curative intent.
7.1 Inclusion Criteria
[6] The patient may  have no m ore than 2 prior lines of systemic therapies 
(neoadj uvant and adjuvant therapi es will not be considered as a prior line of 
therapy ) for locally advanced or metastatic disease and is suitable to receive 
gemcitabine and docetaxel  therapy .  All  previ ous anti cancer treatments must 
have co mpleted â‰¥ 3 weeks (21 da ys) prior to first dose of study drug.
ï‚·In the Phase 2 part, prior olaratumab/doxorubicin combinat ion 
therapy  in 1prior treatm ent line is allo wed.
oPrior olaratum ab therapy  must have been received with 
doxorubi cin as indicated on the olaratumab label.
oPriorolaratum ab therapy  must have included at least 2 full 
cycles of olaratum ab/doxorubicin ( that is, a minimum of 4 
doses of ol aratumab).
I5B-MC-JGDL( c) Clinical Protocol Page 133
LY3012207oPatients,who completed at least 2 cy cles of combinat ion 
olaratum ab/doxorubi cin therapy  then discont inued 
doxorubi cin due to toxi city or maximum dosing and 
proceeded to olaratumab mo notherapy ,are eligible.
oThe m ost recent dose of olaratumab must have been 
received wit hin 180 days of rando mizat ion in this study.
[9] The patient has adequate hematologic, organ ,and coagul ation function wi thin
2 weeks (14 days) prior to enrollment (Phase 1b) or randomizat ion(Phase 2) :
ï‚·The patient has an adequa te coagul ation function as defined by Internat ional 
Norm alized Rat io (INR) â‰¤1.5 Ã—ULN or prothrombin t ime (PT) â‰¤1.5 Ã—ULN, and
partial thromboplast in time (PTT or aPTT) â‰¤1.5 Ã—ULN (unless receiving 
anticoagulation therapy ).  Pati ents receiving oral ant icoagulants are recommended 
to swi tch to l ow m olecular weight heparin and have a chieved stable coagulat ion 
status prior to first d ose of  protocol therapy .if not on ant icoagulant therapy .  For 
patients receiving anticoagulants, except ions to these coagulation parameters are 
allowed if they  are wi thin the intended or expected range for their therapeutic use.
Patients m ust have no hi story  of active bleeding (defined as within 14 days of first 
dose of study  drug) or pathological condit ion that carri es a high risk of bleed ing 
(for example, tumor involving major vessels or known esophageal varices) .
7.2 Exclusion Criteria
Patients will  be excluded from  the study  if they  meet anyof the fo llowing cri teria:
[15] The patient has received prior treatment with gemcitabine ordocetaxel , and/or 
olaratum ab.
[16] The patient has history  of another pr imary malignancy , with the excepti on of
ï‚·a) cCuratively treated non -melanomatous skin cancer , b)or
ï‚·Ccuratively treated cervical carcino ma in situ ,or
ï‚·c)nNon-metastati c prostate cancer, treated only  with observat ionor
ï‚·d) oO ther primary  nonhematologic malignancies or solid tumor streated 
with curative intent, no known active disease, and no treatment 
administered during the last 3 y ears pri or to enrollment (Phase 1 b) or 
rando mizat ion(Phase 2) .
[23] The patient has a history  of Grade 3 o r 4 infusio n-related reacti on (IRR) to 
olaratum ab or di scont inued olaratumab due to other significant toxicit y.
8.1 Summary of Study Design
Study  I5B-MC-JGDL is a mult icenter Phase 1b /2 study  ofolaratum ab in co mbinat ion wi th 
gemcitabine and docetaxel  in pat ients with locally advanced or metastatic STS, not amenable to 
I5B-MC-JGDL( c) Clinical Protocol Page 134
LY3012207treatm ent wi th surgical  resecti on or ra diotherapy  with curative intent .  The first part (Phase 1b) 
of the study  will consist of an open -label, single -arm, dose-escalat ion assessment of the safet y 
and tol erabilit y of olaratumab administered at 15 mg/kg(Days 1 and 8 ) or20mg/kg (Days 1 and 
8) with gemci tabine (900 m g/m2[fixed dose rate :  10 m g/m2/minute],Days1and 8 ) and 
docetaxel (75 mg/ m2, Day8),on a 21 -day cycle (Figure JGDL.1 ).  After the dose of olaratumab 
in combinat ion with gem citabine and docetaxel  has been determined from the analysis o f the 
Phase 1b part, the Phase 2, randomized, double -blinded , placebo -controlled part of the study will 
open to enrollment.  Patients will be rando mized in a 1 :1 ratio in a double -blinded manner to 
Arm A (ol aratum ab plus gemci tabine and docetaxel) or Arm B (placebo plus gemcitabine and 
docetaxel).   
Figure JGDL.1 illustrates the study design.
[Deleted figure below ]
[Inserted figure below ]

I5B-MC-JGDL( c) Clinical Protocol Page 135
LY3012207Abbreviations: D = Day 1; IV = intravenous; n= number of patients .
*  Based on the outcome of the Phase 1b part, the dose selected for the Phase 2 part of 
JGDL will be either 15 mg/kg or20 mg/kg . Depending on the safety and 
pharmacokinetic profile of these dose levels, it is possible that an intermediate dosing 
regimen of 2loading doses of 20 mg/kg during Cycle 1followed by 15 mg/kg in every 
subsequent cycle could be utilized in Phase 2, as is being studied in the Phase 3 Study 
JGDJ.
Figure JGDL.1. Illustration of study design.
8.1.1 Phase 1b Dose Escalation 
The Phase 1b part is a single -arm dose escalat ion to determine the recommended dose of 
olaratum ab for the Phase 2 part that may be safely  administered in combinat ion with gemci tabine 
(900 m g/m2) and docetaxel  (75 m g/m2) inpatients wi th locally advanced or m etastati c STS .  This 
dose escalat ion has a starting o laratumab dose of 15 mg/kg and the highest ol aratum ab dose of 
20mg/kg. No intrapatient dose escalat ion is permitted. Patients in any cohort who do not 
complete Cycle 1 treatm ent for reasons other than a DLT will be replaced.
8.1.2 Phase 2
After the dose of olaratumab in co mbination wit h gemcitabine and docetaxel has been 
determined fro m the Phase 1b part, the Phase 2 randomized, double -blinded partof the study  will 
open to enrollment.  In the Phase 2 part, approximately 166 256 patients wi ll be rando mized 
1:1to receive eit her olaratum abplus gemcitabine and docetaxel (Arm  A) or pl acebo pl us 
gemcitabine and docetaxel  (Arm  B).  Out of the 256 patients, 166 patients will be olaratumab 
naÃ¯ve and 90 patients will be o laratumab pretreated.   Rand omization will be stratified by prior 
treatm ent wi th olaratumab (y es versus no), number of prior systemic therapies for locally  
advanced or metastati c disease (0 versus â‰¥1), histological tumor ty pe (leiomyosarcom a versus 
non-leiomyosarco ma), ECOG performan ce status ( PS)(0 versus 1) ,and prior pelvic radiati on 
(yes versus no).
8.1.3 Definitions of Study Periods
ïƒ˜Follow -up for survival -Patients will be fo llowed every 
2 3months (Â±7 days) for the first 2 years, then every  6 months 
(Â±14 day s) unt il the patientâ€™s death or overall study  com pletion.
8.1.4 Baseline and Study Treatment Period Assessments
Phase 2 :
Patients in the invest igational Arm A will receive:
ï‚·Olaratum ab (15 or 20 m g/kg IV infusio n)on Days 1 and 8 of every  21-day cycle over 
60 minutes, fo llowed by  a 1-hour observat ion period for the first 2 cycles. If there is 
no evidence of an IRR after the D ay1 and D ay8 infusio ns in the first 2 cycles, no 
observat ion peri od is requi red for subsequent treatment cy cles.  In the event that a 
I5B-MC-JGDL( c) Clinical Protocol Page 136
LY3012207Grade 1 or 2 IRR occurs after Cy cle 2, the 1 -hour observat ion peri od will  be 
reinst ituted for a minimum of 2 cycles.  The reinst ituted observat ion peri od m ay be 
suspended after 2 cy cles if the patient shows no further signs or symptoms of an IRR.   
The dose of olaratumab will be determined from the Phase 1b part of the study .  
Depending on the safet y and PK profile of the Phase 1b dose levels, it is possible that 
an intermediate dosing regimen of 2 loading doses of 20 mg/kg during Cycle 1 
followed by 15 mg/kg in every subsequent cycle could be utilized in Phase 2, as is 
being studied in the Phase 3 Study  JGDJ.
8.1.5 Postdiscontinuation Follow -Up Period A ssessments
For pati ents that discont inue study  treatm ent after obj ectively measured PD, the fo llowing 
inform ation will be co llected every 2 3months (Â±7 day s) for the first 2 years, then every  6 
months (Â±14 days) unt il the pat ientâ€™s death, or overall study  com pletion:
8.1.6 Study Completion and End of Trial
Phase 1b
The Phase 1b partof the study  will be considered complete following determinat ion of the 
recommended Phase 2 dose of olaratumab that may be safely administered in combinat ion with 
gemcitabine plus docetaxel  
to patients with locally advanced or metastatic STS (Figure JGDL.2 ).
Phase 2
This study  will be considered com plete (that i s, the sci entific evaluation will be co mplete [study
completion]) fo llowing final analysis o fthe OS endpoint ( at least 108 OS events in the 
olaratum ab-naÃ¯ve cohort )hasbeen performed and evaluated, as determined by Lilly  
(Figure JGDL.3 ).  Invest igators will continue to follow the study schedule for all patients until 
notified by Lilly  that study  com pletion has occurred .
Abbreviations:  iDMC = independent Data Monitoring Committee; OS = overall 
survival; PK = pharmacokinetic.
The iDMC safety reviews will occur when approximately 60 patients (approximately 
30patients from each ar m) have received at least 2 cycles of treatment or discontinued 
all study  treatment due to any reasons prior to Day 8 in Cy cle 2.  An interim PK 
analy s
is will accompany  the iDMC safety review .  Subsequent iDMC meetings will 
occur approximately every 6 months thereafter until approximately 1year after 
completing enrollment.
Figure JGDL. 3. Phase 2: Study period and continued access diagram.
I5B-MC-JGDL( c) Clinical Protocol Page 137
LY30122078.1.8 Committees
Independent Data Monitoring Committee ( iDMC )
Phase 2:
Addit ionally , the i DMC will perform  the int erim efficacy analysis according to specificat ions in 
iDMC charter and study  statist ical analysis plan .
8.1.9 Study Duration
From  first pati ent visi t in the Phase 1b part to last patient visit in the Phase 2 part, the estimated 
study  durati on is 44 47 months.
Table JGDL.1 Treatment Regimens/Dosing Schedule
aAdminister olaratumab as an infusion over 60 minutes (Â± 5 minutes) , not to exceed 25 mg/min . Note exceptions 
when the infusion times of olaratumab are longer than 60 minutes (Section 9.4.1.2.2.1 9.2.1 ). Premedicate all 
patients with the following medications (or equivalent) intravenously : a histamine H1 antagonist ( for example , 
diphenhydramine) and dexamethasone 30 to 60 minutes prior to the olaratumab doses on Days 1 and 8 of Cycle 
1.  For subsequent cycles, premedicate all patients with a histamine H1 antagonist ( for example , 
diphenhydramine) intravenously 30 to 60 minutes prior to each dose of olaratumab.  See also Section 9.2.1 for 
more details.   Additional premedication may be provided at the investigatorâ€™s discretion.  Premedication must be
provided in the setting of a prior Grade 1-2 olaratumab/placebo IRR, as detailed in Section 9.4.1.2.2.1 .  All 
premedication administered must be adequately documented in the eCRF.
Treatment Regimens/Dosing Schedule (concluded)
dAdminister docetaxel as an infusion over 60 minutes (Â± 5 minutes) after gemcitabine .  Premedica tion for 
docetaxel may be administered according to institutional guidelines and/or clinical practice .  All premedication 
administered must be adequately documented in the eCRF .  Docetaxel premedication , if needed, must not be 
administered before the end o f olaratumab/placebo infusion or before completion of the observation period (if 
applicable).  Exception is given to dexamethasone premedication that is started 1 day prior to docetaxel per 
package insert.
9.2.1 Olaratumab/Placebo
CAUTION:   Infusion -related reacti ons may  occur during or following olaratumab/placebo 
administration (see Section 9.4.1.2.2.1 for a definit ion of Grade 3 and 4 IRRs).  During the 
administration of olaratumab/placebo, patients should be in an area with resu scitation equi pment 
and treatments necessary  for advanced life support and cardiopulmo nary resusci tation (CPR), 
such as bronchodilators, vasopressor agents (for example, epinephrine), oxy gen, gl ucocorti coids, 
antihistamines, IV fluids, and so forth.  A 1-h our observat ion peri od is requi red after the 
administration of the first and second cy cles of olaratum ab/placebo.  If there is no evidence of an 
IRR during the init ial 2 cycles of olaratum ab/placebo, then no observation period is required for 
subsequent tr eatment cy cles.  In the event that a Grade 1 or 2 IRR occurs after Cy cle 2, the 1 -
hour observation period will be reinst ituted for a minimum o f 2 cycles.  The reinst ituted 
I5B-MC-JGDL( c) Clinical Protocol Page 138
LY3012207observat ion peri od m ay be suspended after 2 cy cles if the pat ient shows no further s igns or 
symptoms of an IRR.   See Section 9.4.1.2.2.1 for management of infusio n rate wi th Grade s1 and 
2 IRRs.
9.3 Method of Assignment to Treatment
Phase 2:
The I WRS will assign patients to treatment arms according to a stratified method of 
randomizat ion (that is, independent randomizat ion within each of 16stratuam or cells ), defined 
by the fo llowing 4 5prognosti c factors:
ï‚·Prior treatm ent wi th olaratumab (y es versus no)
ï‚·Number of prior systemic therapies for locally advanced/metastatic disease (0 versus â‰¥1)
9.4.1.2 Dose Delays, Modifications, and Discontinuations
To begin dosing at each cy cle (Day  1), the fo llowing cri teria must be f ulfilled:
ï‚·ANC â‰¥1.5 Ã— 103cells/ÂµL ( â‰¥1500 cells/ÂµL; â‰¥1.5 Ã— 109/L), with no G -CSF in the prior 48 
hours
ï‚·Platelets â‰¥100 Ã— 103cells/ÂµL ( â‰¥100,000 cells/ÂµL; â‰¥100 Ã— 109cells/L) , with no platelet 
transfusio n in the prior 72 hours
Delays:
Treatment may be delayed for up to 14days to allo w a patient sufficient time for recovery  from 
study  drug -related toxici tyor non -study -drug-related events at the investigatorâ€™s discret ion (for 
example, an autom obile accident).
Dose Modificat ions:
Any pat ient who requires a dose reduction for drug -related toxicit y will cont inue to receive the 
reduced dose for the remainder of the study , except in the situat ion described in Table JGDL.2 , 
footnote b .  For gem citabine or docetaxel , any pat ient who has had 1 2 dose reductions and who 
experiences a toxicit y that woul d cause a thirdsecond dose reducti on m ust be discont inued from 
study  treatm ent.  For ol aratum ab, a ny pat ient who has had 2dose reductions and who 
experiences a toxicit y that woul d cause a thirddose reducti on m ust be discont inued fro m study  
treatm ent.
I5B-MC-JGDL( c) Clinical Protocol Page 139
LY3012207Table JGDL.2. Dosing Algorithm on Days 1 and 8 for Gemcitabine ,Docetaxel , Olaratumab, and G -CSF Use Based on 
Absolute Neutrophil Count and Platelet Count
Treatment 
DayAbsolute 
Neutrophil 
Count
(cells/Âµl)Platelet 
Count
cells/Âµl)Gem Dose (mg/m2) Doc Dose (mg/m2) Olaratumab/Placebo G-CSF Usea
Day 1
(Olaratumab
/Placebo
Gem)â‰¥1500 and â‰¥100,000 900bNot Applicable Administer Not Applicable
Day 8 
(Olaratumab
/Placebo
Gem ,Doc)â‰¥ 1000 and â‰¥100,000 900b75bAdminister Not required
500 to 
<1000â‰¥75000 675c60cAdministerAdminister as outlined 
in Section 9.1.1.4.
â‰¥500<100,000 
to 75000675c60ccAdministerNot required unless 
ANC meets criteria
<500 Any Omit on Day 8c8dOmit on Day 8c8d Omit on Day 8 (also 
see Table JGDL.6)Administer as outlined 
in Section 9.1.1.4.
Any <75000 Omit on Day 8c8dOmit on Day 8c8d Omit on Day 8 (also 
see Table JGDL.6 )Not required unless 
ANC meets criteria
Abbreviations : ANC = absolute neutrophil count; Doc = docetaxel; G-CSF = granulocyte colony -stimulating factor; Gem = gemcitabine; Âµl = microliter .
a Patients with a prior history of pelvic radiation should receive prophylactic G -CSF in all cycles.  G -CSF use is recommended per the guidelines outlined in 
Section 9.1.1.4 .  Patients with a prior history of pelvic radiation who require chemotherapy dose reduction despite prophylactic G -CSF are not required to 
have prophylactic G -CSF in s ubsequent cycles if per investigator assessment such chemotherapy dose reductions adequately address the risk of further 
myelosuppression.
bIf there has been a previous 1 dose reduction for drug -related toxicity, the dose of gemcitabine is675mg/m2and the dose of docetaxel is 60mg/m2. If there 
have been 2dose reductions for drug -related toxicity, the dose of gemcitabine is 500 mg/m2and the dose of docetaxel is 45 mg/m2.  A Day 8 dose reduction 
of gemcitabine or docetaxel because of Day 8 blood count parameters does not need to be continued on Day 1 of the subsequent cycle .
cIf there has already been 1dose reduction for drug -related toxicity, the dose of gemcitabine is 500mg/m2and the dose of docetaxel is 45mg/m2.  A Day 8 
dose reduction of gemcitabine or docetaxel because of Day 8 blood count parameters does not need to be continued on Day 1 of the subsequent cycle.
cdAfter omission of gemcitabine and docetaxel on D ay 8 due to ANC <500 cells/ ÂµLand/or platelet count of < 75,000 cells/ ÂµL, reduce dose of gemcitabine to 
the next appropriate dose level per Table Table JGDL .3JGDL 3 675 mg/m2and docetaxel to 60 mg/m2for subsequent cycles.
I5B-MC-JGDL( c) Clinical Protocol Page 140
LY3012207Discontinuations:
In the event of permanent discontinuation of o laratumab/placebo therapy  due to an 
olaratum ab/placebo -related toxi city, pati ents m ay continue on gem citabine and docetaxel  
treatm ent per protocol .  If either gemcitabine or docetaxel are permanently discont inued due to 
toxicity, the pati ent shoul d discont inue act ive treatment with the gemcitabine/docetaxel 
combinat ion if it is unclear which individual agent is the cause o f thetoxicit y.  If toxici ty is 
clearly  related to 1agent or the other, for example neuropathy  due to docetaxel, only  that agent 
shoul d be discont inued.   However, Tthe patient may continue treatment with o laratumab/placebo
alone, at the discret ion of the inves tigator , if gemcitabine and/or docetaxel are permanent ly 
discontinued.  Any changes in treatments being added to or removed fro m patient care will be 
recorded on the eCRF.
9.4.1.2.1 Gemcitabine and Docetaxel
9.4.1.2.1.1 Dose Level Reductions
Theinfusio n time o f gemcitabine after i ts dose reducti on may  be maintained at 90 minutes 
(Â±5min) or 70 minutes (Â±5 min) may be shortened to keep a rate of approximately 
10mg/m2/min according to discret ion of the investigator.  The infusio n start and stop t imes must 
be recorded.
Table JGDL. 3. Dose Level Reductions for Gemcitabine and Docetaxel
Study Drug Starting Dose Dose Reduction 1 Dose Reduction 2
Gemcitabine 900 mg/m2675mg/m2500 mg/m2
Docetaxel 75 mg/m260mg/m245mg/m2
Table JGDL.4 General Guidelines for Gemcitabine and Docetaxel Dose 
Modification Due to Other Hematologic Toxicity
Toxicity Required Dose Modification
Granulocyte nadirs lasting less than 7 days and with 
no complicationsNo dose modification needed
I5B-MC-JGDL( c) Clinical Protocol Page 141
LY3012207First occurrence of febrile neutropenia and/or 
documented Grade 4 neutropenia persisting â‰¥ 7 daysReduce gemcitabine to 675 mg/m2and docetaxel to 
60mg/m2.  Prophylactic G -CSF recommended in 
subsequent cycles.  If patient experiences of febrile
neutropenia and/or documented Grade 4 neutropenia in a 
subsequent cycle despite dose reduction and prophylactic 
G-CSF, a second dose reduction (to gemcitabine 
500mg/m2and docetaxel 45 mg/m2) is allowed.  If 
febrile neutropenia or documented Grade 4 neutropenia 
occur in further cycles, the patient should be 
disco ntinued from the gemcitabine and docetaxel 
combinatio n.
Grade 3 thrombocytopenia (platelet count 25,000/ÂµL
to Ë‚50,000 /ÂµL) associated with clinically significant
bleeding Reduce gemcitabine to 675 mg/m2and docetaxel to 
60mg/m2for all subsequent cycles.  If the event recurs in 
a subsequent cycle despite dose reduction, a second dose 
reductio n (to gemcitabine 500 mg/m2and docetaxel 
45mg/m2) is allowed.  If Grade 3 thrombocytopenia with 
clinically significant bleeding o ccurs in further cycles, 
the patient should be discontinued from the gemcitabine 
and docetaxel combination.
Grade 4 thrombocytopenia (pl atelet count 
<25,000/Âµ L)Reduce gemcitabine to 675 mg/m2and docetaxel to 
60mg/m2for all subsequent cycles.  If the event recurs in 
a subsequent cycle despite dose reduction, a second dose 
reductio n (to gemcitabine 500 mg/m2and docetaxel 
45mg/m2) is allowed.  If Grade 4 thrombocytopenia 
occurs in further cycles, the patient should b e 
discontinued from the gemcitabine and docetaxel 
combinatio n.
Abbreviations:  ANC = absolute neutrophil count; G -CSFs = granulocyte colon y-stimulating factors.
Table JGDL.5 Dosage Reduction Guidelines for Docetaxel and Gemcitabine Due 
to Hepatic Toxicities
Toxicity Required Dose Modification
On Day  1, bilirubin > ULN Delay Day 1 ( except for patients with Gilbertâ€™s Syndrome, 
who must have a total bilirubin <3 mg/dL.  See Section 
9.4.1.2 ).
On Day  8, if bilirubin is â‰¤ULN Administer docetaxel on Day 8.
On Day  8, if the bilirubin is > ULN Omit docetaxel on Day 8. For subsequent cycles , omit 
docetaxel until bilirubin returns to â‰¤ ULN (except for 
patients with Gilbertâ€™s Syndrome, who must have a total 
bilirubin <3 mg/dL) .
I5B-MC-JGDL( c) Clinical Protocol Page 142
LY3012207Grade â‰¥3 elevations in SGOT (AST), SGPT 
(ALT), o r alkaline phosphataseReduce gemcitabine to 675 mg/m2and docetaxel to 
60mg/m2for all subsequent cycles . In subsequent 
treatments ,delay  gemcitabine and docetaxel for a maximum 
of 2weeks, until recover y to Grade â‰¤1.  If recover y to 
Grade â‰¤1 does not occur, discontinue gemcitabine and 
docetaxel.   A second dose reduction (to gemcitabine 
500mg/m2and docetaxel 45 mg/m2) is allowed if Grade â‰¥3 
elevations recur.
Abbreviations: ALT = a lanine transaminase; AST = a spartate transaminase ; SGOT = s erum glutamic oxaloacetic 
transaminase ; SGPT = s erum glutamic pyruvic transaminase ; ULN = upper limit of n ormal.
Note:  Bilirubin refers to total bilirubin.
ForGrade â‰¥2 nonhematologic organ -related toxicities(excluding alopecia), delay  treatm ent until 
recover yto Grade â‰¤1 or pre -therapy  baseline .  Treatment may be delayed for up to 14days to 
allow a patien t sufficient time to recover from study drug -related toxi city. If recovery  to Grade 
â‰¤1 does not occur within this allowed time, discontinue gemcitabine and docetaxel. If the patient 
continues to experience the same toxicities, a second dose reduction ( per Table JGDL.3 )is 
allowed.   at the reduced dose, the g Gem citabine and docetaxel  treatm entshoul d be discont inued
if toxi cities recur in spite of 2 dose reductions .In general, Grade 3 nonhematologic toxicit ies 
(excluding electrolyte toxicit ies that res pond to supplemental treatment) require dose reduction 
of gem citabine to 675 m g/m2and/or docetaxel to 60 mg/m2.  Perm anent discont inuat ion of 
gemcitabine and docetaxel  is indicated for Grade 3 organ -related toxi city that recurs despite 
priorup to 2dose r educti ons.  Docetaxel  shoul d be reduced to 60 m g/m2for Grade 2 neurologic 
toxicity and permanent ly discont inued for Grade 3 neuro logic toxi city.  Gem citabine and 
docetaxel should be permanently discont inued for Grade 4 nonhematologic toxicit y unless 
previ ously discussed wit h the Lilly CRP/CRS.
9.4.1.2.2.1 Infusion -Related Reactions
For pati ents who experience a Grade 1 or 2 IRR, the infusio n should be stopped and the patient 
treated with the fo llowing (or equivalent) medicat ions intravenously : a histamine H1 antagonist 
(for example ,diphenhydramine hydrochloride), glucocortico id (for example ,dexamethasone), 
acetaminophen, and oxy gen (as indicated), according to standard medical pract ices.  After 
recovery , the infusio n rate shoul d be decreased 50% for the duration of the infusio n. 
Forp Patients who have experienced a prior Grade 1 or 2 IRR to olaratum ab (or placebo) , 
patients shoul d be prem edicated wi th the fo llowing (or equivalent) medicat ions:  a histamine H1 
antagonist ( for example , diphenhydr amine) intravenously and gl ucocorti coid (for example , 
dexamethasone) intravenously , acetaminophen, and any  other m edicat ionsas appropri ate for
prophylaxis of IRR , approximately  30to 60 minutes prior to all subsequent olaratumab/placebo 
infusio ns.  In add ition, the 1hour post infusio n observat ion peri od shoul d be reinstated as per 
Section 9.2.1.  If subsequent infusio ns are then tolerated with the use of premedicat ions as above 
and a 50% decrease in infusio n rate, the infusio n rate m ay be increased to a r ate deemed 
appropriate by  the investi gator, as l ong as i t does not exceed 25 mg/min.  For olaratumab -
I5B-MC-JGDL( c) Clinical Protocol Page 143
LY3012207pretreated patients who experienced a Grade 1 or 2 IRR during their prior treatment regimen 
(that is, prior to randomizat ion in this study ), the infusio n rate that was last tolerated should be 
the infusion rate for both doses of olaratumab in Cycle 1.  If tolerated, in subsequent cy cles,the 
infusio n rate m ay be increased to a rate deemed appropriate by  the investi gator, as l ong as i t does 
not exceed 25 mg/min.
Table JGDL.6 General Guidelines for Olaratumab/Placebo Dose Modification Due 
to Hematologic Toxicity Deemed Related to Olaratumab
Toxicity Required Dose Modification
Neutropenia
  ANC Grade 1 -3 No dose modification required
  ANC <500 cells/ ÂµL (Grade â‰¥4) No treatment administered; treatment cycle delayed
  At retreatment:
  If  â‰¥Grade 3 neutropenic fever/infection has 
occurredWithhold dose until ANC is â‰¥ 1000 cells/ÂµL; for thea
15-mg/kg dose level cohort , reduce dose to 12 mg/kg; for 
thea 20- mg/kg cohort dose level , reduce dose to 15 
mg/kg. 
  If Grade 4 neutropenia lasting >1week has occurred Withhold dose until ANC is â‰¥ 1000 cells/ÂµL; for thea
15-mg/kg cohort dose level , reduce dose to 12 mg/kg; for 
thea 20-mg/kg cohort dose level , reduce dose to 15 
mg/kg.
  Grade 4 ANC without fever/infection lasting â‰¤ 
1weekAdminister the next olaratumab/placebo at full dose at
investigator â€™sdiscretio n with recommended use of 
prophylactic G -CSFs
  Second incidence of either:  
  1) â‰¥Grade 3 neutropenic fever/infection
  2) Grade 4 neutropenia lasting >1 weekFor thea 15-mg/kg cohort dose level , discontinue 
olaratumab/placebo , gemcitabine, and docetaxel ; for the 
20-mg/kg cohort dose level , a second dose level 
reductio n to 10 mg/kg.  Modify/discontinue gemcitabine 
and docetaxel as perTable JGDL.4 .
Abbreviations:  ANC = absolute neutrophil count; G -CSFs = granulocyte colon y-stim ulating factors.
9.4.1.2.2.3 Nonhematologic Toxicity
General guidelines for dose modificat ion for other nonhematologic toxicit ies related to 
olaratum ab/placebo are shown in Table JGDL.7 .  If more than 2 toxi city-related 
olaratum ab/placebo dose reducti ons are requi red, all  study  treatm ent will be permanent ly 
discontinued.
Table JGDL.7 General Guidelines for Dose Modification Due to Nonhematologic 
Toxicities Deemed Related to Olaratumab/Placebo
Reaction Grade Required Dose Modification
Grade 1 No dose modification is required.
I5B-MC-JGDL( c) Clinical Protocol Page 144
LY3012207Reaction Grade Required Dose Modification
Grade 2 At the investigatorâ€™s discretion, the pat ient may  continue to receive olaratumab/placebo per 
protocol, provided that the event does not pose a serious health risk or is easily treated.
Grade 3 For a Grade 3 toxicity not adequately controlled with appropriate supportive care, the dose 
must be withheld until organ toxicity is â‰¤ Grade 1 or has returned to pretreatment baseline; 
then treatment may resume at a reduced dose of 12 mg/kg for the 15 -mg/k g cohort (Phase 1b)
dose level and reduced dose of 15 -mg/kg for the 20-mg/kg cohortdose level .  If toxicity 
recurs after therapy resumes, a second dose reduction ( second dose reduction of 10 mg/kg for 
the 15 mg/kg cohort dose level and12 mg/kg for the 20 -mg/kg dose level cohort) )is 
permitted.
   Grade 4 The dose must be withheld until dose toxicity is â‰¤ Grade 1 or has returned to baseline.  
Permanent discontinuation should be considered for any patient exper iencing Grade 4 
nonhematologic toxicity assessed as related to olaratumab/placebo. However, if resumption 
of dosing is deemed appropriate by the investigator, treatment may resume only after 
consultation with the Lilly study physician, with the dose reduc ed to 10 mg/kg for the 15 -
mg/kg dose level cohort ; dose reduced to 15 mg/kg for the 20 -mg/kg cohort dose level .  If 
Grade 4 toxicity recurs after therapy resumes, all study treatment will be discontinued.
9.5 Blinding
Phase 2:
This is thedoubl e-blind edpart of the study .
During enro llment and prior to the interim efficacy analysis To preserve the blinding of the study , 
only a minimum number of Lilly  personnel  will see the randomizat ion table and treatment 
assignments before the study  is com plete.   Individuals (IWRS, clinical trials materials 
management, Global Pat ient Safet y, and data management personnel) validat ing the database 
willnot have access to aggregate summary  reports or stati stics.  PK and/or immunogenicit ydata 
that coul d unblind the study  will not be reported to invest igative sites or other blinded personnel 
until the study has been unblinded.
Upon final analyses of the overall study  completion (see Secti on 8.1.6 ), invest igators may 
unblind pati ents to study  treatm ent assignment.
10.1.2 Radiographic A ssessments during the Study Period 
Postdiscontinuation Follow Up
For those patients who discont inue study  treatm ent wi thout obj ectively measured PD, the 
investigat ive sites will cont inue to monitor patients and peri odically  evaluate tum or response 
every 6 weeks (Â±7 days) as calculated from enrollment (Phase 1b) or randomizat ion (Phase 2) by  
the sam emethod used at baseline and throughout the study  until the pati ent has object ive disease 
progression, or until the final analysis of OS.  After the patient has objective disease progression, 
radiologic tests are no longer required and the patient will shoul dbe followed up approximately  
every 2 3months (Â±7 day s) for the fi rst 2 years, then every  6 months (Â±14 days) unt il the 
patientâ€™s death or overall study  com pletion.
I5B-MC-JGDL( c) Clinical Protocol Page 145
LY301220710.2 Patient -Reported Outcomes/Resource Utilization
Patient reported pain will be assessed using the mBPI -sf (Cleeland et al . 1991).  Health -related 
qualit y of lifewill be assessed with the EORTC QLQ- C30 (Aaronson et al. 1993).  Health status 
will be assessed using the EQ -5D- 5L (Janssen et al. 2008).  The PRO measures will be co llected 
on Day  1 of every  cycle and at the 30 -day short term fo llow-up visit.  For th ose pati ents who 
discontinued for reasons other than PD, a full due diligence will be taken to collect PRO 
measures during long- term follow-up, every  6 weeks (Â±7 day s) unt il PD.
Table JGDL.10 provi des the Fridericiaâ€™s Bazettâ€™s QT heart rate correction formula.
Table JGDL.10 Fridericia â€™sBazettâ€™s QT Heart Rate Correction Formula
FormulaFridericia Bazett
QTc F= QT (HR/60)1/2= QT / (RR)1/2 1/3
Type of formula Nonlinear
Use Most commonly used in clinical practice
Unique limitations Over -corrects QT at fast HRs
Under-corrects QT at low HRs (the risk of TdP which frequently occurs at low HRs, may 
not be evident)
Abbreviations:  QT = ECG interval measured from the onset of the QRS complex to the offset of the T wave ; QTc = 
corrected QT interval ; QTcF = QT interval corrected for heart rate using Fridericiaâ€™s formula; HR = heart rate; 
RR = time between corresponding points on 2 consecutive R waves on ECG .RR = duration of ventricular 
cardiac cycle; TdP =torsade de pointes (a polymorphic ventricular tachycardia).
12.1 Determination of Sample Size
Phase 1b
The primary  object ive of the Phase 1b partis to determine a recommended Phase 2 dose of 
olaratum ab that m ay be safely administered in combinat ionwith gemci tabine (900 m g/m2)and 
docetaxel (75 m g/ m2)to pati ents wi th locally advanced or metastati c STS .  Section 8.1.1
outlines the study  design for the Phase 1b portion.  Approximately , a total  of 45patients will  
ensure that at l east 1 5patients will be treated at the 15-mg/kg and 30 patients at the 20 -mg/kg 
cohort (see also Section 8.1.1. ).
Phase 2
The primary  object ive of the Phase 2 partis to compare olaratumab plus gemci tabine and 
docetaxel (experimental arm) versus placebo plus gemci tabine/ docetaxel  (control  arm) in term s 
of OS
,in patients with locally  advanced or metastatic STS ,who have not previously been treated 
with olaratum ab (the â€œo laratumab -naÃ¯veâ€ cohort).
The Phase 2 part of thestudy will screen approximately 200 olaratum ab-naÃ¯ve patients to 
rando mize 166 olaratum ab-naÃ¯ve patients in 1:1 randomizat ion (83 pati ents in the experimental 
arm and 83 patients in the control arm).  The primary  ITT sample size of 166 was selected 
assuming the final analysis of OS will occur when at least 1 08OS events in rando mized 
olaratum ab-naÃ¯ve patients have been observed (35% censoring).
I5B-MC-JGDL( c) Clinical Protocol Page 146
LY3012207The final total of 1 08OS events (deaths) in olaratumab -naÃ¯ve patients provides 80% statist ical 
power for a two- sided log-rank test at a 0. 20significance level (assuming the true OS HR is 
0.665).  An OS HR of 0.6 65corresponds approximately to an increased median survival fro m 15 
months (est imated fro m published clinical data in various t ypes of pat ients wi th advanced or 
metastati c STS) in placebo pl us gemcitabine and docetaxel to 22.5 months for olaratum ab plus 
gemcitabine and docetaxel .
Akey secondary  objective of the study  will be to com pare OS between the experimental arm and 
the control arm in pat ients with locally  advanced or m etastati c STS, who have previously  been 
treated with o laratumab (the â€œo laratumab -pretreatedâ€ cohort).  The Ph ase 2 part of the study  will 
screen approximately 114 olaratum ab-pretreated patients to randomize 90 olaratumab -pretreated 
patients in 1:1 randomizat ion.
The sample size of 90 patients in the secondary cohort of â€œo laratumab -pretreatedâ€ patients was 
selecte d based on both statist ical and quali tative considerati ons.  See Secti on 12.2.14 for further 
discussio n of the rationale.
There is nowill be aninterim efficacy analysis planned for the Phase 2 partof the study .All 
available data on patient c haracteri stics, efficacy , and safet y outcom es will be included for 
consideration as part of the interim efficacy analysis.  The primary  efficacy  hypothesis will be 
tested at the interim efficacy analysis using a no minal alpha level o f 0.00001.  The final a nalysis 
of the primary  efficacy hypothesis will therefore be adjusted and tested at a nominal alpha level 
of 0.19999.
See Secti on 12.2.14 and the studyâ€™s Statist ical Analysis Plan (a separate document) for further 
details regarding the interim efficacy ana lysis.
12.2.1 General Considerations
Unless specifically described otherwise, all baseline, efficacy, safety , and heal th outcom es 
analyses will be performed separately for the olaratumab- naÃ¯ve and olaratumab -pretreated 
cohorts.
12.2.2 Analysis Populations
Phase 2
The Intent -to-Treat (ITT)population:   will include sall rando mized patients .  InThe ITT 
analysis of efficacy  data will  consider popul ation,allocat ion of patients will be allocated to 
treatm ent groups as randomized, and not by  actual  treatm ent received. This populat ion will  
be used for baseline, efficacy, and healt h outcom e analyses.
A key  subset of the ITT popul ation is the LMS populat ion (rando mized patients with LMS),  
Unless oth erwise indicated, all efficacy analyses will be performed for both the full ITT 
popul ation and the LMS populat ion.
I5B-MC-JGDL( c) Clinical Protocol Page 147
LY301220712.2.7 Primary Outcome and Methodology 
Phase 2
The primary  efficacy  outcome for the Phase 2 part of the study is OS in the olaratumab -naÃ¯ve 
cohort of the ITT populat ion.  The final analysis o f OS will be based on the stratified log -rank 
test, stratified by  3 of the 4 randomizat ion factors: number of prior sy stemic therapies for locally
advanced or metastati c disease (0 versus â‰¥1), histological tumor ty pe (leiomyosarcom a versus 
non-leiomyosarco ma), and ECOG PS (0 versus 1).  
Overall survival curves, the median wit h 95% CI and survival rates at various time points for 
each treatment group will be est imated using the Kapl an-Meier m ethod (Kapl an and Meier 
1958).  The HR will be est imated using a stratified Cox regression model (Cox 1972) , stratified 
the sam e as the l og-rank test described above.   by the 3rando mizat ion strata (number of prior 
systemic therapies for advanced or metastatic disease [0 versus â‰¥1], histol ogical tum or type 
[leiomyosarco ma versus non -leiomyosarcoma], and ECOG PS [0 versus 1]).  All ITT populat ion 
will be included in the analysis o f this endpo int.
12.2.8.2 Additional Efficacy A nalyses
Addit ional analyses of the measures defined in Secti on 10.1.4 , as well as any other pre -planned 
efficacy  analyses, will be defined in the SAP.  In the event that efficacy is observed to be very 
similar between the olaratumab- naÃ¯ve and o laratumab -pretreated cohorts, it may  be reasonable to 
concl ude a uniform  efficacy across cohorts; in that case, additional ef ficacy  analyses m ay be 
perform ed pooling these 2popul ations, in order to obtain pooled estimates of efficacy 
param eters.
12.2.11 Analyses of Patient -Reported Outcomes (PROs)
Data will be separately summarized descript ively. Analyses will be performed sep arately  by 
cohort (ol aratum ab naÃ¯ve and o laratumab -pretreated). The m ain efficacy measure for the pain 
endpo int will be the time to first worsening of the mBPI -sf â€œworst painâ€ score. Time to first 
worsening in pain will be described using the method of K aplan -Meier and analyses will be 
made between the 2 arms by  a log-rank test.  â€œWorseningâ€ will be defined as either a â€œworst 
painâ€ increase of â‰¥2 points post -baseline (Farrar et al. 2001; Rowbotham 2001) or an analgesic 
drug class increase of â‰¥1 level.  However, other approaches to defining clinically  meaningful  
worsening in pain might be considered.  Further details will be provided in the SAP.
12.2.12 Safety A nalyses
All safet y summaries and analyses will be based upon the Safet y Popul ation as defined in 
Secti on12.2.2 . Analyses will be performed for olaratumab -naÃ¯ve and o laratumab -pretreated 
cohorts separately as well as pooled between these cohorts.
I5B-MC-JGDL( c) Clinical Protocol Page 148
LY301220712.2.14 Interim Analysis
There will be a safet y interim analysis reviews for both Phas e 1b and Phase 2 parts.  
Phase 2
Only the iDMC is authorized to evaluate unblinded safet y analyses .  Study  sites will  receive 
inform ation about interim results ONLY if they need to know for the safet y of their pati ents. 
Unblinding det ails are provided in the blinding section of the protocol (Section 9.5).
The i DMC safet y reviews will be performed for all randomized patients .The first iDMC 
meet ing to review interim data will occur when approximately  60 pati ents (approximately  
30patients fro m each arm ) have received at l east 2 cy cles o f treatm ent or discont inued all study 
treatm ent due to any  reasons pri or to Day 8 in Cycle 2.  An interim PK analyses will acco mpany 
the iDMC safet y review and the PK analyses will be perform ed by a Lilly  PK scient ist 
independent fro m the study  team .  These data will be provided to the iDMC up on request.  
Subsequent iDMC meetings will occur approximately every  6 months thereafter until 
approximately  1year after complet ing enrollment .  Enrollment and treatment will cont inue 
during the iDMC safet y assessments.  In the event a safet y signal is detected, addit ional meetings 
may occur as needed.  Details as to the process and communication plan will be provided in the 
iDMC Charter.
As described in Secti on 12.1, an interim efficacy analysis is also planned for the Phase 2 part of
the study .  The i DMC will be responsible for init ial conduct of the interim efficacy  analysis 
according to the specificat ions of the iDMC charter and statistical analysis plan.  If there is an 
evidence of interim efficacy to warrant a sponsor internal rev iew of the data, resul ts of this 
interim efficacy  analysis may provide informat ion to help inform the init iation of new studies, 
but will not be used to modify  the design and conduct of this current trial.
The interim efficacy analysis will occur after obs erving approximately 40 OS events among the 
olaratum ab-pretreated cohort of the ITT populat ion.  Due to the larger size of the olaratumab -
naÃ¯ve cohort, it is expected that there will be at least another 40 OS events in the olaratumab -
naÃ¯ve cohort at the ti me of this analysis.  The decisio n to perform interim efficacy analyses after 
40 OS events in each cohort was based on both statist ical and qualitat ive considerations.  An 
observat ion of a very  strong efficacy in one of these cohorts, based on 40 events, s hould be 
sufficient to consider further development for that cohort.  For example, an observed OS 
HR<0.60 would imply  at least an 80% (Bay esian noninformat ive) probabilit y that the true HR is 
less than 0.80.  The evidence will be stronger if both cohorts s how similar efficacy, allowing for 
pooling of the cohorts.  With 80 pooled events, an observed pooled OS HR<0.67 would imply  at 
least a 79% probabilit y that the true pooled HR is less than 0.80.  Other efficacy and safet y 
outcom es will  be evaluated, so the se scenarios for the interim OS HR are included here merely 
as a reference, to illustrate the kind of evidence that might lead to the init iation of addit ional 
studi es.  For further details, refer to the studyâ€™s Statist ical Analysis Plan (a separate documen t).
A second interim efficacy  analysis may  optionally be perform ed depending on the expected 
timing of the final analysis and the results of the first interim efficacy analysis.  If a second 
I5B-MC-JGDL( c) Clinical Protocol Page 149
LY3012207interim efficacy  analysis is performed, it will be conducted appl ying a no minal alpha level of 
0.00001 to the primary OS analysis in o laratumab -naÃ¯ve pat ients.
A limited number of pre -identified individuals may gain access to the limited unblinded data, as 
specified in the unblinding plan, prior to the interim or final database lock, in order to init iate the 
final populat ion PK/pharmacodynamic model deve lopment processes for interim or final 
analyses.  Informat ion that m ay unblind the study  during the analyses will not be reported to 
study  sites or b linded study  team  until the study has been unblinded.
Unblinding details are specified in the blinding section of the protocol ( Secti on9.5).  If changes 
to the unblinding plan occurred after protocol approval, they  may be described in either a 
protocol  amendment, the unblinding plan sect ion of the SAP, or in separate unblinding plan 
docum ent.
14. References
Tap WD, Jones RL, Van Tine BA, Chmie lowski B, Elias AD, Adkins D, Van Tine BA, Agulnik 
M, Cooney MM, Livingston MB, Pennock GK, Hameed MR, Shah GD, Qin A, Shahir A,
Croni er DM, Ilaria RL, Conti  I, Cosaert J, Schwartz GK.  Olaratumab and doxorubicin versus 
doxorubi cin alo ne for treatment of soft-tissue sarcom a:  an open -label phase 1b and 
rando mized phase 2 trial.
A rando mized phase Ib/II study  evaluat ing the safety and efficacy o f olaratumab (IMC -3G3), a 
human ant i-platelet-derived growth factor Î± (PDGFRÎ±) monoclonal ant ibody , with or wi thout 
doxorubi cin (Dox), in advanced soft tissue sarcoma (STS). J Clin Oncol . 201 65;33388:488 -
497.suppl; Presented at American Societ y of Clinical  Oncol ogy annual  meeting, 2015b. 
Associ ated wi th Abstract 10501).
I5B-MC-JGDL( c) Clinical Protocol Page 150
LY3012207Attachment 1 Protocol JGDL Study Schedule
Treatment Period Schedule (Phase 1b and Phase 2)
Study Period Treatment Period
Procedure 
CategoryProtocol 
SectionsRelative Day within Cycle 
(21 day cycle Â± âˆ’3 days)1a8a
Physical 
Examination9.4, 
10.3.1Physical Examination X XPhysical examination during treatment period includes weight and BSA measurement.  Patients 
should be weighed at D1 and D8 of each cycle and BSA calculated.
Att. 4 ECOG Performance Status X Complete prior to treatment infusion. 
10.3.1 Vital signs X XVital signs include blood pressure, pulse, respiratory rate, and temperature.
Please refer to Table JGDL.1 footnote b for the times when vital signs should be collected.
Lab/
Diagnostic TestsAtt. 2 Hematology X XLaboratory assessments may be done within 3days prior to D1 and D8 of each cycle.  See 
Attachment 2 for details.
Att. 2 Serum Chemistry X XLaboratory assessments may be done within 3days prior to D1 and D8 of each cycle.  See 
Attachment 2 for details.
Att. 2 Coagulation Profile XPerform within 3days prior to D1 of every other cycle or as clinically indicated.  See 
Attachment 2 for d etails.
Att. 2 Pregnancy Test XSerum or urine pregnancy test on D1 of every cycle or per local practice (whichever is of 
shorter duration).  If the pregnancy test performed on D1 of the cycle is positive, confirm with a 
serum pregnancy test (pregnancy test results are not recorded on the eCRF).
10.4.4 PK SamplesSee Attachment 6 for 
specific time pointsWhole blood samples collected and processed into serum (olaratumab) or plasma
(gemcitabine/docetaxel) .  If a patient experiences an IRR to olaratumab, blood samples for 
immunogenicity and PK analysis will be taken at the following time points:  (1) as soon as 
possible after the onset of the IRR, (2) at the resolution of the IRR, and (3) 30 (Â± 3 days) days 
after onset of the IRR event.
10.4.3 Immunogenicity SamplesSee Attachment 6 for 
specific time pointsWhole blood samples collected and processed into serum. If a patient experiences an IRR to 
olaratumab , blood samples for immunogenicity and PK analysis will be taken at the following 
time points:  (1) as soon as possible after the onset of the IRR, (2) at the resolution of the IRR, 
and (3) 30 (Â± 3 days) days after onset of the IRR event.
10.4.2.1Pharmacogenetic (DNA) Whole 
Blood SampleSee Attachment 6 for 
specific time point.Whole blood sample collected.  It is highly recommended to draw the whole blood sample prior 
to the first dose (C1D1 at predose); however, it can be collected later during the study if 
necessary.
10.4.2.3 Plasma sample for biomarkersSee Attachment 6 for 
time points .Whole blood samples collected and processed into plasma .
10.3.2.1 ECG XIn Phase 1b, twelve -lead ECGs are to be performed as single ECGs within 3 days prior to Day 1 
of every cycle, until PD or treatment discontinuation, whichever comes first.
Patient reported 
outcomes 10.2PRO Assessments (mBPI -sf, 
EORTC QLQ C30, EQ -5D-5L)XThe Patient Reported Outcome (PRO) measures will be coll ected on Day 1 of every cycle 
(Phase 2 only).
Efficacy
Assessment10.1.1
Att. 5Imaging Studies (CT/MRI)
Tumor Assessments ( according to 
RECIST v1.1)XImaging studies and tumor assessments are be obtained every 6 weeks (Â±7 days), irrespective of 
treatment cycles as calculated from enrollment in Phase 1b or randomization in Phase 2, until 
documented progression for patients with CR, PR, or SD, and/or for patients who have 
discontinued study treatment due to toxicity or reasons other than PD.  Refer to Section 10.1.1 
for details.
I5B-MC-JGDL( c) Clinical Protocol Page 151
LY3012207Study Period Treatment Period
Procedure 
CategoryProtocol 
SectionsRelative Day within Cycle 
(21 day cycle Â± âˆ’3 days)1a8a
Adverse Events 
Collection/
CTCAE Grading10.3.1 Toxicity Assessment X XAll AEs considered at least possibly -related to study treatment will be followed until resolution, 
stabilization, return to baseline, or until deemed irreversible.
Concomitant 
Therapy9.6 Concomitant Medications X XConcomitant medications will be recorded throughout the treatment period, including those 
taken during the 30 days after the last dose of all study treatment.
Premedication9.1.1.1 , 
9.1.1Administer premedication prior to 
olaratumab or placebo.X XPremedicate all patients with the following (or equivalent) medications intravenously : a 
histamine H1 antagonist (e .g., diphenhydramine) and dexamethasone 30 â€“60 minutes prior to 
the olaratumab/placebo doses on Days 1 and 8 of Cy cle 1.  For subsequent cycles, premedicate 
all patients with a histamine H1 antagonist (e .g., diphenhydramine) intravenously 30 -60 
minutes prior to each dose of olaratumab or placebo.
Study Treatment9.2.1 Administer olaratumab or placebo . X XAdminister until progressive disease (PD), unacceptable toxicity, death, or other withdrawal 
criteria are met.  No crossover will be permitted in the Phase 2 part.
9.2.2 Administer gemcitabine . X XAdminister until progressive disease (PD), unacceptable toxicity, death, or othe r withdrawal 
criteria are met.
9.2.3 Administer docetaxel . XAdminister until progressive disease (PD), unacceptable toxicity, death, or other withdrawal 
criteria are met.
Patient DispositionAt the time that the patient is discontinued from any component of the study treatment or Study 
Participation, information regarding the patient status will be collected.
I5B-MC-JGDL( c) Clinical Protocol Page 152
LY3012207Post-Treatment Discontinuation Schedule
Study Period Post-discontinuation Follow -Up
Short -Term Follow -Up Long -Term Follow-Up
Visit 801 802-8XX
Duration 30 Â±7 days See footnote for duration
Procedure 
CategoryProtocol 
SectionProcedure Comments
Physical 
Examination 9.4,10.3.1 Physical examination X Physical examination will include weight.
Att. 4 ECOG performance status X
10.3.1 Vital signs X Includes blood pressure, pulse, respiratory rate, and temperature.
Lab/
Diagnostic 
TestsAtt. 2 Hematology X See Attachment 2 for details .
Att. 2 Serum chemistry X See Attachment 2 for details.
Att. 2 Coagulation profile X See Attachment 2 for details.
Att. 2 Urinalysis XIncludes a routine urinalysis (UA), and if clinically indicated a microscopic 
analysis.  If urine dipstick or routine analysis indicates proteinuria â‰¥2+, obtain 
urine protein/creatinine ratio on spot urine or a 24-hour urine collection (to 
assess protein) must be obtained (up to 3 business days is allowed if the 
weekend) .
Att. 2 Pregnancy test XSerum or urine pregnancy test.  If the pregnancy test is positive, confirm with 
a serum pregnancy test (pregnancy test results are not recorded on the eCRF).   
Additional pregnancy tests may be done after short -term follow- up if required 
by local re gulation.
10.3.2.1 ECG XIn Phase 1b only, t welve -lead ECGs are to be performed as single ECGs for 
all patients at the short â€“term follow- up.
10.4.4 PK sample XSee Attachment 6 .  In ad dition, if a patient experiences an IRR to 
olaratumab/placebo, blood samples for immunogenicity and PK analysis will 
be taken at the short -term follow- up after the IRR.
10.4.3 Immunogenicity sample XSee Tap WD .  In addition, if a patient experiences an IRR to 
olaratumab/placebo, blood samples for immunogenicity and PK analysis will 
be taken at the short -term follow- up after the IRR.
10.4.2.3 Plasma sample for biomarkers X See Attachment 6 .
Patient 
Reported 
Outcomes10.2PRO Assessments (mBPI -sf, 
EORTC QLQ C30, EQ -5D-
5L)X XThe Patient Reported Outcome (PRO) measures will be collected at the 30 -day 
short -term follow- up visit.
For those patients who discontinued for reasons other than PD, a full due 
diligence will be taken to collect PRO measures during long -term follow- up 
every 6 weeks [Â±7 days] until PD .
Efficacy 
Assessments10.1.1 , 
Att. 5Imaging/Tumor Assessments 
(according to RECIST v1.1)X (if applicable) XFor patients who discontinue study treatment for any reason without 
objectively measured PD, imaging studies and tumor assessments are be 
obtained every 6 weeks (Â±7 days), irrespective of treatment cycles as 
calculated from enrollment in Phase 1b or from randomization for Phase 2, 
until documented progression.
8.1.3Survival Information , All 
Subsequent Anti -Cancer 
Treatments ,and Associated XFor patients enrolled in Phase 1 b and randomized in the Phase 2 part that
discontinue study treatment after objectively measured PD the following 
information will be collected every 2 3months (Â±7 days) for the first year, 
I5B-MC-JGDL( c) Clinical Protocol Page 153
LY3012207Post-Treatment Discontinuation Schedule
Study Period Post-discontinuation Follow -Up
Short -Term Follow -Up Long -Term Follow-Up
Visit 801 802-8XX
Duration 30 Â±7 days See footnote for duration
Procedure 
CategoryProtocol 
SectionProcedure Comments
Disease Progression Date then every 6 months (Â±14 days) until the patientâ€™s death, or overall study 
completion :  details on all subsequent anticancer treatment (start/stop dates 
and treatments administered ; first post -study treatment disease progression 
date; and survival status.
Adverse Events 
Collection/
CTCAE 
Grading10.3.1 Toxicity assessment XAll AEs considered at least possibly -related to study treatment will be 
followed until resolution, stabilization, return to baseline, or until deemed 
irreversible.  After the 30 -day short -term follow -up visit, only new and 
ongoing SAEs deemed related to study treatment will be collected.
Concomitant 
Medication 
Notation9.6 Concomitant medications X
Patient Disposition X XAt the time that the patient is discontinued from Study Participation,
information regarding the patient status will be collected.
Abbreviations:  AE = adverse event; CT = computed tomography; CTCAE = Common Terminology Criteria for Adverse Events; ECG = e lectrocardiogram; ECOG =Eastern Cooperative Oncology 
Group; LCSS = L ung Cancer Symptom Scale; PD = progressive disease; PRO =patient -reported outcome; QoL = quality of life; RECIST = Response Evaluation Criteria in Solid Tumors; 
SAE =serious adverse event.
Short-term follow -upbegins the day after the patient and the inv estigator agree that the patient will no longer continue study treatment and lasts approximately 30 days (Â±7 days).  The date of this 
agreement is to be reported on the CRF as the date of Discontinuation from study treatment.
Long -term follow -up:begins the day after short -term follow- up is completed .
ï‚· Follow -up for progression: Patients that discontinue study treatment for reasons other than progression will be followed eve ry 6 weeks (Â±7 days) until PD.
ï‚· Follow -up for survival:  Patients will be followed every 23months (Â±7 days) for the first 2years, then every 6 months (Â±14 days) until the patientâ€™s death or overall study completion.
Attachment 2. Protocol JGDL Clinical Laboratory Tests
Clinical Laborat ory Tests
Hematologya,bClinical Chemistrya,b
Hemoglobin Serum Concentrations of the following:
Hematocrit Sodium
Erythrocy te count (RBC) Potassium
Mean cell volume Total bilirubin
Mean cell hemoglobin concentration Alkaline phosphatase
Leukocytes (WBC) Alanine aminotransferase (ALT)
Neutrophils Aspartate aminotransferase (AST)
Lymphocy tes Gammaglutamyl transferaseg
I5B-MC-JGDL( c) Clinical Protocol Page 154
LY3012207Monocytes Blood urea nitrogen (BUN)
Eosinophils Creatinine
Basophils Uric acidg
Platelets Calcium
Glucose, random
Coagulation TestaAlbumin
Partial thromboplastin time (PTT or aPTT)
Prothrombin time (PT or INR )Total protein
Chloride
Thyroid-stimulating hormoneg
Urinalysisa,cDirect bilirubin
LDH
Specific gravity
pH Pregnancy testa,e
Protein
Glucose Follicle -stimulating hormone (FSH) a,f
Ketones
Blood Exploratory Biomarker Testsd
Refer to Section 10.4.2 .Urine leukocyte esterase
Otherd
Immunogenicity samples
PK samples
I5B-MC-JGDL( c) Clinical Protocol Page 155
LY3012207Abbreviations:  CRP = clinical research physician; D = Day; INR = international normalized ratio; LDH =lactate dehydrogenase ; PK = pharmacokinetics; 
WOCBP = women of childbearing potential .
aAssay ed by local or investigator -designated laboratory .
bDuplicate samples will also be a ssayed by Sponsor -designated laboratory .
cIf urinary  protein is â‰¥2+ at evaluations, a 24 -hour urine collection (to assess protein) must be collected , or alternatively, a urine protein/creatinine ratio on spot 
urine.   Note: UPC ratio of spot urine is an estimation of the 24 -hour urine protein excretion â€“a UPC ratio of 1 is roughly equivalent to a 24 -hour urine protein 
of 1000 mg.  UPC ratio is calculated using one of the following formulae:
ï‚·[urine protein]/[urine creatinine] â€“if both protein and creatinine are reported in mg/dL 
ï‚·[(urine protein) x 0.088]/[urine creatinine] â€“if urine creatinine is reported in mmol/L .
dAssay ed by a Sponsored -designated (central) laboratory. Refer to Attachm ent 6.
eSerum pregnancy test will be performed at screening in females of childbearing potential only (if the baseline serum test is positive, a repeat serum and urine 
pregnancy test will be done; if those results are positive, the investigator is to cons ult with the Lilly CRP regarding if dosing should occur and which follow -
up laboratory tests are performed).  While on -study, urine pregnancy test will be performed in females of childbearing potential only on D1 of ever y cycle or 
per local practice (which ever is of shorter duration) and at short -term follow -up visit .  If the serum pregnancy test performed for inclusion purposes is positive 
confirm by repeating the serum and performing a urine pregnancy test.  If the urine pregnancy test performed on D1 of each cycle is positive, confirm with a 
serum pregnancy test.
fPerformed only at screening in menopausal women that have experienced spontaneous amenorrhea for 6 to 12 months.  To be done for women only when 
needed to confirm postmenopausal status.
g  Per formed locally at screening only, repeat not required but should be obtained if clinically appropriate.
L e o  D o c u m e n t  I D  =  3 5 4 9 0 7 5 9 - 8 a e 6 - 4 1 a 5 - b 0 4 c - e a 3 4 2 f b d 8 c d 0 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  1 8 - J u l - 2 0 1 7  1 7 : 0 6 : 4 7  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  1 9 - J u l - 2 0 1 7  0 0 : 3 1 : 0 9  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d P P D 
P P D 